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Energy expenditure in humans is partially understood. Sympathetic drive is an important stimulator 
of brown-adipose tissue-mediated increases in energy expenditure, and it is known that leptin-
mediated pathways in part contribute to this.  
This thesis has sought to understand human energy expenditure further by two different methods. 
Firstly, we have characterised the first rare human mutations in G protein-coupled receptor 10 
(GPR10), a G protein coupled receptor expressed in key brain areas associated with energy 
homeostasis. GPR10-mediated signalling in the dorsomedial hypothalamus is necessary for the 
thermogenic effects of leptin. We have undertaken a detailed functional study of the mutations found 
from the whole exome and targeted resequencing of patients with severe early onset obesity, 
recruited to the Genetics of Obesity Study (GOOS). We have demonstrated that thirteen of the fifteen 
mutations found result in a complete or partial loss of function in vitro. We have additionally 
demonstrated that the mutations resulting in a complete loss of function on wild type receptor. This 
is important because the human mutations are found in heterozygous form. 
Secondly, we have conducted a randomised cross-over study of the effects of mild cooling on healthy 
lean men. We have demonstrated that exposure to temperatures of 16oC for two hours results in an 
increase in systolic blood pressure and pulse rate, relative to thermoneutral conditions. Cold exposure 
resulted in a drop in circulating leptin, which in common with previous studies on macronutrient 
preference in patients with disrupted leptin-melanocortin signalling, is associated with an increase in 
consumption of high fat food.  
Cooling is known to be neuroprotective in acute brain injury, and recent published data suggests a 
protective effect in chronic neurodegenerative conditions by improvements in synaptic plasticity. We 
have demonstrated an improvement in neurocognition after two hours of mild cooling. We have 
additionally shown increases in docoshexaenoic acid, a polyunsaturated fatty acid known to play a 
role in neuroprotection, with a role in maintaining membrane fluidity.  
These studies broaden our knowledge of human energy homeostasis. They provide evidence for the 
role of GPR10 in human energy homeostasis, and a rationale for the targeting of GPR10-mediated 
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1.1. Obesity   
1.1.1. The rising prevalence of obesity in society and its associated health consequences 
Obesity is defined as an increase in fat mass sufficient to adversely affect health (Kuri-Morales, 
Emberson et al. 2009).  Body mass index (BMI, weight/height2 (kg/m2) is used as a surrogate marker 
for fat mass, and the World Health Organisation categorises obesity as a BMI >30 kg/m2. Using this 
definition, the prevalence of obesity has increased dramatically in developed countries over the past 
three decades. In 2008, 10% of men and 14% of women in the world were obese (BMI ≥30 kg/m2), 
compared with 5% for men and 8% for women in 1980 (www.who.int), a near-doubling in the 
prevalence of obesity.   
Being overweight or obese is associated with excessive morbidity and mortality.  Obesity is associated 
with increased blood pressure, dyslipidaemia and insulin resistance. Risks of coronary heart disease, 
ischemic stroke and type 2 diabetes mellitus increase with increasing BMI, as does the risk of cancers 
of the breast, colon, prostate, endometrium, kidney and gall bladder.  At an individual level, obesity 
also incurs significant social stigma, and has been associated with lower self-esteem and educational 
attainment (Gavrilova, Leon et al. (1999)).   
 
1.1.2. Aetiology of obesity: genetic and environmental contributors 
Evidence for the environmental influence on obesity prevalence is provided by the inverse relationship 
between BMI and social class and the trend for an increase in BMI in developing countries undergoing 
industrialisation and urbanisation.  Whilst sedentary lifestyles and ready access to highly palatable, 
energy dense foods, are undoubtedly significant factors, there is considerable variability between 
individuals in body weight and fat mass within a given environment, suggesting a complex interaction 
between genetic, environmental and behavioural influences.   
Direct evidence for the role of genetics is provided by a number of seminal studies looking at BMI in 
twins, between family members and in adopted children.  Analysis of waist circumference and BMI in 
over 5000 UK twin pairs growing up during the obesity epidemic demonstrated a heritability of 77% 
for both (Wardle, Carnell et al. 2008).  A similar estimate of heritability was found in analysis of 53 
twin pairs reared apart (Allison, Kaprio et al. 1996). Furthermore, a study comparing the degree of 
obesity in adopted children with those in their full or half siblings raised by the biological parent found 
an increase in BMI of the full sibling when the adoptee was overweight or obese (Sorensen, Holst et 
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al. 1998).  These studies support the contribution of genetics to obesity, and make a genetic approach 
to the delineation of molecular pathways controlling energy homeostasis feasible.   
Several genome-wide association studies (GWAS) have been performed to identify common variants 
(minor allele frequency (MAF) > 5%) associated with BMI or obesity.  For example, the GIANT 
consortium identified 97 BMI-associated loci (P < 5 × 10(-8)), 56 of which were novel, accounting for 
approximately 2.7% of BMI variation (Locke, Kahali et al. 2015). However, using common variants to 
dissect the pathways governing energy homoeostasis is challenging as the effect size associated with 
variants is invariably small, and because variants are often in noncoding regions of the genome.  The 
largest GWAS signal for obesity has consistently come from an area upstream of the FTO gene; 
possession of two copies of the obesity associated allele increases mean BMI by 2.7kg/m2 (Frayling, 
Timpson et al. 2007).   
It has been shown that the characterisation of rare obesity-associated human variants can provide 
information about the molecular pathways controlling body weight. To date such approaches have 
provided important evidence for the role of the leptin-melanocortin pathway in energy homeostasis. 
The majority of these monogenic disorders result in hyperphagia, but there are a small number of 
genetic disorders, involving KSR2 and GNAS1 where obesity may also arise as a result of reduced 
energy expenditure (Chan, Heist et al. 2003, Pearce, Atanassova et al. 2013). 
 
1.1.3. Homeostatic regulation of body weight 
Obesity arises from the persistent imbalance between energy intake and energy expenditure which 
leads to weight gain. In humans, at thermoneutrality, approximately 70% of energy expenditure is 
accounted for by basal metabolic rate (the metabolic cost of processes such as the maintenance of 
transmembrane ion gradients and resting cardiopulmonary activity), with the thermic effect of food 
contributing ~10% and physical activity ~20%.  The dissection of the mechanisms underlying human 
energy expenditure therefore has the potential to reveal novel targets that could be exploited for 
weight loss. Additionally, homeostatic physiological mechanisms compensate for any reduction in 
energy intake.  For example, caloric restriction results in a reduction in total daily energy expenditure 
in overweight participants under free living conditions of up to 633 kcal/day with severe caloric 
restriction (890 kcal/day) (Redman, Heilbronn et al. 2009). The targeting of mechanisms that 
contribute to this adaptive response could provide a useful adjunct to dieting to improve the likelihood 
of successful long-term weight loss. Therefore, the focus of this thesis is on understanding the 




1.2.1. The discovery of leptin as a pivotal regulator of energy homeostasis 
The discovery of leptin in 1994 paved the way for the understanding of the molecular mechanisms 
involved in the regulation of energy balance (Zhang, Proenca et al. 1994). Leptin was discovered 
through the study of the severely obese ob/ob mouse, which occurred as a spontaneous mutation in 
an inbred strain of mice (Ingalls, Dickie et al. 1950).  These mice gained weight rapidly, and were 
distinguishable by 4-6 weeks from their wild type littermates, eventually weighing up to four times 
that of a normal mouse. They developed diabetes mellitus and were sterile.  Parabiosis experiments 
had demonstrated that ob/ob mice were deficient for a blood-borne factor, and it was initially 
hypothesised that this was cholecystokinin (CCK) (Pelleymounter, Cullen et al. 1995).  In 1994 
Friedman and colleagues used positional cloning to demonstrate that the ob gene and the CCK gene 
mapped to different chromosomes.  They then showed, using northern blot analysis, that the ob gene 
encodes an mRNA product found exclusively in adipose tissue. They named the ob gene product leptin 
(Zhang, Proenca et al. 1994). Experiments comparing the effects of saline vs leptin in ob/ob mice 
proved that leptin was a circulating factor that reversed the obesity of these mice (Halaas, Gajiwala et 
al.).  There was no effect administering leptin to obese db/db diabetic mice who were subsequently 
found to harbour mutations in the leptin receptor (Halaas, Gajiwala et al. 1995, Tartaglia, Dembski et 
al. 1995). Subsequent studies in rodents showed that in the arcuate nucleus of the hypothalamus, 
leptin stimulates the expression of pro-opiomelanocortin (POMC) (Schwartz, Seeley et al. 1997), and 
increases the activity of POMC neurons, resulting in the release of POMC peptides (α,β,γ melanocyte 
stimulating hormone (MSH), adrenocorticotrophic hormone (ACTH) and β-endorphin) (Schwartz, 
Seeley et al. 1997). Stimulation of the melanocortin-4 receptor by α-MSH in the paraventricular 
nucleus of the hypothalamus increases sympathetic nervous system (SNS) activity, and together with 
converging signals from multiple other pathways, signals the fed state (Fan, Boston et al. 1997).  
Leptin additionally acts as a potent signal to defend against starvation. The absence of leptin is a 
potent orexigen and results in reduction in energy expenditure. It also has an important role in 
coordinating the neuroendocrine response to starvation. Prevention of starvation-induced falls in 
leptin by exogenous administration blunts the gonadal, thyroid and adrenal axis changes in male mice, 
and prevents the starvation-induced delay in ovulation in female mice. Leptin administration did not 




The effects of leptin on hunger has also been explored in obese subjects, who had undergone a 10% 
reduction in body weight, who were treated with either subcutaneous leptin or placebo, showed 
leptin-reversible increases in neural activity in response to visual food cues in the brainstem, 
parahippocampal gyrus, inferior and middle frontal gyri, middle temporal gyrus, and lingual gyrus. 
There were also leptin-reversible decreases in activity in response to food cues in the hypothalamus, 
cingulate gyrus, and middle frontal gyrus (Rosenbaum, Sy et al. 2008).  This study illustrates that many 
of the neurobehavioral changes induced by caloric restriction are secondary to this partial leptin 
deficiency, and are reversed by restoration of plasma leptin levels.  
The first leptin-deficient humans were described by in 1997 (Montague, Farooqi et al. 1997).  These 
two children, who were first cousins from a highly consanguineous pedigree, were homozygous for a 
frameshift mutation in the LEP gene that led to undetectable leptin levels. They had a normal birth 
weight but developed severe early onset obesity, with marked hyperphagia and hyperinsulinaemia.  
They additionally had normal basal metabolic rate and total energy expenditure (after adjusting for 
age and body composition), hypothalamic hypothyroidism and hypogonadotrophic hypogonadism.  In 
subsequent studies, treatment with recombinant human leptin resulted in a reduction in hyperphagia 
and significant weight loss (Farooqi, Matarese et al. (2002).  
 
1.2.2. The role of leptin in the regulation of energy intake and energy expenditure 
Negative energy balance secondary to caloric restriction results in an acute reduction in circulating 
leptin levels, and thus a state of partial leptin deficiency (Chan, Heist et al. 2003). Studies in rodents 
and humans demonstrate that this fall in leptin drives the homeostatic response. Studies of obese 
subjects who had undergone a 10% reduction in body weight, who were treated with either 
subcutaneous leptin or placebo, have shed light on the homeostatic role of leptin. The weight-reduced 
state was associated with increased hunger and changes in neural activity in response to visual food 
cues in several brain regions. These phenotypes were reversed by the administration of leptin 
(Rosenbaum, Sy et al. 2008).  This study illustrated that many of the neurobehavioural changes 
induced by caloric restriction are secondary to partial leptin deficiency, and are reversed by 
restoration of plasma leptin levels.  
In studies conducted in congenital leptin deficiency, whilst unable to detect a significant difference in 
basal metabolic rate (using indirect calorimetry) or total energy expenditure (using the double-
labelled water method) compared to weight matched controls (Farooqi, Matarese et al. 2002), weight 
loss is usually associated with reductions in energy expenditure, and this is not seen in leptin-treated 
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individuals with leptin deficiency (Galgani, Greenway et al. 2010). Furthermore, leptin deficient 
humans have impaired sympathetic tone (Ozata, Ozdemir et al. 1999), consistent with defects in the 
efferent limb of thermogenesis. Additionally there is some evidence that leptin deficiency may alter 
thyroid function; in one study on the effects of recombinant human leptin administration on three 
children with congenital leptin deficiency, fT4 was significantly increased after two months of therapy 
and subsequently remained constant (Farooqi, Matarese et al. 2002). A second study looked at TSH 
pulsatility in a single homozygous leptin-deficient adult and found that it was highly disorganised when 
compared to healthy controls (Mantzoros, Ozata et al. 2001). In rodents, leptin stimulates fatty acid 
oxidation in skeletal muscle via the stimulation of AMP kinase activity (Minokoshi, Kim et al. 2002). In 
leptin-deficient adults, impaired fat oxidation has been measured by chamber calorimetry (Galgani, 
Greenway et al. 2010).  
Ob/ob mice develop obesity when pair-fed to their wild-type littermates, accumulating up to twice as 
much subcutaneous fat (Alonso and Maren 1955). Mature ob/ob mice are unable to maintain their 
body weight when exposed to cold, and will die if exposed to temperatures of 4oC (Davis and Mayer 
1954). Previous studies have suggested that this thermoregulatory defect is caused by inadequate 
thermogenesis, rather than a failure of heat conservation (Trayhurn, Thurlby et al. 1977). BAT is known 
to be activated by the sympathetic nervous system, with inputs from the dorsomedial hypothalamus, 
possibly via relay in the rostral raphe nucleus (Dib, Rompre et al. 1994). There is also evidence that 
the brown adipose tissue mass can expand in response to demand, and that there are “beige/brite” 
adipose tissue cells that are phenotypically distinct from both brown and white adipose tissue cells, 
can be induced to transform into brown adipose tissue (Young, Arch et al. 1984).  “Browning” of these 
cells is an adaptable and reversible process induced by cold and B3-agonism, and inhibited by 
thermoneutrality and high fat diets (Cousin, Cinti et al. 1992, Giralt and Villarroya 2013) . 
Brown adipose tissue has long been known to play a role in protection from hypothermia in neonates, 
but it has only been recently that a role for active brown tissue has been proposed in adults. The 
presence of BAT in adults was identified from the retrospective analysis of 3640 FDG-PET scans 
performed for other diagnostic purposes. Tissue, more than 4mm in diameter and of the same density 
as adipose tissue was seen and found to be highly metabolically active, with an uptake of FDG of at 
least 2g per millilitre. This tissue was located in the intrascapular, neck and supraclavicular regions.  
Tissue from this region had multiloculated, UCP-1 immunopositive adipocytes, indicating that this was 
brown adipose tissue (Cypess, Lehman et al. 2009).  
Furthermore, leptin stimulates CART expressing neurones and inhibits the action of neuropeptide Y-




Figure 1.  Mutations in the leptin-melanocortin pathway result in hyperphagia and severe obesity 
 
1.2.3. The homeostatic response to temperature change in humans 
Homeothermic animals (those that maintain a constant core body temperature) have the advantage 
of being able to survive in a wide variety of terrains.  However, this comes at a significant energy cost, 
and the efficient maintenance of core body temperature is therefore essential to survival. Brown 
adipose tissue defends ore body temperature, whilst minimising energy expenditure. Human brown 
fat mass can be expanded and this has beneficial metabolic consequences (Labbe, Mouchiroud et al. 
2016).   
Initial research into the homeostatic mechanisms involved in the maintenance of body temperature 
were performed with the aim of defining human physiology (Pembrey MS, 1904).  He defined that a 
normal core body temperature for humans can range from 36oC to 37.8oC, and noted that this did not 
change if the human lived in the tropics or the Artic. He also noted that “cold is a stimulant more 
powerful in its effect on metabolism than any drug”, noting an increase in CO2 output of 50-60% on 
cold exposure. 
In the 1960s the focus of research was on the ability of research and military workers to operate in 
extreme cold (Davis TR, 1961). They compared the effect of exposure to an air temperature of 11.8oC 
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for 8 hours per day for 31 days on 10 nude men in March to the effect of an air temperature of 13.5oC 
for 8 hours per day for 31 days in 6 nude men in September.  He noted by day 14 there was a significant 
decrease in shivering, and a decrease in heat production on the winter group but not the summer 
group. They did not find an effect on basal metabolic rate. Metabolism was estimated by measuring 
the amount of oxygen in the expired air, and the presence of shivering by surface electrodes.  
More recently interest has focussed on the possibility of using BAT activation as a tool for weight loss. 
The demonstration of cold-induced brown adipose tissue in adult men was first described in 2009 (Van 
Marken Lichtenbelt, NEJM 2009). They compared both lean and obese men when exposed to 
thermoneutral conditions and mild cold (16oC). They used (18)FDG-PET and indirect calorimetry to 
measure putative BAT activation and energy expenditure, respectively.  They showed that BAT activity 
was observed in 23/24 individuals, but that this effect was lower in obese subjects. 
 
1.2.4. Mechanisms of cold detection and physiological response 
Changes in environmental temperature are detected by thermoreceptors in the skin.  
Thermoneutrality is defined as the environmental temperature that keeps bodily temperature at an 
optimal point at which the least amount of oxygen is consumed by metabolism. In humans this is a 
temperature of 25oC, in mice it is 26-28 oC in adult mice weighing >25g.  
Afferent signals are detected by temperature sensitive neurons in the lateral preoptic area that feed 
into the median preoptic area. A coordinated response is then produced.  Glutaminergic signals 
relayed via the lateral parabrachial nucleus to the spinal intermediolateral nucleus control the 
innervation of brown adipose tissue (Hinuma, Habata et al. (1998). GABAergic signals to the 
dorsomedial hypothalamus control both homeostatic and pyretic prostaglandin E2-mediated changes 
in temperature, and in turn communicate with seratonergic neurons in the rostral raphe pallidus that 
also relay with the spinal intermediolateral nucleus.  This area additionally relays, via the thalamus, to 
the cerebral cortex to stimulate behavioural change in response to changes in environmental 
temperature.  
The complex coordinated metabolic response to cold has only been partially elucidated. Cold exposure 
has been shown to reduce leptin expression in rodents.  Mice exposed to 4oC for between 2-18h 
showed a reduction in ob gene expression in their white adipose tissue (Trayhurn, Thomas et al. 1995).  
There is also some published data that suggests a similar response in humans. Cold air exposure (6.3oC) 
in adult females for 30, 60 or 90 minutes resulted in a reduction in circulating leptin of 14%, 17% and 
22% respectively, with corresponding increases in norepinephrine levels (Ricci, Fried et al. 2000). The 
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relationship between cold-induced BAT activation and circulating leptin levels has been further 
explored in rodents; in lean Sprague Dawley rats hypothermia-induced increases in sympathetic 
nervous system drive to intrascapular BAT were significantly augmented by leptin (Hausberg, Morgan 
et al. 2002).  These data suggest a circuitry by which cold exposure results in a drop in circulating 
plasma leptin levels, resulting in an increased sympathetic drive and consequent BAT activation. 
 
1.2.5. Central pathways that mediate the effects of leptin on thermogenesis 
As leptin appears to play a role in the coordinated response to cold, it is important to consider the 
mechanisms by which it may be acting. Central leptin-melanocortin signalling has a direct effect on 
sympathetic tone, and has been implicated as the link between fat mass and blood pressure in mice 
(Hall, Ferrario et al. 1997) and due to the observations that obese subjects with defects in these 
signalling pathways have much lower than expected levels of hypertension, lower systolic blood 
pressures and evidence of impaired sympathetic tone (Greenfield, NEJM, 2009). The neurocircuitry 
responsible for these observations were dissected by Simonds and colleagues (Simonds, Pryor et al. 
2014), who demonstrated that C57BL/6J mice fed a high fat diet (43% fat) had a significantly increased 
heart rate by 4 weeks, and blood pressure by 12 weeks of feeding, when compared to chow-fed 
littermates (4.3% fat), which paralleled the increase in circulating leptin concentrations seen with 
their weight gain. Comparison of this phenotype to obese mice lacking leptin (ob/ob) or the leptin 
receptor (db/db) showed that only mice with DIO developed the increases in HR and BP, and showed 
that obesity alone was not enough to drive this change.  Treatment of ob/ob mice with leptin (30ug 
per day via osmotic mini-pump) resulted in decreased food intake and body weight, but despite this 
increases in HR, sBP and to a lesser extent dBP were seen. Peripheral administration of a leptin 
antibody or central administration of a leptin receptor antagonist significantly reduced heart rate, 
systolic and diastolic blood pressure in mice with DIO, compared to those treated with vehicle alone. 
To locate the precise site of action, both leptin receptor antagonist and AAV-expressing short hairpin 
RNA directed against the leptin receptor via a catheter into the DMH, resulting in a decrease in sBP 
within 7 days and 4 weeks, respectively. Selective LepR deletion in the DMH also reduced systolic BP. 
Reactivation of LepR here rapidly increased both sBP and HR. Measurement of BP in the fasted, rested 
state in 8 children with homozygous loss of function mutations in the leptin gene (with undetectable 
levels of circulating leptin) showed a significantly lower systolic BP (but no difference in dBP) when 
compared to 42 age- and BMI-matched controls, whose circulating leptin levels were appropriate for 
their degree of adiposity.  
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The role of leptin in activating the sympathetic nervous system has consequences for energy 
expenditure and non-shivering thermogenesis. The leptin receptor expressing population in the 
dorsomedial hypothalamus increases sympathetic outflow to brown adipose tissue. A DREADD 
system designed to selectively activate DMH LepRb receptors also stimulated BAT thermogenesis, 
and the increased energy expenditure was partially blocked by the administration of a B3 antagonist.  
Use of a virally driven cre-recombinase to selectively delete the LepRb in the DMH resulted in acute 
impairment of the thermoregulatory response and an overall impairment of energy expenditure 
(Rezai-Zadeh, Yu et al. 2014). The downstream targets of these leptin effects are therefore of interest 
as they have the potential for pharmacological manipulation.    
Prolactin releasing peptide (PrRP) is an endogenous ligand for G protein-coupled receptor 10 (GPR10), 
a G protein coupled receptor (GPCR) expressed in brain areas involved in energy homeostasis and 
subsequently shown to play a role in mediating the thermogenic effects of leptin (Dodd, Worth et al. 
2014). Prolactin releasing peptide is a member of the RFamide family, a group of neuropeptides 
defined by their carboxy terminal arginine (R) and aminidated phenylalanine (F) residues (hence 
RFamides) (Osugi, Ukena et al. 2006). These highly evolutionarily-conserved peptides (PrRP, 
kisspeptin, QFRP, LPXRFa and Neuropeptide FF (NPFF)) are involved in a wide range of biological 
functions, from muscle contraction to neuroendocrine function. A role in eating behaviour was 
proposed when FMRFamide was shown to be anorexigenic in mice (Kavaliers and Hirst 1985).  Several 
members of the RFamide family have been shown to play a role in energy homeostasis; centrally 
administered NPFF and PrRP reduce food intake (Sunter, Hewson et al. 2001, Bechtold and Luckman 





Figure 2. Unrooted phylogenetic tree of the identified and the putative RFamide peptides in 
mammals and other vertebrates. (Bechtold and Luckman 2007) 
PrRP is a promiscuous ligand, binding with high affinity to both GPR10 and neuropeptide FF receptor 
2 (NPFFR2) (KD 0.4nM and 5.9nM, respectively (Gu, Geddes et al. 2004)), but experiments indicate 
that its central effects are mediated through GPR10, as PrRP does not bind to cell membranes 
extracted from the brains of GPR10 null mice (Gu, Geddes et al. 2004).  Furthermore, PrRP does not 
reduce food intake or increase energy expenditure in GPR10 -/- mice (Bechtold and Luckman 2006), 
indicating that these effects are not mediated via signalling through an alternative receptor.  
Several studies have demonstrated that GPR10-mediated signalling plays a role in energy 
homeostasis.  Both receptor and ligand are highly expressed in the dorsomedial and paraventricular 
nuclei of the hypothalamus, the brainstem, ventrolateral medulla and nucleus of the tractus solitarius 
(NTS) (Maruyama, Matsumoto et al. 1999).  Colocalisation studies have shown that in the brainstem, 
PrRP-containing neurons colocalise with tyrosine hydroxylase, the rate-limiting enzyme for 
catecholamine biosynthesis, indicating that these likely relate to the A1 (VLM) and A2 (NTS) 
noradrenergic cell populations (Ellacott, Lawrence et al. 2002).  Double immunohistochemistry has 
shown that PrRP colocalises with the leptin receptor in the dorsomedial hypothalamus, suggesting 
that it may mediate its effects at this site. Expression of PrRP mRNA is highly sensitive to feeding status 
as rats fasted for 48 hours showed reductions of PrRP mRNA of 32% in the DMH, 34% in the NTS and 
55% in the ventrolateral medulla (Ellacott, Lawrence et al. 2002).  Furthermore, PrRP mRNA is reduced 
by other states of negative energy balance, such as lactation (Lawrence, Celsi et al. 2000).  Central 
administration of PrRP leads to reduced post-fast refeeding and increases core body temperature 
(Lawrence, Celsi et al. 2000). This effect is seen in both fasted and ad libitum fed rats, and the observed 
effect is not altered by the timing of injection (light vs dark phase).  Central injection of PrRP-31 
(4nmol) also resulted in an increase in VO2 and induced UCP-1 expression in brown adipose tissue in 
rats, before any effects are seen on body weight (Lawrence, Celsi et al. 2000, Lawrence, Liu et al. 2004).   
 
1.2.7. Disruption of PrRP/GPR10 signalling results in late-onset obesity in mice 
PrRP null mice generated on a C57BL/6 background fed ad libitum with standard chow (13% fat) 
develop late onset obesity, with female mice gaining weight earlier than male (females significantly 
heavier by 14 weeks, males by 22 weeks, (Mochiduki, Takeda et al. 2010)).  This weight gain was largely 
due to increased white adipose tissue, although increases in brown adipose tissue were also seen 
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(Takayanagi, Matsumoto et al. 2008, Mochiduki, Takeda et al. 2010). A similar picture was seen in the 
GPR10 -/- mice generated on a C57BL/6 background (Gu, Geddes et al. 2004).   
Cumulative food intake was increased in the PrRP knockout mice, but this was only significant from 
the age of 18 weeks, and this was secondary to increased meal size and not meal frequency (measured 
by minute-by-minute recordings of food intake by an automated food counter) (Takayanagi, 
Matsumoto et al. 2008).  Food intake in the GPR10 knockout mice was also increased, with null animals 
consuming 22% more per week than their wild-type littermates (Gu, Geddes et al. 2004).  Knockouts 
were also more susceptible to a high fat diet (30% fat): PrRP -/- mice gained significantly more weight 
than their wild type littermates within 2 weeks on this diet. Mice show increased leptin in keeping 
with their increased WAT mass.  Both hepatic and plasma triglyceride levels were increased (20% 
higher than WT mice), as were insulin (increased 350%), and glucose levels in a glucose tolerance test 
(Takayanagi, Matsumoto et al. 2008). Similar results were seen in the GPR10 -/- mouse (Gu, Geddes 
et al. 2004).  
Experiments in pair-fed animals treated with PrRP indicate that PrRP plays a role in energy expenditure 
as well as food intake.  Animals treated with PrRP have a reduction in weight gain of 42%, compared 
to 30% for pair fed littermates (Lawrence, Celsi et al. 2000).  However, pair-feeding experiments in 12 
week old single-housed male PrRP-null mice do not show a difference in body weight gain in either 
chow of high fat diet-fed mice (Takayanagi, Matsumoto et al. 2008).  No change in locomotor activity 
is seen in the PrRP knockout mice (Takayanagi, Matsumoto et al. 2008).  This group also reported no 
change in energy expenditure as measured by indirect cage calorimetry in 11 week old wild-type, null 
and knockdown animals (following icv injection of an anti-PrRP monoclonal antibody).  Bjurstell 
(Bjursell, Lenneras et al. 2007) found a reduction in energy expenditure in female 21 week old GPR10 
null mice, compared to wild-type littermates, but the difference did not reach significance in the male 
mice.  Dodd (Dodd, Worth et al. 2014) showed 10-11 week old PrRP null mice had a lower VO2 than 
wild-type littermates. These data support a possible role for both increased food intake and reduced 
energy expenditure in the obesity observed in mice with disrupted GPR10-mediated signalling.   
 
1.2.8. PrRP/GPR10 expressing neurons modulate energy homeostasis in response to 
peripheral hormones 
Cholecystokinin is released from the enteroendocrine cells (I cells) in the duodenum in response to 
food ingestion, particularly of lipids. CCK has local effects on the gut, inhibiting gastric emptying, 
decreasing gastric acid secretion, and stimulating the acinar cells of the pancreas to release pancreatic 
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enzymes. It also increases the production of bile, and stimulates gall bladder contraction, and 
relaxation of the sphincter of Oddi.  Central effects of CCK are largely mediated via the vagal nerve 
and direct action on central CCK receptors distributed widely throughout the CNS, including in the 
brainstem.  Administration of CCK reduces meal size and increases energy expenditure via stimulation 
of BAT via the CCK-1R (King, Yang et al. 2015). Mice deficient in CCK are resistant to high fat diet-
induced obesity (HFD for 10 weeks) and have increased energy expenditure (King, Yang et al. 2015 
2010).  
Centrally administered PrRP (4nmol, icv) reduced the latency period in the rodent behavioural satiety 
sequence in Sprague Dawley rats, suggesting that it may be a satiety factor.  Male rats treated ip with 
CCK show c-fos activation of PrRP-containing neurons in the VLM and NTS of the brainstem (Lawrence, 
Ellacott et al. 2002).  GPR10 -/- mice fail to reduce food intake when treated with CCK, in contrast to 
wild type mice (Bechtold and Luckman 2006).  Further work by the same group has used targeted 
deletion and rescue experiments in mice to show that the PrRP neurons in the brainstem are required 
for the satiating effects of CCK, likely acting via vagal afferents on these centres (Dodd, Worth et al. 
2014).   
PrRP is also expressed at high levels in a small subregion posterior to the compact zone of the 
dorsomedial nucleus of the hypothalamus.  100% of PrRP-expressing neurons here also express the 
signalling form of the leptin receptor (LepRb) (Dodd, Worth et al. 2014), whereas the PrRP-positive 
neurons only account for 10% of the LepRb neurons here (Ellacott, Lawrence et al. 2002).  PrRP 
expression in the NTS and DMH (but not the VLM) is responsive to energy status (Dodd, Worth et al. 
2014).  Administration of PrRP and leptin led to 24% and 18% reduction in food intake respectively, 
with resultant reductions in body weight gain of 56% and 55%.  Coadministration of leptin and PrRP 
resulted in a 54% reduction in food intake, resulting in a net loss in body weight (Ellacott, Lawrence et 
al. 2002).   
Administration of the same doses of leptin and PrRP resulted in increases in core body temperature 
when given singly, icv, to adult male Sprague Dawley rats.  Again an additive effect was seen when 
they were given in combination (Ellacott, Lawrence et al. 2002). Takayanagi (Takayanagi, Matsumoto 
et al. 2008) investigated the effects of both ip (2.5mg/kg body weight) and icv (0.2ug) leptin in PrRP 
null mice, when compared to wild type littermates in male 16 week old and 18-19 week old mice, 
respectively.  They found that both methods of administration resulted in pSTAT3 expression in PrRP-
expressing neurons in the NTS and DMN of the hypothalamus.  Wild-type littermates showed 
significant reductions in both food intake and body weight with both the centrally and peripherally 
administered leptin, whereas in the null mice this effect was attenuated. Interestingly, blockade of the 
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melanocortin 3/4 receptors with a centrally administered antagonist (SHU-9119, 0.1nmol icv) did not 
blunt the effects of centrally administered PrRP-31 (Lawrence, Liu et al. 2004). Collectively, these data 
point to a role for PrRP-expressing neurons in leptin-mediated anorexia, but indicate that these effects 
may not be mediated via classical melanocortin signalling.   
 
1.2.9. The thermogenic effects of leptin are mediated by the DMH population of PrRP 
neurons 
Dodd (Dodd, Worth et al. 2014) defined a population of PrRP expressing cells in the DMH that were 
activated by leptin. Transgenic mice created using the lox-STOP-lox method to globally delete PrRP 
were significantly heavier than wild type littermates from 18 weeks.  A similar phenotype was achieved 
by a brain-specific knockout of PrRP.  Both failed to increase core body temperature or induce BAT 
UCP-1 in response to intraperitoneal leptin.  They additionally did not reduce their food intake in 
response to leptin or CCK.   
Selective rescue of PrRP in TH-positive cells in the NTS and VLM of the brainstem rescued the obese 
phenotype, the satiating effects of CCK, and reduced hyperphagia, but did not rescue leptin’s effects 
on energy intake or thermogenesis.  It can therefore be concluded that the PrRP cell populations in 
the brainstem are necessary for the satiating effects of CCK, and do not mediate the PrRP-dependent 
effects of leptin. Growth curves for GPR10 +/- mice are identical to the wild-type (Gu, Geddes et al. 
2004), as are those for PrRP +/- mice, both on standard chow, and a high fat diet (Takayanagi, 
Matsumoto et al. 2008).   
1.3.1. GPR10 signalling is involved in other physiological processes 
GPR10 signalling plays a role in several other physiological systems including the stress response and 
blood pressure regulation. OLETF rats, which lack functional GPR10, display a less anxious phenotype 
when tested using different rodent behavioural models. They visit a novel, aversively-lit area more 
frequently than controls in the open field test, they spend longer in the open arms of the elevated 
plus maze test and they spend more time in the open (rather than the more secure tube) in the 
defensive withdrawal test (Watanabe, Okuno et al. 2007). A similar trend was explored in GPR10 null 
mice, but it did not reach statistical significance (Laurent, Becker et al. 2005).  
Baroreceptors in the great vessels, activated by hypotension, transmit signals to the NTS of the 
brainstem, prompting a homeostatic neuroendocrine response.  PrRP-expressing neurons in the 
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brainstem became c-fos immunopositive within two hours of hypotensive haemorrhage, as do 
vasopressin and CRH neurones in the PVN.  Retrograde tracer studies indicate that PrRP-containing 
neurones deliver the signal from the brainstem to the cells in the paraventricular nucleus (Uchida, 
Kobayashi et al. 2010).  Bacterial lipopolysaccharide reduces feeding through activation of the 
hypothalamo-pituitary-adrenal (HPA) axis. Administration of LPS (125-500ug, ip) in conjunction with 
PrRP (4nmol, icv) reduced feeding in a dose-dependent manner, and caused a dramatic rise in plasma 
corticosterone 90 minutes after injection. However, there was no significant difference in the 
response between wild-type and GPR10 null mice.   
In support of a role of GPR10-PrRP signalling in regulating the HPA axis, Laurent (Laurent, Becker et al. 
2005) found that GPR10 null mice had lower circulating corticosterone levels, and a blunted 
corticosterone response to hypoglycaemic stress.  However, Mochiduki (Mochiduki, Takeda et al. 
2010) demonstrated that PrRP knockout mice (C57BL/6 background) exposed to 1 hour of restraint 
stress using a wire mesh had an increase in plasma corticosterone compared to wild-type littermates.  
Plasma ACTH levels were unchanged, as was c-fos expression in the paraventricular hypothalamus.  
There are therefore mixed data on the role of GPR10-PrRP signalling on the modulation of the HPA 
axis.   
Icv PrRP raises blood pressure and heart rate, with readings peaking 5 minutes after central 
administration.  Yamada (Yamada, Mochiduki et al. 2009) further investigated the role of these 
neuroendocrine neurones (vasopressin and CRH) in executing the effects of PrRP.  They found that 
while V1-R antagonists administered before PrRP did not attenuate the effects of PrRP (4nmol, icv), 
the effects of PrRP on MAP and heart rate were significantly reduced by pre-treatment with α-helical 
CRH, a CRH receptor antagonist (Yamada, Mochiduki et al. 2009).  Coadministration of PrRP with the 
central CRH receptor antagonist astressin (7.5 mg/kg or 20ug icv) significantly reduces PrRP-induced 
anorexia in 18 week old male C57BL/6J mice (Lawrence, Liu et al. 2004, Bechtold and Luckman 2006). 
There are also effects on pain sensation and sleep. 
Both isoforms of PrRP (PrRP-20 and PrRP-31 at concentrations of 0.4nmol or 4nmol) were found to 
increase mean arterial pressure (external carotid artery pressure measured by an external pressure 
transducer attached to an implanted indwelling catheter) in conscious, unrestrained adult male 
Sprague Dawley rats when administered icv.  Results were comparable to 0.1nmol (a pressor dose) of 
angiotensin II (Samson, Resch et al. 2000).   
 
1.3.1 Evidence for the role of GPR10 signalling in human energy homeostasis 
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Previously, using a candidate gene approach to sequence 94 patients with severe, early-onset obesity 
from the Genetics of Obesity (GOOS) cohort, a common polymorphism in GPR10, P305L, was 
described, which was shown to result in a partial loss of function. Genotyping this variant in 1084 
participants from the Ely study found that whilst there was no significant association with obesity, 
subjects possessing the variant had on average a 5mmHg reduction in both systolic and diastolic blood 
pressure.  
 
To date, the variants in this project are the first rare human obesity-associated variants in GPR10 to 




1.3. Hypotheses and aims 
 
1.3.1. Hypotheses 
1. Novel and rare human mutations in GPR10 result in a loss of function and contribute to the 
subject’s obesity. 
2. Cooling in humans results in a coordinated metabolic response, some of which is leptin 




1. To functionally characterise human mutations in GPR10 identified in a severely obese cohort. 
2. To examine the effects of mild cooling on healthy, normal weight adult males and to 




























2.1 Functional characterisation of human mutations in GPR10 
Mutations identified from the whole exome and targeted resequencing of a population of subjects 
with severe early onset obesity were taken forwards for functional characterisation. Constructs were 
created using site-directed mutagenesis and placed in a plasmid vector. These were transfected into 
cell lines for further study as described below. The cell surface expression, ligand binding and signalling 
of ach of the receptors was assessed. As the mutations are found in heterozygous form, and 
heterozygous-knockout mice are not known to be obese, the possibility of a dominant-negative effect 
was explored. 
 
2.1.1. Identification of mutations in GPR10 
The whole exome sequencing of 737 Caucasian patients with severe, early onset obesity, and 
subsequent targeted resequencing of 1,811 patients was performed in collaboration with Dr Ines 
Barroso at the Wellcome Trust Sanger Institute, as previously described (Hendricks, Bochukova et al. 
2017). 
 
2.1.2. Creation of Constructs 
Mutant receptors were constructed using mutant primers (Sigma Aldrich) and the Quikchange II XL 
site directed mutagenesis kit (Agilent) as per kit instructions. The engineered cDNAs were cloned into 
the eukaryotic expression vector pCMV-Tag2B (Stratagene) encoding N-terminal FLAG tag. All 
constructs were verified by DNA sequencing. 
 
2.1.3. Cell culture and transfection  
Cos-7 and HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies) 
supplemented with 10% fetal bovine serum (Thermo Fischer), 2mM L-glutamine (Sigma Aldrich) and 
penicillin and streptomycin antibiotics (Sigma Aldrich).  Cells were removed by trypsinisation or 
incubation with 10mmol EDTA, and counted with a haemocytometer before seeding into 96 well 
plates previously coated in poly-D-lysin (Sigma Aldrich).  Transfection was performed using 
Lipofectamine 2000 (Invitrogen) in Optimem medium (Life Technologies).  Transfection was stopped 
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the next day by substituting Optimem medium for DMEM, and were grown for 24 h before further 
experiments were performed.   
 
2.1.4. Enzyme-linked Immunosorbent Assay (ELISA) 
Cos-7 cells were seeded in poly-D-Lysin coated 96 well plates at a density of 20,000 cells per well and 
were transfected the next day with 5ng FLAG-tagged receptor DNA/well as described above.  
Following incubation, cells were placed on ice and washed twice with ice-cold PBS containing 
magnesium and calcium (Sigma Aldrich).  Cells were blocked for 30 minutes with 3% dry milk blocking 
buffer containing 5% 50mM Tris pH 7.4 in phosphate buffered saline (PBS, Sigma Aldrich) on ice.  
Blocking buffer was substituted for primary antibody (anti-FLAG M2, Sigma Aldrich), diluted 1:1000 in 
blocking buffer for 2h on ice.  Cells were washed twice with ice-cold PBS containing calcium and 
magnesium on ice for 10 minutes, and were then fixed with 3.7% formaldehyde for 10 minutes on ice 
and then 10 minutes at room temperature.  Cells were washed 4 times using a plate washer 
(AquaMax), using standard PBS.  Cells were again blocked with blocking buffer for 30 minutes at room 
temperature with gentle shaking at 300rpm.  Cells were treated with secondary antibody (Goat anti-
mouse with conjugated horse-radish peroxidase, BioRad), diluted 1:1250 in 1.5% dry milk buffer and 
incubated for 1h at RTP with shaking at 300rpm.  Cells were washed 4 times using the plate washer.  
The ELISA was developed by adding 100ul per well of Quanta Blu Fluorogenic Peroxidase substrate 
(Thermo Scientific) for 20 minutes with shaking at 350rpm, before the reaction was stopped as per kit 
instructions.  150ul of solution was transferred to a black 96 well plate and fluorescence measured.  
Results were analysed using GraphPad Prism 6.0. 
 
2.1.5. Confocal microscopy visualisation of fluorescently-tagged constructs 
150,000 HEK293 cells were seeded onto sterile 19mm glass coverslips in 12 well plates and were 
coated in poly-D-lysin.  24 hours later cells were transfected with 300ng/well of receptor DNA using 
lipofectamine 2000.  Transfection was stopped after 5 hours by substitution of lipofectamine-DNA 
media with HEK media (high glucose DMEM supplemented as described), and cells were incubated 
overnight (37oC, 5% CO2).  Cells were washed in PBS and fixed for 10 minutes with 4% formaldehyde 
in PBS.  Cells were washed twice before application of 100ul Alexa 647-tagged wheat germ agglutinin 
(Life Technologies) diluted in HBSS (Sigma Aldrich) to 10ul/ml for 10 minutes.  Cells were washed 3 
times with HBSS, before permeabilisation for 5 minutes with 0.1% Triton-x100 (Sigma Aldrich).  Cells 
43 
 
were washed twice for 5 minutes with PBS.  Non-specific binding was blocked by incubation with 3% 
BSA (Sigma Aldrich, diluted in PBS) for 1 hour.  150ul of anti-FLAG-M2 antibody (Sigma Aldrich), diluted 
1:100 in blocking buffer, was added and cells incubated for 1 hour.  Cells were washed three times 
with PBS.  1ml of DAPI (Invitrogen), diluted 1:1000 in PBS was added and incubated for 10 minutes.  
Cells were washed again twice with PBS.  150ul of Alexa 488 anti-mouse antibody (Life Technologies) 
was added dropwise to the coverslips, diluted 1:200 in PBS, and incubated for 1h in the dark.  Cells 
were washed 3 times, before mounting onto cells using DAPI-containing mounting medium 
(Vectashield H-1200, Vector), and sealing with clear nail varnish.  Cells were visualised using the Leica 
SP8 confocal microscope. 
 
2.1.6. Inositol Monophosphate Accumulation Assay 
COS-7 cells were seeded at a density of 20,000 cells per well as described.  Cells were transfected with 
5ul/well of DNA using lipofectamine 2000. Transfection was stopped the next morning by substituting 
optimem medium with 100ul/well of low glucose DMEM, supplemented with Myo-[2-3H]-inositol 
(5ul/ml, Perkin-Elmer) and cells were cultured overnight.  The next morning cells were washed with 
200ul plain HBSS, and then 100ul HBSS containing 10mM LiCl was dispensed per well.  Cells were 
stimulated with 5ul/well of ligand (PrRP-31, Bachem, concentration 1x10-6 – 1x10-12, or diluent alone), 
and incubated for 1 hour at 37oC, 5% CO2.  Cells were then placed on ice and assay buffer substituted 
with 50ul/well ice cold 10mM formic acid, for at least 1 hour.  20ul of cell lysate was transferred to a 
white 96-well plate containing polylysine YSi SPA bead suspension (Perkin Elmer).  Plates were sealed 
with Topseal (Perkin Elmer), and manually shaken for 10-15 seconds.  Radioactivity was counted using 
a microplate scintillation counter (Topcount) after an 8h delay to stabilise the signal.  Remaining lysate 
in the assay plate was frozen at -20oC, in case reanalysis was desired.  Results were analysed using 
GraphPad Prism 6.0. 
 
2.1.7. Generation of stably transfected cell line 
pCMV-Tag2B plasmid, resistant to kanamycin and neomycin antibiotics, and containing wild type 
GPR10 DNA  was transiently transfected into HEK293 cells in T75 flasks (10ug/flask) using 
lipofectamine 2000 (1.5ml optimem medium supplemented with 30ul lipofectamine). The following 
day, plain high glucose DMEM medium was substituted for that supplemented with genectacin 
44 
 
(G418). Killing curve experiments were first done to identify the optimal dose of genectacin, for 
selection of stably transfected cells; a dose of 250ug/ml was chosen.  
Pooled clones of stably transfected cells were grown in T75 flasks, in standard high glucose DMEM 
medium supplemented with 250ug/ml genectacin. Cells were harvested by trypsinisation as 
previously described, and seeded in white 96-well plates at a density of 20,000 cells per well for the 
cAMP accumulation assay. 
 
2.1.8. cAMP accumulation assay 
Measurement of ligand-induced cAMP generation in HEK 293 cells stably transfected with GPR10 wild 
type construct (one day after transfection) was done using HitHunter cAMP assay (DiscoverX, 90-
0075SM) according to manufacturer’s protocol with modifications. Cells were washed with PBS and 
incubated in 30 μL PBS supplemented with 0.5 mM 3isobutyl-1-methylxanthine (IBMX, Cayman 
Chemical, 13347) for 30 min prior to stimulation with agonist. Cells were stimulated with forskolin 
(20mM) and serial dilutions of agonist (1.5 μL/well, 20x dilution) for further 30 min at 37°C. 
Intracellular cAMP detection was carried out directly after the ligand stimulation. 10 μL anti-cAMP 
antibody followed by 40 μL chemiluminescent substrate/lysis buffer/enzyme donor-cAMP complex 
mix prepared according to manufacturer’s protocol were added and plates were incubated shaking 
for 1 hour at ambient temperature. Finally, 40 μL enzyme acceptor was dispensed and 
chemiluminescent signal was quantified after 4-5 hours in a TopCount Microplate Scintillation Counter 
(Packard). 
 
2.1.9. Radioligand Binding Assay 
COS-7 cells were seeded in plain white 96-well plates at a density of 20,000 cells per well and 
transfected with 5ul/well receptor DNA.  The next day transfection was stopped by substituting the 
lipofectamine-DNA complex solution with fresh COS-7 media (low glucose DMEM supplemented as 
previously described).  After overnight incubation (37oC, 5% CO2) the cells were washed with 200ul 
assay buffer (20mM HEPES buffer pH7.4 containing 119mM NaCl, 4.7mM KCl, 5mM MgCl2, 5.5mM 
glucose, 1mg/ml BSA) and placed on wet ice.  5ul/well cold ligand was dispensed (1x10-6 – 1x10-12 
concentrations used), swiftly followed by 50ul of “hot” ligand solution (5ul/ml of 125I-PrRP-31 diluted 
in binding buffer, Perkin Elmer) and plates were stored at 4oC for 5h.  Plates were washed with 
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200ul/well buffer solution twice.  25ul/well 0.1M NaOH was dispensed and cells were shaken at 
1000rpm for 2 minutes.  100ul/well scintillant (Microscint TM-20, Perkin Elmer) was added, plates 
were sealed (Topseal, Perkin Elmer), and again shaken x1000rpm for 5 minutes.  Radioactivity was 
counted using a microplate scintillation counter (Topcount) after a 3h delay to stabilise the signal.  
Results were analysed using GraphPad Prism 6.0.   
 
2.1.10. Dominant Negative Experiments 
Cos-7 cells were seeded in poly-D-Lysin coated 96 well plates at a density of 20,000 cells per well and 
were transfected the next day with 2.5ng/well of wild-type receptor DNA, plus mutant DNA.  The 
following ratios of WT:MT DNA were explored: 1:3, 1:2, 1:1, 1:0.5, 1:0.2.  Transfection with additional 
empty pCMV DNA was performed to keep the total concentration of DNA across experiments 
constant.  Lipofectamine 2000 was used for all transfections.  Inositol monophosphate accumulation 
was measured as previously described.   
 
2.2. C. elegans strains and growing conditions 
Worm strains were maintained at 20oC on nematode growth medium (Langmead, Szekeres et al.) 
plates seeded with E. Coli OP-50. The N2 strain, wildtype control, and npr-6 (tm1497) mutant worms 
were carefully synchronised from time of egg laying to ensure uniformity of stage (in collaboration 
with Dr Birgitta Olofsson). They were individually picked and mounted on a 2% agarose patch using 
M-9 C. elegans buffer. Sodium azide was used to anaesthetise and immobilise the worms. Three 
worms of each genotype were mounted on slides alternately to ensure accurate synchronisation. L4 
larvae and young adults were imaged and analysed independently. 
 
2.2.1. CARS microscopy set up 
Lipid was visualised using coherent anti-Stokes Raman scattering (CARS) microscopy in conjunction 
with the Dr Lorraine Berry and Dr Stefanie Reichelt at the Light Microscopy Core Facility at Cancer 
Research UK, Cambridge Biomedical Campus.   
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A ti:sapphire laser and an optical parametric oscillator (OPO) laser were synchronized to each other 
through an electronic module controller. The two parallel-polarized laser beams, pump and Stokes, 
were collinearly combined and sent into a laser scanning confocal microscope. Pump and Stokes lasers 
were tuned to 836 nm and 1104 nm, respectively, to be in resonance with the CH2 symmetric stretch 
vibration at 2845 cm−1. The combined beams were focused into the sample through a 40x water 
immersion microscope objective with a 1.0 numerical aperture. Forward-detected CARS signal was 
collected by an air condenser with a 0.55 numerical aperture, transmitted through a 675/67 nm 
bandpass filter, and detected by a photomultiplier tube. Simultaneously, back-reflected TPEF signal 
was collected by the same illuminating objective, spectrally separated from the excitation source, 
transmitted through a 525/50 nm bandpass filter, and detected by a photomultiplier tube mounted 
at the back port of the microscope. To obtain Raman spectra of lipid droplets, the Stokes beam was 
blocked and the pump-laser induced Raman scattering signal was directed toward a spectrometer to 
permit spectral analysis from 642 cm−1 to 709cm−1, which covers the CH-stretch vibration regions. The 
combined Stokes and pump laser power was kept constantly at 40 mW. For all Raman spectral 
measurements, pump laser power was reduced to 10 mW. 
 
2.2.2. CARS imaging conditions and data analysis 
To evaluate the levels of lipids and auto-fluorescent bodies, a probe volume with dimensions of 102 
µm×102 µm was defined covering the intestinal cells most proximal to the worm pharynx of wild type 
or mutant worms. Simultaneous depth imaging with CARS and TPEF along the vertical (z) axis was 
performed at 1 µm step size. Total CARS and TPEF signal arising from worms were integrated over the 
frames and divided by the worm volumes to obtain average pixel intensity values. Thus, the average 
pixel intensity values were not affected by size variability among worms. Background CARS and TPEF 
signal were defined as those arising from the worm bodies devoid of lipid droplets or auto-fluorescent 
granules. Background CARS and TPEF pixel intensity were subtracted from the average pixel intensity 
of CARS and TPEF signal to obtain CARS signal for fat stores and TPEF signal for auto-fluorescent 
granules, respectively.  
ImageJ software was used for particle analysis; all the droplets in the field of view were measured, 
and this total was divided by the number of droplets counted. To measure average lipid droplet 
density (the number of droplets per defined area), a defined area proximal to the pharynx was chosen 
with a diameter of 15,000 pixels. The total number of droplets in this area was then counted. The 
average of two separate comparisons was made.  
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2.3. Cooling study 
Lean, healthy men were recruited to the cooling study. Consent was taken along with baseline bloods 
at the screening visit. They all attended for two overnight visits which were identical with the 
exception of the temperature intervention. Core body and skin temperature was measured, together 
with energy expenditure, changes in hunger, fat preference and neurocognition. Bloods were taken 
and analysed as described. 
2.3.1. Cooling study protocol 
All studies were approved by the Cambridge Local Research Ethics Committee (17/EE/0069) and 
undertaken with informed consent. Lean individuals were recruited from the local population by 
advertisement. Exclusion criteria were use of any medication, any medical or psychiatric disease, shift 
work, regular cold exposure (for instance, cold water swimming), excessive caffeine use and smoking.  
Screening visits were conducted at 9am on the Wellcome Trust Translational Research Facility after 
an overnight fast. An ACE-III questionnaire was performed, to screen for pre-existing cognitive 
impairment; a score <88 was used as a cut off for study exclusion. A fasting blood screen was taken; 
any significant abnormality resulted in study exclusion. Subjects were familiarised with the unit and 
the equipment used, including the Gas Exchange Monitor (GEM) and the cooling suit. 
A fat preference test was then administered, as described in our previous paper (van der Klaauw, 
Keogh et al. 2016). Briefly,  we developed a three choice, ad libitum meal paradigm (Quorn Korma and 
Rice) in which fat content was covertly manipulated (by adding rapeseed oil) to provide 20 (low), 40 
(medium) and 60% (high) of the total caloric content, without altering appearance, texture or taste. 
Participants were initially provided with ‘tasters’ (15 g) of the three meals and liking/disliking ratings 
obtained using VAS before meal consumption. We then provided large dishes containing the 
low/medium/high fat quorn korma curry and rice (finely chopped and mixed to prevent selection of 
specific components) in excess (10 MJ; ∼2,390 kcal). Participants were encouraged to try the three 
dishes without explicitly stating that the three meals were different and instructed to eat until they 
were comfortably full. The amount consumed was covertly weighed. After the meal, liking ratings 
were measured as before. 
If participants met eligibility criteria, they were invited to attend the Wellcome Trust Translational 
Research Facility for two study visits, spaced two weeks apart. The study visits were identical, with the 
exception of the temperature intervention (thermoneutral visit (visit A), temperature 25oC; cooling 
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study visit (visit B), temperature 16oC). The order of the visits was randomised, and participants were 
not informed of the study order before the temperature intervention. 
Participants arrived at 3pm on the first study visit day. Two actiheart heart rate monitors (Camntech) 
were fitted. Participants were given a fixed amount of water, and a fixed evening meal and snack. 
Consumption of food and drink not directly administered by the study team was prohibited.  
Participants were woken at 0700h the next morning, and a set of observations were taken. Subjects 
were asked to pass urine and dress in standardised light clothing. Digital skin temperature monitors 
(iButtons, Maxim Integrated), set up in accordance with the manufacturer’s instructions, and was 
taped bilaterally to the patient’s skin in seven locations (forearm, supraclavicular fossa, chest, 
abdomen, thigh, calf and foot). The EMG recording was set up in accordance with the manufacturer’s 
instructions (BrainAmp EMG); electrodes were taped bilaterally to the chest and abdomen. 
Continuous recording was made in both study arms until the end of temperature intervention.  
18 gauge cannulae were inserted into each antecubital fossae. A blood pressure cuff was applied on 
one side, and the subject put on the water-perfused cooling suit, which was then connected to a Julabo 
cooling unit.  The temperature of the perfused water was set to 25oC, and the room was dimly lit and 
quiet. 
After 1 hour (Tn60 time point) blood samples were taken with minimal disturbance (for a full list of 
samples taken please refer to table 1). Basal metabolic rate and respiratory quotient were determined 
by indirect calorimetry using an open circuit, ventilated, canopy measurement system (Europa Gas 
Exchange Monitor; NutrEn Technology), and a set of observations was taken. The skin temperature 
measured by one of the foot iButtons was recorded, and a visual analogue scale performed. A brief 
set of cognitive tasks, comprising a verbal fluency test and a digit span was performed. The 
temperature of the cooler unit was then set in accordance with the study arm (either 16oC or 25oC); 
on reaching the temperature intervention the time was recorded (Ti0). The room was kept quiet and 
dimly lit throughout. Bloods, observations and skin temperature were taken according to the sample 
sheet, Table 1, and processed as standard: EDTA and lithium heparin samples were placed on wet ice 
immediately, and spun straight away (3,000rpm for 10 minutes at 4oC), before snap-freezing on dry 
ice. Serum sample were left to clot for 30 minutes before being processed in the same way. PAXgene 
samples for RNA were left at room temperature before being placed in a -80oC freezer.  All samples 
were carefully labelled with barcode and stored at -80oC.  
After 2 hours of temperature intervention a further gas exchange monitor reading was performed to 
measure energy expenditure, and the visual analogue scale was repeated. The cooling unit was 
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switched off, but cognitive tasks were performed with the patient remaining in the suit. These 
comprised a RAVLT test, Hayling sentence completion task, verbal fluency, trails test, digit span and 




2.3.1.1 Copies of cognitive tasks 














The Rey diagram 
This figure is placed horizontally in front of the participant. The time taken to copy the figure is 
recorded. The diagram and the subject’s drawing are then removed and 1 minute is times. The subject 
































Once this was complete the time was recorded (Tp0). Subjects were allowed to dress, and light levels 
were returned to normal. After 60 minutes, a further fasting blood sample was taken, and participants 
were taken for a fat preference meal (procedure as described above). Further blood samples were 







Table 1. Sample sheet illustrating blood sampling and interventions. Taken on the second study day 
of both study arms. EMG, electromyogram; sBP, systolic blood pressure; dBP, diastolic blood pressure; 
P, pulse; Tc, core temperature (measured tympanically); skin temp, skin temperature (iButton 
measurement from foot); VAS, visual analogue scale; GEM, gas exchange monitor; cog task, cognitive 
tasks; fat pref, fat preference meal. 
 
 








 EDTA LiHEP Serum Gluc PAX EMG sBP dBP P Tc      
On waking                
1h (Tn 60) X3 X2 X2 X1 X1           
Ti 10’ X3 X2 X2  X1           
Ti 20’  X2 X2             
Ti 30’ X3 X2 X2  X1           
Ti 60’ X3 X2 X2  X1           
Ti 90’  X2 X2             
Ti  120’ X3 X2 X2 X1 X1           
Tp 0’                
Tp 60’ X3 X2 X2  X1           
Tp 120’ X3 X2 X2  X1           
Tp 180’ X3 X2 X2  X1           
Tp 240’ X3 X2 X2  X1           
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2.3.2. Sample Analysis 
Biochemistry samples were sent to, and processed by Dr Keith Burling, Core Biochemical Assay 
Laboratory (CBAL), Addenbrooke’s Hospital, Cambridge. Lipidomic and metabolomic samples were 
sent to and processed by Dr Albert Koulman, NIHR BRC Core Metabolomics and Lipidomics 
Laboratory, Department of Biochemistry, Addenbrooke’s Hospital, Cambridge. The assays utilised are 
listed here: FT3 was assayed using the QPulse human FT3 Diasorin Liaison kit, and FT4 using the QPulse 
Human Diasorin Liaison FT4 kit, both of which utilise the solid phase antigen linked technique (SPALT). 
TSH was analysed using the Diasorin TSH liaison kit, using a sandwich chemiluminescent immunoassay 
technique. These used the Advia Centaur machine. Insulin was assayed using Diasorin Liaison insulin 
kit, utilising a sandwich chemiluminescence assay. Leptin was measured using an in-house two-site 
microtitre plate-based DELFIA assay which has been automated on the Perkin Elmer AutoDELFIA 
analyser. Glucagon was measured using a solid-phase two-site enzyme immunoassay (ELISA), using a 
kit from Mercodia AB, Sweden. Glucose was measured using a kit by Siemens Healthcare on the 
Siemens Dimension EXL analyser, which utilises an adaption of the hexokinase-glucose-6-phosphate 
dehydrogenase method. Cortisol was assayed using the Diasorin cortisol kit, based on the SPALT 
principle. BDNF (Brain-Derived Neurotrophic Factor) was measured using an in-house two-site plate-
based assay on the MesoScale Discovery platform, using antibodies and standards from R&D systems.  
 
2.3.3. Data analysis 
Data was analysed using GraphPad Prism 6.0 and XLSTAT add-in for Excel software. Statistical tests 
were applied as stated in the thesis. Further details of analysis for the cooling study are given in 
chapter 4.  
 
2.3.4. Lipidomics sample extraction 
We adapted a method for open profiling of lipids by DIHRMS (Han and Gross 2003, Graessler, 
Schwudke et al. 2009). An automated method for the extraction of lipids was developed using an 
automated liquid handler (Integra Viaflo96, SLS, Nottingham, UK). Eighty samples, four blanks, and 12 
QC samples in 1.2 mL Cryovials were randomized to 96-wells plate format, 100 µL of MilliQ H2O was 
added to each of the wells and mixed, and then 100 µL of the mixture was transferred to a glass coated 
2.4 mL deep well plate (Plate+™, Esslab, Hadleigh, UK). Next, 250 µL of MeOH was added containing 
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17 internal standards, followed by 500 µL of methyl tert-butyl ether (MTBE). The plates were then 
sealed (using Corning aluminium micro-plate sealing tape [Sigma Aldrich Company, UK]) and shaken 
for 10 min at 600 rpm, after which the plate was transferred to a centrifuge and spun for 10 min at 
6,000 rpm. Each well in the resulting plate had two layers, with an aqueous layer at the bottom and 
an organic layer on top, from which 25 µL of the organic layer was transferred to a glass coated 240 
µL low well plate (Plate+™, Esslab, Hadleigh, UK), and 90 µL of MS-mix (7.5 mM NH4Ac IPA:MeOH [2:1]) 
was added using a Hydra Matrix, after which the plate was sealed and stored at –20 °C until analysis. 
 
2.3.5. Direct infusion high-resolution mass spectrometry 
All samples were infused into an Exactive Orbitrap (Thermo, Hemel Hampstead, UK), using a Triversa 
Nanomate (Advion, Ithaca, US). The Nanomate infusion mandrel was used to pierce the seal of each 
well before analysis, after which, with a fresh tip, 5 µL of sample was aspirated, followed by an air gap 
(1.5 µL). The tip was pressed against a fresh nozzle and the sample was dispensed using 0.2 psi 
nitrogen pressure. Ionization was achieved with a 1.2 kV voltage. The Exactive started acquiring data 
20 seconds after sample aspiration began. The Exactive acquired data with a scan rate of 1 Hz 
(resulting in a mass resolution of 65,000 full width at half maximum [fwhm] at 400 m/z). After 72 
seconds of acquisition in positive mode the Nanomate and the Exactive switched over to negative 
mode, decreasing the voltage to –1.5 kV. The spray was maintained for another 66 seconds, after 
which the analysis was stopped, and the tip discarded, before the analysis of the next sample began. 
The sample plate was kept at 15 °C throughout the analysis. Samples were run in row order and 
repeated multiple times if necessary to ensure accuracy. 
 
2.3.6. Lipidomics data processing and peak picking 
The resulting mass spectrometry data files were decompressed and converted to mzXML format using 
the “msconvert” tool in ProteoWizard (Chambers MC, Nature Biotechnology, 2012). For each infusion, 
an average spectrum was calculated from the user-defined time window. The R package “xcms” 
(Smith, Want et al. 2006) was used to average fifty spectra per mode using an m/z window of 185–
1,000 and a retention time window of 20–70 seconds for positive ionization mode and 95–145 seconds 
for negative ionization mode. 
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A list of m/z identity pairs, based on expected and possible lipids in human serum, was used to extract 
small windows of data around the target m/z in the average spectrum. The peak maximum was 
measured and the two closest points to the half-height on either side were found, resulting in four 
points. The points with which a horizontal line at half-height intersected a line connecting the two 
points on either side of the peak (one above the half-height and one below) was used for a peak-width 
calculation (distance of the line) and a more accurate m/z value for the peak maximum (midpoint of 
the line). For all m/z identity pairs, the maximum intensity was recorded as well as the deviation of 
the peaks’ accurate m/z. The final step was the combination of all the signals and deviations into their 






2.3.7. Metabolomics measurements 
The levels of 175 metabolites were measured across samples in both study arms by the AbsoluteIDQ® 
Biocrates p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria) as reported elsewhere in detail (Illig, 
Gieger et al. 2010, Walsh, Broadhurst et al. 2012). We used a Waters Acquity UPLC (Waters ltd, 
Manchester, UK) system coupled to ABSciex 5500 Qtrap (Sciex ltd, Warrington, UK). In short: samples 
were derivatised and extracted using a Hamilton STAR liquid handling station (Hamilton Robotics Ltd, 
Birmingham, UK). Flow injection analysis coupled with tandem mass spectrometry (FIA-MS/MS) using 
multiple reaction monitoring (MRM) in positive mode ionisation was performed to measure the 
relative levels of acylcarnitines, phosphatidylcholines, lysophosphatidylcholines and sphingolipids; in 
negative ionisation mode the level of hexose was measured. Liquid chromatography coupled with 
tandem mass spectrometry (UPLC-MS/MS) using multiple reaction monitoring (MRM) was performed 
to measure the absolute concentration of amino acids and biogenic amines. The chromatography 
consisted of a 5 minute gradient starting at 100% aqueous (0.2% Formic acid) increasing to 95% 
acetonitrile (0.2% Formic acid) over a Waters Acquity UPLC BEH C18 column (2.1 x 50 mm, 1.7 μm, 
with guard column). Isotopically labelled internal standards are integrated with in the Biocrates p180 
Kit for quantification. Data was processed in the Biocrates MetIDQ software. 
 
2.3.8. Analysis of metabolomic data 
Metabolomic data was first analysed using Metaboanalyst software to examine hierarchical clustering 
of the data. LIMMA, a program that was devised to fit linear models to microarray data, was used to 
fit a linear model to both lipidomic and metabolomic data. KEGG pathway analysis was conducted on 
amino acid measurements.  An equivalent was not available for the analysis of lipid data, which was 



















CHAPTER THREE: IDENTIFICATION AND FUNCTIONAL 





GPR10 is a G protein coupled receptor expressed in key brain areas involved in the regulation of energy 
homeostasis, including the brainstem, and the dorsomedial nucleus and paraventricular nucleus of 
the hypothalamus. We hypothesised that disruption of GPR10 signalling may contribute to human 
obesity based on the phenotype of GPR10 null mice, which have are obese with reduced energy 
expenditure. The whole exome sequencing of 737 patients with severe early onset obesity, and the 
targeted resequencing of a set of obesity genes in a further 1811 patients identified 15 heterozygous 
variants in 17 patients. Identical methods applied to control exomes from the UK10K identified 5 
heterozygous variants in 1117 subjects. These variants were taken forward for functional 
characterisation. 
An enzyme-linked immunosorbent assay showed that none of the mutations significantly reduced cell 
surface expression. Second messenger assays, conducted with and without chimeric G protein to allow 
the detection of Gi-coupled pathways, demonstrated that the receptor signalled through Gq- and Gi-
coupled pathways, and the mutations had a spectrum of effect, with three of those found in cases 
resulting in a complete loss of function.  Radioligand binding assays, testing the ability of unlabelled 
PrRP to displace a radiolabelled version of the ligand, showed a similar range of effect, with the 
aforementioned three loss of function receptors failing to bind ligand. Collectively, these experiments 
showed that none of the mutations reduced cell surface expression. Thirteen of the 15 variants found 
in cases, and 4 of the 5 found in controls showed a degree of functional impairment, with 3 of each 
showing complete loss of function.  
As the heterozygous-null mice appear to have a wild type-like phenotype on standard chow, it was 
hypothesised that the GPR10 variants might exert a dominant negative effect on the wild type 
receptor. Second messenger accumulation in cells co-transfected with varying doses of both wild type 
and selected mutant receptor DNA showed a dose-dependent inhibition of wild type signal by the 
mutant receptor, without alteration of wild type cell surface expression. Additionally, the viability of 





GPR10 is a G protein coupled receptor, and is stimulated by the RFamide, prolactin releasing peptide 
(PrRP). GPR10 and PrRP are expressed in key brain areas involved in the regulation of mammalian 
energy homeostasis, including the nucleus tractus solitarius and ventrolateral medulla in the 
brainstem, where PrRP colocalises with A1 and A2 noradrenergic neurons (Uchida, Kobayashi et al. 
2010), the dorsomedial nucleus of the hypothalamus, where both GPR10 and PrRP colocalises with 
the leptin receptor (Dodd, Worth et al. 2014) , and in the paraventricular nucleus. GPR10 null mice on 
a C57BL/6 background are obese, with increased food intake and reduced energy expenditure 
(measured by cage calorimetry on a normal chow diet) (Takayanagi, Matsumoto et al. 2008).  The 
biological basis of this phenotype has only been partially explained. Neurons in the brainstem are 
responsive to the gut hormone cholecystokinin, whilst neurons in the dorsomedial hypothalamus are 
necessary for the thermogenic effects of leptin ((Dodd, Worth et al. 2014) and unpublished data) and 
project to a number of key brain areas, including the medial preoptic area and the paraventricular 
nucleus (unpublished data from Professor Luckman’s group has shown that these are not oxytocin 
neurons). Additionally, intact GPR10-mediated signalling contributes to the anorectic effects of leptin 
(Ellacott, Lawrence et al. 2002).  
PrRP was first discovered using a reverse pharmacology approach (Hinuma, Habata et al. 1998). They 
identified a pituitary-expressed orphan receptor which they termed hGR3, which showed sequence 
homology to the previously described GPCR UHR-1. They then applied bovine hypothalamic extract 
and purified the ligand that resulted in its stimulation. They termed this protein prolactin-releasing 
peptide, because it seemed to release prolactin from when applied to a cell culture of the anterior 
pituitary cells of lactating rats. However other groups were unable to replicate this data, and there is 
a lack of staining of PrRP in the median eminence of the anterior pituitary. It is now accepted that 
release of prolactin is not the primary effect of PrRP. 
GPR10 signalling has been implicated in modulating the stress response.  Hypotensive haemorrhage 
causes c-fos activation in PrRP immunoreactive neurones in the nucleus tractus solitarius, and in CRH 
and vasopressin immunopositive neurons in the paraventricular nucleus of the hypothalamus. 
Injection of a retrograde tracer into these cells in the PVN showed that the brainstem PrRP-containing 
neurons conveyed this signal (Uchida, Kobayashi et al. 2010). They have impaired nociception, and 
PrRP can reverse opioid-induced analgesia (Laurent, Becker et al. 2005). Centrally administered PrRP 
promotes wakefulness and can suppress sleep oscillations on EEG and EMG (Lin, Arai et al. 2002). 
Additionally, injection of PrRP into the ventrolateral medulla results in dose-dependent increases in 
mean arterial blood pressure, heart rate and renal sympathetic nerve activity (Horiuchi, Saigusa et al. 
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2002). Interestingly it has been shown that the increase in blood pressure associated with obesity is 
mediated through the population of leptin receptors that reside in the dorsomedial hypothalamus, 
and proportion of which colocalise with PrRP-containing neurons (Simonds, Pryor et al. 2014).  
The precise molecular mechanisms through which GPR10 mediates its effects have only partially been 
explored prior to this study. Langmead has previously demonstrated that GPR10 has both high and 
low affinity binding sites for PrRP (KD 0.026 ± 0.006 and 0.57 ± 0.14 nM, respectively), and that both 
isoforms of PrRP (PrRP-20 and PrRP-31) are potent full agonists and result in calcium release from the 
endoplasmic reticulum, indicating Gq-coupled signalling. They additionally showed that PrRP does not 
increase basal cAMP levels (and therefore does not signal through Gs-coupled pathways), and in 
contrast to our findings does not reduce forskolin-stimulated cAMP levels (therefore concluding that 
there was no evidence of signalling through Gi-coupled mechanisms) (Langmead, Szekeres et al. 2000). 
Biased signalling, rather than a complete disruption of signalling is another mechanism by which 
mutations in GPCRs may exert an effect.  GPCRs may couple to more than one secondary messenger 
pathway, and the “tone” between these signalling pathways may be affected by mutations carried by 
the receptor.  An example of this is the distinct roles attributed to different second messenger 
pathways stimulated by MC4R activation; disruption of Gq-mediated pathways in the paraventricular 
nucleus result in hyperphagic obesity, increased linear growth and hypothalamo-pituitary-adrenal 
inactivation, whereas inactivation of Gs-coupled pathways outside the PVN is responsible for the 
impairments of glucose metabolism and energy expenditure seen in MC4R deficiency (Li, Shrestha et 
al. 2016). As a result we explored the roles of Gs, Gq and Gi-coupled pathways in both the wild-type 
receptor and in all the mutations. 
There was no segregation with gender. Insufficient family data was available to fully determine 
segregation with phenotype. However as the phenotype of these patients is severe, and all the GPR10 
mutations are found in heterozygous form, it raises the possibility of either haploinsufficiency or a 
dominant negative effect.  
It has been well established that rhodopsin-like group A GPCRs can form both homodimers and 
heterodimers by using molecular tools such as immunoprecipitation, enzyme complementation assays 
and bioluminescent resonance energy transfer (BRET); for example the alpha1-adrenoceptor has been 
shown to dimerize with the chemokine receptor, CXCR (Milligan, Wilson et al. 2005). There are also 
examples where this interaction has been shown to have a dominant negative effect, for example 
mutant forms of the TSH receptor can dimerize with the wild type receptor, resulting in a dominantly 
inherited form of TSH resistance (Calebiro, de Filippis et al. 2005). This is therefore a feasible 
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explanation for the severe phenotype we observe in our patients with heterozygous GPR10 variants, 
and was explored further here. 
While no rare human variants in GPR10 have been described, our group has previously detailed a 
common variant, P305L (Bhattacharyya, Luan et al. 2003). 94 patients with severe early onset obesity 
were screened for variants in GPR10. Two non-synonymous variants were found, one of which, P305L, 
had functional consequences and reduced endoplasmic calcium release on ligand stimulation relative 
to wild type. This was typed in 1084 UK Caucasians, and was found to have a MAF 7%. While this 
variant was not associated with an increase in BMI, it was associated with a lower systolic blood 
pressure (5mmHg, p<0.05) and diastolic blood pressure (4mmHg, p<0.01).  
In this study we examined whether GPR10 is involved in human energy homeostasis by testing 
whether rare variants in GPR10 are associated with severe human obesity, and secondly by 





The human GPR10 gene (Genbank Association number NM_004248.2) comprises 2 exons located on 
chromosome 10. In collaboration with Prof Ines Barroso at the Wellcome Trust Sanger Institute, the 
whole exome and targeted resequencing was undertaken of 2548 patients with severe early onset 
obesity, and a further 1118 subjects sequenced using the same methods as art of the UK10K project. 
This identified 15 variants in 17 cases, and 5 variants in controls.  Having identified rare variants in 
GPR10 we undertook functional studies in order to ascertain whether these mutations disrupted the 
function of GPR10 protein. 
We firstly created the mutants with N-terminal FLAG in a pCMV-Tag2B construct by site-directed 
mutagenesis using the Quikchange II kit. We then set out to define the function of wild type GPR10, 
determining the signalling pathways triggered by ligand application by using second messenger assays. 
Stimulation of GPR10 failed to increase cAMP, indicating that GPR10 is not a Gs-coupled receptor. 
Stimulation of GPR10 did increase the cellular concentration of inositol monophosphate, a breakdown 
product of inositol triphosphate, indicating that GPR10 signals through Gq-coupled pathways. Gi-
coupled signalling was explored in to ways; firstly the inositol monophosphate accumulation assay 
was repeated in cells co-transfected with GαΔ6qi4myr, a chimeric G protein that couples Gi binding 
residues to Gq signalling, allowing for a readily detectable response. This showed a dose-dependent 
increase in IP1, indicating signalling through Gi-coupled residues.  However, this is an artificial system. 
To further test whether wild type GPR10 does signal through Gi-coupled pathways a HEK293 cell line 
stably transfected with wild type GPR10 was stimulated with forskolin, a receptor-independent 
stimulator of adenylate cyclase. Stimulation with ligand resulted in a dose-dependent reduction in 
cAMP, thereby confirming that the receptor signals via Gi-coupled mechanisms, in addition to Gq.  The 
IP1 assay, performed with and without GαΔ6qi4myr therefore formed the basis of the functional 
characterisation of mutation impact on signalling.  
An in-house ELISA, with primary antibody directed at N-terminal FLAG, was used to assess the cell 
surface expression of mutants. This demonstrated that none of the mutations reduced cell surface 
expression. Results were confirmed by confocal microscopy in HEK293 cells, with anti-FALG antibody 
used to localise GPR10 and wheat germ agglutinin to show cell membrane.  
A competition radioligand binding assay was used to explore the effect of the mutations on radioligand 
binding.  As all the variants were found in heterozygous form, and the heterozygous-null mouse is not 
known to be obese we tested the possibility of the mutant receptor exerting a dominant negative 
effect on the wild type receptor by measuring IP1 accumulation in cells co-transfected with varying 
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doses of wild type and mutant cDNA in COS7 cells. A second wildtype construct tagged with c-myc was 
created to allow differentiation of their relative levels of cell surface expression by ELISA assay. The 
three complete loss of function variants found in cases (A121D, P193S, P237R) were selected for 





3.4.1. Identification of rare variants in GPR10 in the GOOS cohort 
3.4.1.1. Genetic studies  
In collaboration with Dr Ines Barroso at the WT Sanger Institute, we performed exome sequencing of 
737 UK GOOS patients in whom known causes of obesity have been excluded. Using the Agilent Sure-
Select Human All Exon 50Mb array followed by Illumina HiSeq, high quality sequence data was 
obtained.  These data were compared to 1,117 exomes from the UK10K exomes, comprised of DNA 
from patients with other diseases, and consented controls, analysed using the same multiple sample 
calling techniques. This identified one heterozygous mutation in GPR10, L350S.  The targeted 
resequencing of a set of obesity genes in a further 1,811 patients was then undertaken (Hendricks AE, 
Science reports, 2017), identified a further 13 heterozygous GPR10 mutations in 15 patients.  Sanger 
sequencing failed to confirm three of these mutations, resulting in a total of 11 mutations in 13 
patients, and no mutations in control exomes. Based on the statistically significant enrichment in the 
GOOS cohort, compared to the ExAC database, these mutations were taken forward for further study.  
However, in 2015, a second data release was made, where data had been analysed using a different 
multiple sample calling algorithm; four additional mutations were identified in cases and five in 
controls. The prevalence of non-synonymous mutations was no longer enriched in the GOOS cohort, 
when compared to UK10K controls (Table 2).  It should be noted that the control exomes in the UK10K 
cohort are taken from patients with other diseases, who were included in the UK10K project. No BMI 
data are available for these patients, so it is possible that these individuals may also be obese. 
Insufficient family data was available to state whether they segregated with phenotype. Both males 




 GOOS UK10K controls 
 Variants Cohort size % variants cohort Variants Cohort size % variants cohort 
 17 2,548 0.67 5 1,117 0.447 
OR   1.5    
p value   0.5    
 
Table 2. Analysis of GPR10 variants found in the GOOS cohort in comparison with controls. 
Comparison of variant frequency between the GOOS cohort and the UK10K controls.  
 
3.4.1.2. Location of mutations within the GPR10 molecule 
Mutations were located throughout the GPR10 molecule, with no clustering in any one region. Some 
of the mutations found affected highly conserved residues (P193S, P237R). The functional 







Figure 3. Two dimensional model of GPR10. ENSG00000119973 (GPR10), showing its seven trans-
membrane structure.  Mutations found in cases are shown in black, and those found in controls are in 
green.  This was constructed using homology modelling of other GPCRs, based on the alignment of the 





Figure 4. Molecular structure of GPR10 generated by homology modelling with protein structure 
prediction server Robetta. Secondary structure represented by ribbons is shown as parallel to the 
membrane plane, with extracellular side of the receptor on top and cytoplasmic side on the bottom, 
respectively. In the front plane from left to right, in panel A, transmembrane (TM) domain V, TM-VI, 
TM-VII with helix 8 and TM-I, whereas in panel B, TM-II, TM-IV, TM-V with TM-III going across behind 
TM-IV from extracellular end of TM-II towards intracellular end of TM-V. Amino acid residues affected 
by mutation are presented in orange. 
 
3.4.2. Functional characterisation of rare variants in GPR10 
Functional studies were performed on 15 variants in GPR10 found in cases and 5 in controls to test 
whether these genetic changes have functional consequences on the protein.  Mutations were created 
by site-directed mutagenesis using the Quikchange II kit, and successful mutagenesis was confirmed 








Figure 5. Sequence alignment of variants found in the GOOS cohort and UK10K controls. A species 
alignment of GPR10 proteins was performed using Geneious software.  All variants occurred in 
residues conserved across mammals, and in some cases (V162L, P193S, R222S, P237R, D340V/N) to 
the level of the nematode Caenorrhabditis elegans. GOOS cohort shown in red and UK10K controls in 
green.  A previously published common variant, P305L (add ref), is shown in orange. 
 
3.4.2.1. Cell surface expression of mutant forms of GPR10 
To test the levels of cell surface expression of variants relative to wild type receptor an in house 
enzyme-linked immunosorbent assay was established in which FLAG-tagged variants were detected 
with a primary anti-FLAG murine antibody, which was then in turn detected by a goat anti-mouse 
antibody conjugated to horseradish peroxidase allowing for its detection. Initially a gene-dosing 
experiment (5 - 200ng cDNA/well) was performed to validate the assay and define the optimal gene 
dose for future experiments (1-25ng/well; 5ng/well was selected).  
Cell surface expression was studied in COS7 cells (35,000 cells/well) transiently transfected with FLAG-
tagged constructs encoding wild type or mutant GPR10 or empty pCMV-Tag2B vector DNA. These 
experiments showed that none of the mutations reduced cell surface expression compared to the 
wild-type receptor.  Two of the mutations (V261M, I357L) were expressed at a higher level than the 
wild type receptor (Figure 5).  This was an unexpected result, further experiments were therefore 
undertaken to test the effect of the mutations on cell surface expression. Firstly, it was proposed that 
the result of the ELISA may in part be down to the protocol; cells are fixed before the application of 
the primary antibody, and it was proposed that this may make cells permeable to the antibody, 
allowing for detection of intracellular FLAG.  This possibility was explored using an alternate ELISA 
protocol, where the primary antibody was applied before cell fixation, and cells were kept on ice until 
after fixation to slow cellular metabolism.  The results from these experiments were similar to those 
of the standard ELISA technique, and it was therefore concluded that the standard ELISA results were 






























































Figure 6. Mutations in GPR10 do not reduce the cell surface expression of receptor, relative to wild 
type.  COS 7 cells were seeded at a density of 25,000 cells per well into 96-well plates and transiently 
transfected with 5ng/well of either mutant or wild type GPR10 in a pCMV-Tag2B construct. After 24 
hours cells were fixed and an enzyme-linked immunosorbent assay (ELISA) performed to determine 
relative levels of cell surface expression.  Results were fitted to a non-linear regression curve and 
normalised relative to wild type in GraphPad Prism 6.0. An unpaired T test was performed for each 
variant; after a Bonferroni correction, none of the variants were expressed at significantly different 


















































































































A. Cell surface expression of variants found in cases relative to wild type. 





3.4.2.2. Cellular localisation of GPR10 using confocal microscopy 
Confocal microscopy of cells transiently transfected with selected mutants was performed to ascertain 
cellular localisation. A HEK 293 cell line (University of Dundee) was used, as the high ratio of cytoplasm 
to cell volume in this cell line allows for easier visualisation of the cellular sublocalization of fluorescent 
signal. Wheat germ agglutinin and DAPI were used to stain cell membranes and nuclei, respectively.  
FLAG-tagged mutant or wild type GPR10 was targeted with an Alexa 488 anti-FLAG M2 antibody.  For 
each mutation, 20 representative images were taken.  Images were viewed and analysed using ImageJ 
software.   
Cells transfected with the empty vector, pCMV-Tag2B were used as a negative control, and did not 
show any Alexa 488 signal.  Cells transfected with wild type receptor showed clear signal at the cell 
membrane.  Three loss of function mutations, A121D, P193S and P237R were tested for comparison 
to wild type together with selected other mutants. All showed receptor present at the cell membrane, 







Figure 7. Cellular localisation of FLAG-tagged mutant GPR10.  FLAG-tagged GPR10 was visualised in 
HEK293 cells with the anti-FLAG antibody seen in green. Wheat germ agglutinin shows cell membranes 
in red.  DAPI nuclear staining was performed, but has been removed from these images for ease of 
visualisation. Wild type GPR10 was seen at the cell membrane, and little cytoplasmic staining was 
seen. GPR10 loss of function mutations were all seen at the membrane, as were selected other 
mutations tested, with little or no mutant seen at other cellular locations.   
 
3.4.2.3. GPR10 signals through both Gi and Gq pathways 
GPR10 mediates signalling by prolactin-releasing peptide (PrRP). Based on studies in rodents, two PrRP 
isoforms exist: PrRP-31 and a truncated form, PrRP-20. Existing literature indicates that these ligands 
bind to GPR10 with comparable affinity, and no significant difference in potency has been 
demonstrated. For my initial experiments I tested the signalling response to stimulation with both 
ligands at a concentration of 20x10-6M and found no difference in potency. All subsequent 
experiments were performed with a range of 20x10-12 - 20x10-6 M concentration of PrRP-31.  
To test the signalling profile of WT human GPR10, a series of assays were performed. To test Gαs 
mediated signalling, a cAMP accumulation assay using the HitHunter assay platform in HEK293 cells 
transiently transfected with WT GPR10 was used, and found that there was no evidence of cAMP 
accumulation.  
To test Gq-coupled signalling, COS 7 cells transfected with wild type GPR10 and stimulated with PrRP-
31 were assessed using an inositol monophosphate accumulation assay which measures activity of 
the IP3/calcium coupled intracellular pathway. Dose-dependent accumulation of IP1 was 
demonstrated.  
Gi signalling is challenging to assay, as it results in a reduction in cAMP, which is difficult to measure. 
Gi signalling was therefore explored using two methods. Firstly, cells were co-transfected with both 
wild-type receptor and a promiscuous chimeric G protein, GαΔ6qi4myr, which couples Gi binding 
residues on the internal surface of the GPCR to a Gq signalling pathway, allowing for a detectable 
response.  This assay showed a dose-dependent increase in IP1 with increasing concentrations of PrRP-
31 (Figure 9).  
The use of chimeric G protein is an artificial system, and therefore it was important to test the PrRP-
stimulated activity of Gi-coupled pathways by an independent method.  COS-7 cells were stably 
transfected and stimulated with forskolin, a receptor-independent stimulator of adenylyl cyclase.  The 
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reduction in cAMP was then measured on stimulation with PrRP-31, which occurred in a dose-
dependent manner, thereby confirming the results of the chimeric G protein assay (Figure 7). This 
resulted in dose-dependent accumulation of IP1 on stimulation with PrRP-31.   
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Figure 8. Stimulation of HEK293 cells stably transfected with GPR10, with and without forskolin. The 
data in black shows inhibition of intrinsic cAMP levels with increasing doses of PrRP-31. The data in 
red demonstrates inhibition of forskolin-stimulated levels of cAMP. Data was fitted to a non-linear 
regression curve and normalised in GraphPad Prism 6.0. Cumulative data from 4 individual 
experiments is shown with mean and standard deviation.  
 
3.4.2.4. GPR10 mutants impair signalling through Gq pathways when stimulated with PrRP-
31 
To test the effects of GPR10 mutant on signalling, mutant constructs were transiently transfected into 
COS7 cells. An inositol monophosphate assay was used to assess signalling through the Gq receptor. 
Cells cultured in medium supplemented with myo-[3-H]-inositol were treated with lithium chloride to 
prevent the dephosphorylation of inositol monophosphate into myoinositol. Cells were stimulated 
with varying doses of PrRP-31, and a scintillation proximity assay was performed to measure the 
relative amounts of radiolabelled IP1 that accumulated.  
Of the 15 variants found in cases that were tested on the Gq assay platform, four showed a complete 
loss of function (A121D, P193S, P237R, A266D), with a further six showing a partial loss of function.  
Of the five variants found in controls, three showed a complete loss of function, one a partial loss of 
function, and one demonstrated a wild type-like response. An additional common variant, P305L, 
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reported previously was tested in addition to wild type receptor and mock transfected cells as a 
further control.  This is a common variant previously described by our group, that is associated with a 
lower blood pressure that weight-matched controls, but not with obesity. This showed a partial loss 




A. Normalised response of COS-7 cells transiently transfected with variants found in cases,  
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B. Normalised response of COS7 cells transiently transfected with variants found in controls, 




Figure 9. GPR10 mutations found in cases (A) or controls (B) impair signalling through Gq pathways 
when stimulated with PrRP-31.  COS7 cells transiently transfected with either mutant or wild type 
DNA were cultured in media supplemented with myo-[3-H]-inositol. Cells were treated with 10mM 
lithium to prevent degradation of inositol monophosphate, and were stimulated with PrRP-31. Inositol 
monophosphate accumulation was measured using a scintillation proximity assay. Three variants 
found in cases resulted in a complete loss of function (A121D, P193S, P237R), with a further nine 
causing a partial loss of function. Of the variants found in controls, three resulted in a complete loss 
of function. One caused a partial loss of function, and one had no effect. Each graph represents the 
normalisation of a minimum of three independent experiments and is plotted showing the standard 
error of mean (Castellano, Navarro et al.).  The potency (IC50) and efficacy (Emax) with standard error 
of mean were calculated from normalised data fitted to a non-linear regression curve in GraphPad 
Prism 6.0.  
 
3.4.2.5. GPR10 mutants impair signalling through Gi pathways when stimulated with PrRP-
31 
Cells co-transfected with either wild type or mutant DNA and GαΔ6qi4myr chimeric G protein were 
assessed for they ability to generate inositol monophosphate as previously described. Three of the 
variants found in cases demonstrated a complete loss of function (A121D, P193S, P237R), with a 
further 10 showing a partial loss of function.  One mutation, I357L, which demonstrated a gain of 
function of both Gq and Gi signalling (Figure 9). Interestingly this receptor also showed an increase in 
cell surface expression on the ELISA, and so it may be that the increase in IP1 accumulation is due to 
an increased presence of receptor at the cell membrane, rather than an increased ability of the 
receptor to signal. 
Of the four mutations that showed a complete loss of function on the Gq platform, three showed a 
complete loss of Gi signalling too, with one showing a partial loss of function (A266D).  Two of the 
mutations that had shown wild type-like signalling on the Gq platform showed a partial loss of Gi 
signalling (H206N, D340N), thereby providing a possible explanation as to their pathogenicity. One 
mutation that had shown a partial loss of Gq signalling showed wild type-like levels of Gi signalling. 
These data indicate that some mutations in GPR10 result in a signalling bias towards either Gi or Gq 
signalling.   
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A. Gi-coupled signalling of variants found in cases. Data is normalised relative to wild type and 
shows inositol monophosphate accumulation in COS7 cells co-transfected with receptor and 
chimeric G protein (n=3-8). 
 

























W ild  ty p e
A 1 2 1 D
P 1 9 3 S
0
V 1 6 2 L
H 2 0 6 N

























W ild  ty p e
0
R 2 2 0 L
R 2 2 2 S
L 2 4 2 F
P 2 3 7 R


























W ild  ty p e
V 2 6 1 M
A 2 6 6 D
P 3 0 5 L
D 3 4 0 N


























W ild  ty p e
0
D 3 4 0 V
L 3 5 0 S
K 3 5 6 E
I3 5 7 L

























W ild  ty p e
V 1 1 I
C 1 1 3 R
A 1 9 1 V
P 2 5 8 S
0
A 3 2 8 V
  
B. Gi-coupled signalling of variants found in controls. Data is normalised relative to wild type and shows 




Figure 10. GPR10 mutations found in cases (A) or controls (B) impair signalling through Gi pathways 
when stimulated with PrRP-31. COS7 cells transiently transfected with either mutant or wild type 
DNA plus the chimeric G protein, GαΔ6qi4myr, and were cultured in radiolabelled myoinositol. Cells 
were treated with lithium to prevent degradation of inositol monophosphate, and were stimulated 
with PrRP-31. Inositol monophosphate accumulation was measured using a scintillation proximity 
assay.  The potency (IC50) and efficacy (Emax) with standard error of mean were calculated from 
normalised data fitted to a non-linear regression curve in GraphPad Prism 6.0.  
 Three of the mutations found in cases demonstrated a complete loss of function (A121D, P193S, 
P237R), with a further 10 showing a partial loss of function. Some of the results were discordant with 
the findings of the IP1 assay conducted without chimeric G protein; mutations H206N, R220L, L242F 
showed a partial loss of function in the Gi assay, whereas signalling through Gq was comparable to 
wild type. Conversely mutations V162L and L350S appeared wild type like in the Gi assay, but caused 




3.4.2.6. Human mutations in GPR10 impair binding of PrRP-31 
To examine the functional consequences of the mutations on the binding of ligand, we performed a 
competition binding assay where the displacement of radioactive 125-I-PrRP-31 by non-radioactive 
(cold) PrRP-31 was measured in a scintillation proximity assay. All three of the mutations found in 
cases that showed a complete lack of ability to generate inositol monophosphate either with or 
without the use of chimeric G protein also failed to bind ligand.  All of the remaining mutations, with 
the exception of variants V162L and I357L, showed a partial reduction in their ability to bind ligand. 
Of the three loss of function variants found in controls, two failed to bind ligand, with the remaining 
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Figure 11. GPR10 mutations found in cases (A) or controls (B) impair ligand binding.  
COS7 cells were transiently transfected with either FLAG-tagged mutant or wild type DNA in a pCMV-
Tag2B construct. 125I-PrRP-31 was applied, followed by varying doses of unlabelled PrRP-31. 
Radioactivity was measured using scintillation. Three mutations fond in cases showed a complete 
impairment of binding, with a further ten showing a partial loss of binding. Two of the variants found 
in controls showed impaired binding, with three responding in a manner comparable to wild type. The 
A. Competition binding assay showing normalised data of variants found in cases relative to wild type (n=4) 




potency (IC50) and efficacy (Bmax) with standard error of mean, were calculated from normalised 




Summary Data: Impact of Human GPR10 mutations on receptor function 
GPR10 
variant 
Cell surface expression 
[%WT] 
Ligand binding (radioligand competition) 
Affinity (IC50) 




Number of binding 
sites (Bmax) [%WT] 
Cases Mean   SEM n Mean   SEM n  Mean   SEM n 
WT 100   N/D 12 2.2 ± 1.0 6 N/D 100 ± N/D 8 
A121D 117 ± 7.4 4 N/D (cLoF) 4 N/D N/D (cLoF) 4 
V162L 108 ± 15 4 1.3 ± 0.2 3 0.6 91 ± 10 3 
P193S 129 ± 7.6 4 N/D (cLoF) 4 N/D N/D (cLoF) 3 
H206N 124 ± 1.7 4 1.6 ± 0.5 4 0.7 65 ± 6.2 4 
R220L 116 ± 8.9 4 1.0 ± 0.3 4 0.5 81 ± 7.8 4 
R222S 115 ± 5.1 4 1.0 ± 0.5 3 0.5 13 ± 3.2 4 
P237R 97 ± 3.5 4 N/D (cLoF) 4 N/D N/D (cLoF) 3 
L242F 129 ± 14 4 0.9 ± 0.2 4 0.4 80 ± 9.2 4 
V261M 152 ± 7.9 4 1.0 ± 0.2 3 0.5 86 ± 6.0 4 
A266D 98 ± 7 4 1.3 ± 0.5 3 0.6 63 ± 3.7 3 
D340N 123 ± 11 4 1.0 ± 0.1 3 0.5 46 ± 4.2 3 
D340V 87 ± 12 4 1.8 ± 0.5 3 0.8 46 ± 3.3 3 
L350S 123 ± 9.2 4 1.3 ± 0.3 4 0.6 30 ± 6.1 4 
K356E 97 ± 17 4 3.8 ± 2.0 3 1.7 26 ± 4.1 3 
I357L 167 ± 7.6 4 0.5 ± 0.04 4 0.2 99 ± 23 4 
Controls              
V011I 102 ± 7.8 4 1.7 ± 0.4 3 0.8 85 ± 4.7 3 
C113R 91 ± 20 4 N/D (cLoF) 3 N/D N/D (cLoF) 3 
A191V 124 ± 9.8 4 6.9 ± 0.3 3 3.1 11 ± 3.0 4 
P258S 138 ± 20 4 1.4 ± 0.8 3 0.6 84 ± 3.5 3 
A328V 93 ± 11 4 1.6 ± 0.4 3 0.7 108 ± 3.9 4 
Common 
variant 
             
P305L 108 ± 4.0 4 1.3 ± 0.4 3 0.6 36 ± 2.2 3 
 
Table 3. Mutation impact on receptor cell surface expression and radioligand binding. Cell surface 
expression of mutant receptor relative to wild type was calculated from normalised data using 
GraphPad Prism 6.0.  The number of receptor binding sites and affinity were calculated with standard 




Gq signalling (IP-1 accumulation) Gi/o signalling (IP-1 accumulation with GαΔ6qi4myr) 
Potency (EC50) 
(Locke, Kahali et al.) 
Fmut 
(varEC50/WTEC50) 
Efficacy (Emax) [%WT] 
Potency (EC50) 






Cases mean   SEM n mean   SEM n mean   SEM n mean   SEM n 
WT 9.4 ± 4.0 7 N/D 100  N/D 7 6.7 ± 2.25 7 N/D 100   N/D 7 
A121D N/D (cLoF) 5 N/D N/D (cLoF) 5 112 ± 17 4 17 17 ± 4.8 4 
V162L 5.0 ± 1.2 4 0.5 71 ± 6.5 4 6.3 ± 3.9 3 0.9 92 ± 1.6 3 
P193S N/D (cLoF) 5 N/D N/D (cLoF) 5 N/D (cLoF) 3 N/D N/D (cLoF) 3 
H206N 16 ± 3.9 4 1.8 125 ± 13 4 14 ± 8.6 3 2.1 123 ± 13 3 
R220L 10 ± 3.8 3 1.1 126 ± 22 3 5.7 ± 3.2 3 0.8 128 ± 17 3 
R222S 53 ± 29 3 5.7 64 ± 10.0 3 34 ± 19 3 5.0 86 ± 10 3 
P237R N/D (cLoF) 5 N/D N/D (cLoF) 5 N/D (cLoF) 3 N/D N/D (cLoF) 3 
L242F 14 ± 3.8 4 1.5 105 ± 6.5 4 11.3 ± 7.3 4 1.7 95 ± 15 4 
V261M 8.3 ± 2.5 4 0.9 175 ± 6.4 4 15 ± 4.8 2 2.2 108 ± 4.5 2 
A266D 7.4 ± 3.4 5 0.8 34 ± 6.6 5 6.9 ± 2.6 4 1.0 45 ± 2.4 4 
D340N 16 ± 7.4 5 1.7 115 ± 9.4 5 7.3 ± 2.2 4 1.1 100 ± 11 4 
D340V 5.3 ± 1.5 4 0.6 64 ± 14 4 7.6 ± 2.5 3 1.1 56 ± 8.3 3 
L350S 20 ± 5.5 4 2.1 32 ± 9.6 4 5.2 ± 3.1 4 0.8 56 ± 8.5 4 
K356E 10 ± 5.4 5 1.1 32 ± 8.7 5 6.7 ± 1.9 4 1.0 44 ± 0.9 4 
I357L 20 ± 5.6 5 2.1 149 ± 16 5 4.5 ± 2.2 4 0.7 132 ± 3.4 4 
Controls                   
V11I 4.9 ± 0.7 4 0.5 93 ± 17 4 12 ± 9.7 3 1.8 127 ± 3.3 3 
C113R N/D (cLoF) 6 N/D N/D (cLoF) 6 N/D (cLoF) 3 N/D N/D (cLoF) 3 
A191V N/D (cLoF) 6 N/D N/D (cLoF) 6 N/D (cLoF) 3 N/D N/D (cLoF) 3 
P258S N/D (cLoF) 6 N/D N/D (cLoF) 6 22 ± 17 3 3.3 33 ± 0.7 3 
A328V 13 ± 4.6 5 1.3 76 ± 14 5 8.7 ± 3.8 5 1.3 72 ± 3.3 5 
Common variant                   
P305L 9.1 ± 3.3 4 1.0 77 ± 14 4 2.8   N/D 1 0.4 80   N/D 1 
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Table 4. Mutation impact on receptor ability to trigger Gq and Gi-coupled pathways. Potency and 
efficacy with standard error of mean were calculated from normalised non-linear regression curves, 
using GraphPad Prism 6.0. 
 
3.4.2.7. Human mutations in GPR10 impair the function of wild type receptor in a cell 
system co-transfected with both wild type and mutant receptor 
All of the human variants in GPR10 are found in heterozygous form. The limited amount of data in 
GPR10/PrRP heterozygous null mice suggests they do not develop obesity. To explore whether 
heterozygous mutations in GPR10 might exert a dominant negative effect, c-myc tagged wild type 
receptor was created from the FLAG-tagged wild type receptor using a restriction endonuclease 
approach.  This allowed for the relative levels of expression of wild type and mutant receptor to be 
distinguished.  20,000 cells/well were co-transfected with varying doses of c-myc-tagged wild type 
receptor (1-5ng/well) and FLAG-tagged mutant DNA (1-5ng/well). The ability of wild type GPR10 to 
generate IP1 in the presence of increasing doses of mutant DNA was tested. Cell surface expression 
levels were assayed to determine whether any observed effects were due to alterations in cell surface 
expression. The three complete loss of function mutations A121D, P193S and P237R were tested for 
a possible dominant negative effect. Total concentration of DNA transfected was kept constant by 
supplementation with empty vector to ensure this did not affect results. 
At all concentrations of wild type receptor, increasing concentrations of mutant receptors reduced 
the amount of inositol monophosphate accumulation (Figure 11), and this reached statistical 
significance for A121D and P237R.  An ELISA using a primary antibody targeting c-myc confirmed that 
increasing doses of mutant receptor did not reduce the expression of the wild type receptor. We 
therefore conclude that for the three mutants tested, the presence of the mutant receptors tested 
exerted a dominant negative effect on the ability of the wild type receptor to signal, and this reached 









Figure 12. Mutations in GPR10 exert a dominant negative effect on the wild type receptor: cases 
and controls.  
An inositol monophosphate assay was performed to assess the effect of varying concentrations of c-
myc-tagged wild type and FLAG-tagged mutant DNA on the signal generated. Increasing doses of 
mutant DNA reduced IP1 accumulation on stimulation with 20x10-6M PrRP-31, independent of cell 
surface expression.  Results show normalised values of three independent experiments, with error 
bars showing standard error of mean on cases (A121D, P193S, P237R) and controls (C113R, A191V, 
P258S, A266D). This shows that the reduction in receptor signalling was significantly reduced in the 
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Figure 13. Expression of wild type receptor is not affected by cotransfection of increasing doses of 
variants A121D (A), P193S (B), P237R (C). An in house ELISA using a primary antibody directed at the 
wild type c-myc tag showed no reduction in signal when COS7 cells were co-transfected with doses (0-







3.4.3. Caenorhabditis elegans as a model for studying the effects of GPR10 on fat 
accumulation  
Demonstrating that the described variants result in the patient phenotype is a problem common to 
all rare variant work. We were interested in exploring model organism systems to test this association. 
Caenorhabditis elegans has an orthologue similar to GPR10, neuropeptide receptor 6 (npr6). We 
explored the use of wild type and npr6 null worms to quantify fat accumulation, with the plan to create 
quantify lipid droplet accumulation in heterozygous null variants of our complete loss of function 
variants if this proved to be a viable method.  
Different methods of lipid droplet visualisation and quantification were explored. We performed 2 
coherent anti-Stokes Raman scattering (CARS) microscopy, rather than the more commonly used 
Sudan black or Nile red stains, as there is evidence that these may stain gut granules in addition to 
lipid droplets, and can therefore provide misleading results. As such, CARS microscopy is the gold 
standard for lipid droplet quantification in C. elegans (Yen, Le et al. 2010). Worms were controlled for 




Figure 14. Sample image from CARS microscopy, demonstrating a wild type worm. Lipid droplets are 









Figure 15. Lipid content analysis of C. elegans. (A). demonstrates average lipid droplet size, 
normalised to the wild type worm. All the droplets in the field of view were measured, and this total 
was divided by the number of droplets counted. (B) shows average lipid droplet density (the number 
of droplets per defined area) normalised to the wild type worm. A defined standardized area bordering 
the larynx measuring 15,000 pixels in diameter was used. The total number of droplets in this area 
was then counted. The npr-6 null worms tended to have a smaller amount of droplets.   
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Both graphs show the lipid droplet size or density of NPR6 null worms normalised to the wild type. 
The average of two separate comparisons was made. Results show mean with standard deviation. 
There was no significant difference for either of the two metrics. 
There was a high degree of variability in the lipid droplet density and size, indicating that this was not 
an ideal platform for determining fat content. Additionally the NPR-6 null worms had a lower lipid 
droplet density than their wild type counterparts. This may be because the knockout worms were not 
as healthy as the wild type worms, but it suggests that the npr6 null worms are not an ideal orthologue 
for assessment of obesity-associated variants in GPR10.  
As these experiments have not proved consistent enough to test whether the mutations in GPR10 
result in an increase in fat accumulation in vivo, we have proceeded to collaborate with Professor 
Simon Luckman to create a mouse model of the heterozygous P193S mutation. This was chosen as it 
is highly conserved between species, and functional studies demonstrate a complete loss function and 
a dominant negative effect in vitro. The mutations A121D and P237R were additionally considered; 
however one of these patients was not Caucasian, raising the possibility of an ethnic variant, and the 
other patient also had an SRC-1 mutation, which makes it difficult to be sure of the contribution of 






3.5.1. Identification of rare and novel mutations in GPR10 in the GOOS cohort 
A common polymorphism in GPR10, P305L, which was associated with lower blood pressure than age 
and weight-matched controls, but not obesity has previously been described. This work therefore 
constitutes the first study of rare variants in GPR10. Fifteen heterozygous variants were identified 
from the whole exome sequencing of 2,548 patients with severe early onset obesity recruited to the 
GOOS cohort. A further 5 mutations were found in 1,117 “control” exomes as part of the UK10K 
project, sequenced using the same methods; these exomes comprise of DNA from healthy volunteers, 
and disease exomes from other patients undergoing sequencing. No BMI data is available on the 
subjects used as controls, and it is therefore not possible to exclude that they are not obese. Whilst 
these variants are rare, the enrichment of variants in the GOOS cohort, and the conservation across 
species indicated that there was a reasonable probability that some of the variants would have 
functional consequences, and an in vitro functional characterisation was therefore justified.  
 
3.5.2. Functional characterisation of rare variants in GPR10 identified in the GOOS cohort 
and control exomes 
In this study we have sought to explore mechanisms by which variants may exert an effect on receptor 
function. We have shown that none of the variants found in cases or controls results in a significant 
reduction in cell surface expression.  This finding is unusual as approximately 60% of disease-causing 
human mutations in the melanocortin 4 receptor result in a reduction in cell surface expression (Tan, 
Pogozheva et al. 2009).  Additionally, intracellular retention of the TSH receptor is a documented 
method by which these mutations may cause congenital hypothyroidism (Labadi, Grassi et al. 2015).   
We have shown that the receptor signals through both Gi and Gq-coupled mechanisms, and that three 
variants found in cases, and two in controls results in a complete reduction in Gq-coupled signalling. 
These same variants, when tested with a competition radioligand binding assay showed an absence 
of ligand binding, and it is therefore logical to assume that it is through a lack of ligand binding that 
they fail to signal.  
We have also shown a partial loss of function in all but two of the variants found in cases. Additionally 
two of the variants found in controls had no impact on any of the assays tested.  To summarise, 
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functional studies of mutant GPR10 in cases and controls showed that 13 of 15 variants in cases and   
3 of 5 variants in controls resulted in a LOF by effecting ligand binding and/or signalling. 
 
3.5.3. Limitations of the methods used 
We then progressed to performing a series of second messenger assays. A cAMP assay showed no 
signal, indicating that the receptor does not couple with Gs proteins, whereas an inositol 
monophosphate assay gave a clear dose-dependent response to ligand, both with and without 
chimeric G protein, indicating coupling to both Gi and Gq proteins. The use of chimeric G protein was 
further validated by testing Gi coupling by creating a cell line that was stably transfected with GPR10, 
stimulating it with forskolin and then treating it with PrRP; a dose dependent reduction in cAMP was 
observed. The IP1 assay, used both with and without chimeric G protein to assay Gq and Gi pathways, 
therefore formed the basis of our characterisation of variant impact on intracellular signalling.  
Other groups frequently use alternative methods to look at these pathways. Intracellular calcium 
assays, using a fluorescent calcium binding dye are a common method of assessing Gq-coupled 
activity, and were considered for this study. However, the results from the IP1 assay were extremely 
consistent and as this is a well validated method of assessing Gq-coupled pathway activity we did not 
proceed to corroborate these results with a second assay.  Additionally the signal readout from the 
calcium assay is one step further removed from the interaction of interest, and increasing levels of 
intracellular calcium can reflect intracellular stress, so on balance it was felt that there would be little 
extra gained from the additional use of this assay.  
A competition binding assay was used to assess the binding of ligand to the receptor; in this assay 
radioactive ligand is applied to cells transfected with receptor, which is then displaced by increasing 
doses of “cold” (i.e. non-radioactive) ligand. This assay therefore measures the equilibrium binding of 
a single concentration of radioligand at various concentrations of an unlabelled competitor.  This 
primarily gives information on the affinity of the receptor for the competitor. There are limitations to 
this assay; it does not take into account the possibility of non-specific binding and it assumes that the 
radioactive label does not interfere in any way with the binding of the ligand and that labelled and 
non-labelled ligand have equal receptor affinity. It also has limitations when compared to a saturation 
binding assay in that it cannot be used directly to calculate KD by plotting a Scatchard plot. However, 
the main advantage of the competition binding assay over a saturation assay is that considerably less 
radioligand is used, resulting in a cheaper and safer experiment with fewer issues surrounding disposal 
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of waste. It also provides considerable useful information on ligand binding, allowing determination 
of IC50, and estimation of Bmax, and is sufficient for the purposes of this characterisation.  
 
3.5.3.1. Other GPCR-mediated mechanisms through which mutation effect has not been 
assessed  
β-arrestin recruitment is necessary for receptor internalisation, and has its own well-defined signalling 
pathways. Recruitment allows the response of the activated receptor to be turned off, and allows 
persistent signals to be adapted. The first step to β-arrestin recruitment is phosphorylation of specific 
residues on the activated G protein by specific serine/threonine kinases, called G protein receptor 
kinases (GRKs), preparing the GPCR for β-arrestin recruitment. The β-arrestin molecule then binds, 
inactivating the receptor by blocking further G protein-mediated signalling (it blocks the binding site 
of the heterotrimeric G protein) and signals the receptor for internalisation by linking it to clathrin and 
the clathrin adaptor protein, AP2, promoting the internalisation of the receptor into endosomes.  β-
arrestins are now known to also function as scaffold proteins that link GPCR activation to several 
downstream effectors such as the MAPK cascade (ERK [extracellular signal-regulated kinase] and JNK), 
Src, and calmodulin.   
We have not explored β-arrestin recruitment or signalling in this study, and it is possible that some of 
the effects exerted by the variants utilise these pathways, and this is an area where future work in 
needed.  It is interesting to note the two variants found in cases for which we have no evidence of 
functional impact on ligand binding or signalling are expressed at significantly higher levels that the 
wild type receptor, and this may be consistent with impaired β-arrestin recruitment.  
 
3.5.5. Further characterisation of dominant negative effect  
We have demonstrated in this study that co-expression of wild type GPR10 with A121D and P237R 
variants found in cases results in an in vitro loss of function results in a dose-dependent reduction in 
inositol monophosphate accumulation from the stimulated receptor.  We have shown that this effect 
is not caused by a reduction in the expression of the wild type receptor; however we have not provided 
a conclusive mechanism by which the observed effect occurs.  
To explore this further it would first be important to test whether the wild type and mutant receptors 
have a direct physical interaction. Practically, this could be done using an enzyme complementation 
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assay, or by using wither bioluminescent or fluorescent resonance energy transfer (BRET/FRET), which 
would provide direct information about receptor interaction.  
It is possible that the observed dominant negative effect on signalling is a result of altered ligand 
interaction. None of the three mutants that were selected for coexpression studies binds ligand when 
tested alone, and we know from the ELISA studies that coexpression of wild type and mutant receptor 
does not reduce the wild type expression. It would therefore be possible to compare the competition 
binding curves of wild type receptor expressed alone to that when it is expressed with mutant 
receptor. However this method could not be used more generally to explore the effects on binding 
with other mutants that themselves bind radioligand.  
We know from the inositol monophosphate assay that the downstream effect of co-expression is a 
reduction in signalling, but we have not explored the upstream cause of this.  A possible mechanism 
by which the mutant receptor might exert its effect is by altering interaction of the wild type receptor 
with its cytosolic targets. This could either be through steric hindrance by physically making its binding 
sites inaccessible, or by altering the receptor conformation in a way that changes the binding sites of 
cytosolic proteins.  This could affect the recruitment of phospholipase C, thereby hindering the 
degradation of PIP2 into IP3 and the triggering of intracellular signalling cascades.  Again, this is not 
something that we have explored in this study, but could be approached using an enzyme 
complementation assay. 
We have only tested 3 of the loss of function variants found in cases. However, all variants are found 
in heterozygous form, and it therefore important to test whether they too exert a dominant negative 
effect on the wild type receptor.  
 
3.5.6. Final conclusions 
Described here are the first rare human mutations in GPR10, a molecule known to play a key role in 
energy expenditure in rodents. We have demonstrated that the wild type receptor signals through Gi 
and Gq-coupled pathways, and that the described mutations have variable impact, with three 
mutations resulting in a complete loss of signalling and ligand binding. As the mutations are found in 
heterozygous form in humans we have explored and demonstrated a dominant negative effect of 
mutant receptor on wild type function. We have explored C. elegans as a model system for directly 




The characterisation of rare obesity-associated GPR10 variants provides some evidence for its role in 
human disease. Further exploration of GPR10 signalling and its pharmacological manipulation has 











CHAPTER FOUR: THE PHYSIOLOGICAL, METABOLIC, AND 













We hypothesised that energy deficit, regardless of cause (whether secondary to caloric restriction, 
exercise or increased expenditure from cold exposure) is detected and responded to by a central 
mechanism, and this mechanism is leptin-mediated.   
To test this hypothesis, we recruited 15 healthy, normal weight (BMI 18.5-26) male volunteers.  
Subjects were screened for pre-existing medical conditions, medication use, neurocognitive 
dysfunction and biochemical abnormalities. Successful subjects were then invited to participate in a 
randomised cross-over trial involving two overnight study visits, each identical with the exception of 
the temperature intervention, which was exposure to either 25oC or 16oC for two hours via a 
specialised cooling suit (Chapter 2, Methods).  We assessed heart rate variability, skin and core body 
temperature and energy expenditure in response to the temperature intervention, using validated 
methods.  Additionally we assessed the effect on the participant’s biochemistry and metabolomics 
profile. As defects in leptin signalling are known to increase preference for high fat foods, we included 
a fat preference meal to determine whether altered food preference was induced by cold exposure, 
a state of partial leptin deficiency. 
As cooling has been associated with long term neuroprotection as a result of improved synaptic 
plasticity secondary to RBM3 induction, we undertook studies into the short term neurocognitive 
effects of cooling.  In collaboration with Professor Malluci’s lab we measured participant RBM3 levels 
and conducted standardised validated tests to assess whether if there were short term effects of 





Hibernation is characterized by a reduction in metabolic rate (by as much as 90%) and body 
temperature set point to maximize energy savings during times of low food availability and 
unfavourable environmental conditions, and may last from days to months, with severe drops in 
body temperature (as low as 1oC above ambient temperatures when in the range of 5 – 15oC). 
Metabolic suppression and cell-level adjustments to manage limited food intake are common 
themes among species. Small-bodied mammalian hibernators in temperate climates suppress 
metabolic, respiratory and heart rates to 1–9 % of basal rates while lowering body temperature to 
enter a state called torpor (Ruf and Geiser 2015).  Larger mammals, such as bears also vary 
metabolism, reaching 25 % of basal values (Toien, Blake et al. 2011) and adopting mass-specific 
metabolic rates that approach those of torpor in small mammals (Geiser and Heldmaier 1995, 
Heldmaier, Ortmann et al. 2004).  Mice and other very small mammals enter torpor, rather than 
hibernation, possibly because they cannot store enough fuel for an extended hibernation. 
Mice can enter torpor when there is a quiet environment, reduced food availability, and a low ambient 
temperature. During deep torpor, mice will maintain their body temperature at 1–2°C above ambient 
temperature, down to a minimum of 16–19°C. Because of plentiful food and adequate room 
temperatures, deep torpor is infrequently seen in laboratory mice. The ob/ob mice are an exception, 
entering deep torpor upon fasting and occasionally entering torpor even when well-fed and housed 
at room temperature (Webb, Jagot et al. 1982). In a study examining the effects of leptin on torpor, it 
was found that wild-type mice entered torpor and dropped their core body temperature by 4oC on 
fasting, and that leptin did not affect this.  However, leptin replacement in ob/ob not only prevented 
the deep torpor, but also the modest 4°C fall. These data demonstrate that leptin plus large energy 
stores (i.e., leptin-treated ob/ob mice) prevents both deep torpor and the modest hypothermic state 
(Gavrilova, Leon et al. 1999).  
While reductions in energy expenditure have not been demonstrated in humans when tested using 
the double-labelled water method (Farooqi, Matarese et al. 2002), it is interesting that leptin-
treated individuals do not display a metabolic adaptation to weight loss i.e. the reduction in energy 
expenditure seen in weight-matched controls on weight loss (Galgani, Greenway et al. 2010). 
Additionally, there is evidence that leptin-deficient adults have impaired sympathetic function 
(Ozata, Ozdemir et al. 1999). Furthermore, whilst humans do not hibernate, they do have to defend 
against low ambient temperatures, and do reduce their metabolic rate in response to caloric 
restriction (Collet, Sonoyama et al. 2017). Therefore studies of human physiology in response to 
cold exposure may yield new insights into this adaptation.  
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There is evidence in rodents that acute cold exposure reduces ob gene expression in white adipose 
tissue (Trayhurn, Thomas et al. 1995), and some evidence of a similar response in humans (Ricci, Fried 
et al. 2000). Many mammals enter a state of cold-induced torpor or hibernation in the winter months, 
which is characterised by significant reductions in energy expenditure. Additionally the picture is 
further complicated by the cold-induced activation of brown adipose tissue (BAT) (Enriori, Sinnayah 
et al. 2011).  Collectively these findings lead us to hypothesise that energy deficit, irrespective of cause, 
is detected and responded to by a common mechanism, and this is leptin-mediated. We hypothesise 
that this cold-induced reduction in circulating leptin will be reflected in altered fat preference, energy 
expenditure, and circulating markers of sympathetic activation.  
The acute neuroprotective effects of cooling have long been observed, and therapeutic hypothermia 
is standard practice under many clinical scenarios where acute neuroprotection is required; for 
example, cardiothoracic surgery.  Recent work in rodents has shown that cold exposure may have the 
potential to induce more long-term neuroprotection. In mouse models of Alzheimer’s disease, 
Parkinson’s disease and prion disease cold exposure results in a marked improvement in the 
histological change of the disease. The underlying mechanism behind this finding is the induction of a 
cold shock protein, RNA Binding Protein 3 (RBM3), which appears to promote synaptic plasticity 
(Peretti, Bastide et al. 2015). RBM3 is widely expressed in the brain, spinal cord and in peripheral 
tissues including the gut and adipose tissue. Loss of synaptic plasticity is an upstream event in many 
neurodegenerative diseases, occurring before symptom onset. The mechanism underlying the loss of 
synaptic plasticity has not yet been elucidated, but it may be secondary to change in lipid membrane 
content.  It is interesting to note that high fat diets, especially those that induce ketogenesis, the 
preference for which may be induced by impairment of leptin-melanocortin signalling, may also be 
neuroprotective (Maalouf, Rho et al. 2009, Rahman, Muhammad et al. 2014). It is known that humans 
who are repeatedly exposed to cold (for instance, cold water swimmers) have elevated levels of RBM3 
(Mallucci, unpublished), although the dynamics of this (for instance the frequency and duration of 
cold exposure) in humans has not been defined. We therefore sought to explore the dynamics of 








4.3.1. Cooling study overview 
Healthy, normal weight (BMI 18.5 – 25.9) men age 18-50 years, with no past medical history and who 
were not taking any medications were invited to attend the Wellcome Trust Clinical Research Facility 
or the Wellcome Trust Translational Research Facility for clinical studies.  An initial screening visit, 
consisting of anthropometric measurements, fasting bloods, DEXA scan to assess body composition, 
and fat preference meal were administered.  Subjects were asked to complete the ACE-III 
questionnaire in order to identify any pre-existing neurocognitive deficit.  
Participants with normal results were then invited to participate in two overnight studies, a fortnight 
apart.  The studies were identical, with the exception of the temperature of the temperature 
intervention (either 16oC or 25oC), and measurements included skin temperature, core body 
temperature, pulse and blood pressure, heart rate variability, energy expenditure, blood parameters, 
and neurocognitive function.  Participants were dressed in standardised light clothing before putting 
the cooling suit on, room temperature was controlled at 22oC, and lights were dimmed at a consistent 
setting. The order of study visits was randomised. 
 
 
Figure 16. Schematic of the cooling study protocol. T0 is the start of the temperature intervention 
(either at 25oC or 16oC). Once post temperature intervention measurements were taken, the time was 
recorded and this was used as a “second T0” (labelled Tp, “time post”) as a benchmark for post-
intervention time points and measurements.  Clinical data is represented as mean ± standard 
deviation. Differences between groups were studied using the unpaired student’s t-test.  
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4.3.2. Statistical analysis and terminology 
These experiments are observational studies of the effects of cooling on a chosen set of physiological, 
biochemical, and neuropsychological parameters.  All individuals underwent two identical 
experiments with the exception of whether they were cooled or not cooled (referred to as 
‘thermoneutral’ and ‘cooling’ groups), and these experiments were two weeks apart with subjects 
randomly allocated to which they had first.   
Table 5 shows a typical data set generated from this experiment, using leptin concentration as an 
example.  One can see several potential problems with this type of data set.  A two-tailed test on the 
mean value or percentage change of the treatment groups loses any potential time interval 
differences, but performing these calculations at each time point will also not be sufficient as this will 
not properly take into account any baseline differences between individuals and/or baseline 
differences between means.  Table 5 and its corresponding figure 20 show that there is a wide 
variation in values between subjects, and this in itself is interesting (see discussion).  Mean values for 
group 1 (thermoneutral) and group 2 (cooling) are 3.5 and 3.7, respectively, and given the small 
variance in means over time, it is likely this would confound analysis.  Theoretically, the means at time 
zero should be identical, especially as the two groups actually contain the same individuals.  There are 
several reasons why this could be, but most importantly regression to the mean will mean that the 
two groups are likely to be different on repeated measurements.  In addition, the fact that the two 
experiments took place sequentially will mean that conditions and participant behaviour will not be 
identical.  It is therefore vital to take into account baseline differences between subjects when 
analysing pre- and post-test scores for both treatment interventions, and using change scores alone 





Leptin concentration (ng/ml) 
Pre-test Post-test 
Individual Group 0 min 30 min 60 min 90 min 120 min 180 min 
1 1 7.9 7.5 7.5 7 6.6 6.2 
2 1 0.2 0.1  0.1 0 0 
3 1 3.4 3.1 3 2.9 2.7 2.5 
4 1 7.1 6.2 6.3 6.5 6 5.1 
5 1  1.9 1.8 1.6 1.6 1.2 
6 1 5.2 5 4.8 4.4 4.8 4.6 
7 1 6.5 5.4 5.6 5.4 5.3 4.9 
8 1 3.1 3.1 2.8 2.6 2.6 2.4 
9 1 1.2 1.1 1 0.9 0.9 0.8 
10 1 4.7 4.2 3.9 3.7 3.5 3.3 
11 1 0.9 0.8 0.7 0.7 0.7 0.6 
12 1 0.3 0.3 0.3 0.2 0.2 0.3 
13 1 1.7  1.5 1.4 1.4  
14 1 3.1 2.9 2.9 2.8 2.7 2.4 
 Mean 3.5 3.2 3.2 2.9 2.8 2.6 
 SD 2.6 2.4 2.3 2.3 2.2 2.0 
1 2 10.4 9.4 9.3   7.4 
2 2 0.2 0.2 0.1   0.2 
3 2 2.9 2.6 2.4 2.4 2.2 1.9 
4 2 9.2 8.4 7.3 7 6.4 5.1 
5 2 1.5 1.7 1.5 1.4 1.5 0.8 
6 2 6.3 5.9 5 4.9 4.6 4.4 
7 2 6.6 5.8 5.2 4.8 4.8 4.1 
8 2 3.3 2.9 2.6 2.5 2.4 2.2 
9 2 1.3 1.2 1.1 1.1  1.1 
10 2 3.1 2.7 2.9 2.4 2.5 2.1 
11 2 0.7  0.6 0.6 0.6  
12 2 0.8 0.6 0.6 0.6 0.5 0.4 
13 2 1.7 1.3 1.3 1.2 1.4  
14 2 3.8 3.8 3.6 3.4 3.4 2.8 
 Mean 3.7 3.6 3.1 2.7 2.8 2.7 
 SD 3.2 2.9 2.7 2.0 1.9 2.2 
 
Table 5.  Leptin concentration measured during the cooling experiment.  Group 1, thermoneutral; 
group 2, cooling.  Missing values are due to technical failure.  Mean and standard deviation (SD) at 





4.3.2.1. Different methods of data analysis 
Although it appears logical to adjust for baseline data of the dependant variable, many large multi-
centre randomly controlled trials (RCTs) do not do this, and interestingly the Consolidated Standards 
of Reporting Trials (CONSORT) guidance on RCT reporting does not cover this issue at all (Twisk, 
Bosman et al. 2018), leaving researchers to decide amongst themselves whether to control for 
baseline differences, and if so, which method to use. 
Analysis of the data in this chapter also needs to take into account overall trends in post-test repeated 
measures at multiple time points, and be able to detect the extent to which time influences variance, 
both independently and as an interaction with group (referred to as the interaction factor 
group*time).  In other words, what independent effect does the treatment group have on the 
dependant variable (dv)? What effect does time have irrespective of treatment? And does treatment 
over time influence variance?  
The final problem encountered is that measurements were not achievable for every single data point.  
There are inherent risks in imputing data for these missing values and if possible, is best not 
performed.  Most statistical packages are unable to perform analysis of variance (ANOVA) with missing 
values, paired t tests performed on areas under the curve (AUC) with missing values is likely to omit 
important information generating misleading results, and analysis of change is not possible if a missing 
value happens to be the pre-test measure.   
There appears to be a consensus amongst researchers that if baseline differences exist, then in a 
repeated measures ANOVA (RANOVA) with a pre-test score and multiple post-test scores, the 
indication of whether a treatment has an effect is not just the presence of a group factor, but also the 
presence of a significant group and time interaction.  This overrides any pre-test differences by testing 
whether the pattern of change differs between groups; a proper adjustment is not achieved by 
performing a regular RANOVA or analysis of change alone (Twisk, Bosman et al. 2018).   
Analysis of change involves the calculation of a gain score by subtraction of the pre-test value from 
every subsequent time point as a way to cancel out the baseline differences (effectively converting 
the pre-test score to zero). This is a useful way to estimate differences between groups, and can also 
be used in ANOVAs and ANCOVAs if the raw data does not fit into a valid model, but is generally not 
used in isolation because of the problem of not correcting for regression to the mean.   
Alternatively, if the pre-test score is used as a quantitative covariate (in addition to using qualitative 
categorical covariates such as group and time), then ANCOVA modelling of post-test scores (referred 
to in this chapter as ‘ANCOVA-POST’) can take place.  This allows one to test whether the pre-test 
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score predicts any change over subsequent readings, rather than just controlling for the pre-test 
(baseline difference) score.  
 
4.3.2.2. Statistical methods used for this study 
Data modelling was performed using the XLSTAT add-on for Microsoft Excel (Addinsoft 2017).  For 
repeated measures ANOVA modelling, two fixed factors (time and group) were used as explanatory 
variables and one interaction factor (time*group) was investigated.  For ANCOVA modelling, pre-test 
scores (0 minutes data) were moved from the dependant variable (dv) portion of results to become a 
fixed covariate for the post-test outcomes for each subject.  Full Factorial used analysis was selected.  
Model validity was determined using goodness of fit statistics (R2) and F value of analysis of variance, 
with its corresponding p value.   
For RANOVA, XLSTAT uses a mixed effect model, and output tables include an analysis of variance that 
determines whether the explanatory variables brings significant information to the model, in other 
words  it asks whether it is valid to use the mean to describe the whole population.  A Z test on the 
covariance parameters shows whether the modelling is appropriate for the data (providing 
significance levels for variance and sigma 1).  The model is further tested using a null model likelihood 
ratio test on the compound symmetry structure used, again providing a significance level for this.  Type 
III tests of fixed effects investigate whether the covariate factors have a significant effect on the dv 
(replacing the type III sum of squares of the classical ANOVA and ANCOVA models. 
For all models used, missing values were excluded from the analysis, but all remaining data for that 
subject was included.  Subjects were only excluded in their entirety if no data was available, and this 
was usually because no blood was available to measure that variable. No data was excluded for 
reasons of outlie.  This is likely in some data sets to lose some signal and reduce power, but subject-
to-subject variability appeared evenly spread with no clear outlier ‘cut offs’ apparent.   
The dependent variable (dv) at the zero time point (t0) is referred to as the ‘pre-test’ value or score 
for both thermoneutral and cooling groups.  All dependent variables at subsequent time points are 
referred to as the ‘post-test’ values or scores, although it is acknowledged that thermoneutral and 
cooling treatments continue at 30 min (t30), 60 min (t60), 90 min (t90), and 120 min (t120).  The treatment 
ends at t120, and so the final time point (180 min, t180) occurs 60 minutes after the end of treatment.  
The terms ‘treatment’ and ‘treatment groups’ refer to both thermoneutral and cooling interventions, 
and it is important to note that subjects within both treatment groups have also been fasted overnight 
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and any effects seen (especially in the thermoneutral group) may naturally arise as a result of this 
fixed intervention, which is not taken into account in the modelling as there are no control groups that 






4.4.1. Demographics of participants recruited to the cooling study 
Healthy, non-smoking males aged 18-50 years were recruited to the cooling study.  All participants 
had normal serum cholesterol, thyroid function, liver and renal function and full blood count. BMI 
ranged from 18.69 – 25.84 kg/m2. No participants had any significant past medical history or took any 
prescribed medications. All participants had normal neurocognitive function, defined as a score >88 
on the ACE-III questionnaire.  The average total percentage body fat, determined by Dual X Ray 
Absorptiometry (DEXA), average was 22.1% (range from 12.6% to 33.5%).  Baseline observations of 
the participants are outlined in Table 6.  
















1 1.782 19 65.85 20.73 112 67 59 36.5 
2 1.879 24 84.2 23.84 121 77 50 35.9 
3 1.785 23 80.2 25.17 131 72 82 36.6 
4 1.929 24 92.1 24.75 124 70 61 36.5 
5 1.757 33 79.8 25.84 116 56 50 36.7 
6 1.751 19 60 19.56 112 66 64 36.3 
7 1.74 19 56.6 18.69 111 68 78 36.3 
8 1.791 24 64.3 20.04 117 63 71 36.1 
9 1.879 19 82.8 23.45 120 77 68 36.1 
10 1.786 20 64.8 20.31 120 77 75 36.2 
11 1.884 18 74.4 20.96 119 73 55 36 
12 1.887 21 70.2 19.71 124 64 62 36.1 
13 1.834 19 75.75 22.52 118 71 82 36.2 
14 1.74 21 61.4 20.28 116 62 53 35.7 
15 1.739 23 60.2 19.90 119 69 61 35.8 
 
Table 6. Baseline observations of participants recruited to the cooling study.  Measures of height, 
weight, systolic and diastolic blood pressure, pulse and temperature are shown for the 15 participants 




4.4.2. Physiological response to cooling 
 
4.4.2.1. Skin temperature response to cooling 
iButtons are digital sensors that are taped to the skin. They record temperature in Celcius to two 
decimal places. The ibuttons were set to record skin temperature every two minutes. Sensors were 
placed bilaterally in seven different sites; the forearms, supraclavicular fossa, chest, abdomen, thighs, 
calves and feet.  iButton temperature measurements demonstrated a significant drop in peripheral 
skin temperature in response to cooling.  However, there was no change in supraclavicular 
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Figure 17. Alteration of temperature in response to cooling. Peripheral (a) and chest (b) temperature 
relative to supraclavicular fossa temperature in response to exposure to 16oC or 25oC (n=15). 
Complete iButton data was available on all 15 participants. An EMG was used to ensure that the 
subjects did not shiver; electrodes were places bilaterally over the pectoral muscles and the rectus 
abdominis as the shivering response starts centrally and spreads peripherally.  This confirmed that 
there was no evidence of shivering in any of the participants.  
 
 iButton recordings showed that there was a difference between the cooling and thermoneutral study 
arms in peripheral skin temperature (p = 0.0048).  However this difference was not seen with 
supraclavicular temperature recordings. Supraclavicular and chest temperature recordings were 
compared to see if this difference was caused by activation of supraclavicular BAT stores, or whether 
the difference was secondary to peripheral vasoconstriction. The difference between supraclavicular 
and chest temperatures were compared at 200 minutes, and they were significant (p = 0.001). 
 
4.4.2.2. Pulse 
Blood pressure and pulse rate were measured after an overnight fast in the semi-recumbent position, 
in a dimly lit, quiet room before the temperature intervention, and every 30 minutes during it. There 
were no statistically significant differences at any time point between the thermoneutral and cooling 
groups (figure 18a), and this was also so for gain score analysis of the data (figure 18b).  ANCOVA 
analysis using pre-test scores as a quantitative covariate to adjust for baseline differences (see 
workings and discussion for leptin, section 4.4.3.1) does not show any significance for the group or 
time factors (p values 0.858 and 0.468, respectively).  The least squares (LS) means derived from this 
modelling is shown in figure 18c, and t tests performed on individual time points are not significant. 
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Figure 18.  Effect of temperature intervention on pulse.  Complete pulse rate data was available on 
13 of the study participants.  (a) Results show mean pulse with standard error of the mean, with 
thermoneutral study arm in black and cooling arm in grey.   There were no apparent differences 
between the temperature intervention groups at any time point after a two-tailed paired t test 
analysis.  (b) Gain scores for pulse at each time point with no significant differences at any time point.  
(c) ANCOVA analysis adjusting for baseline differences between groups did not show any group or 
time differences and multiple t tests of LS means also did not show any differences.   
 
4.4.2.3. Blood pressure 
The raw data shows a trend for an increasing blood pressure (BP) in the cooling temperature 
intervention group as time progresses (figure 19a).  Individual time points were not significant.  
Adjusting for individual participant baseline differences using ANCOVA analysis shows that this 
117 
 
observed difference is real.  Analysis was undertaken separately for systolic and diastolic BP (but 
shown together for illustrative purposes in figure 19b).  The systolic BP ANCOVA model was significant 
(R2 0.562 and p <0.0001) and showed statistically significant differences between groups (p = 0.001) 
and over time (p = 0.039).   The diastolic BP ANCOVA model was significant (R2 0.550 and p <0.0001) 
but showed no statistically significant differences between groups (p = 0.624) nor over time (p = 
0.898).   The least squares (LS) means are shown in figure 19b, and two-tailed paired t tests on 
individual time points were significant for systolic BP at 60 min and 120 min (p values 0.033 and 0.020, 
respectively).  This could be in keeping with an increased sympathetic drive during the cooling 
intervention when compared to the thermoneutral arm of the study.   
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Figure 19.  Effect of temperature intervention on blood pressure.  Complete blood pressure data was 
available on 13 participants.  (a) Mean systolic and diastolic blood pressure at each time point with 
error bars (SEM) suggesting a trend for higher BP in the cooling group.  (b) Least squares mean systolic 
and diastolic BP derived from ANCOVA modelling adjusting for individual participant baseline 
differences, showing an overall significant difference between systolic BP thermoneutral and cooling 
groups.  Error bars (SEM) also shown.  Post-analysis t tests on individual time points of the least 
squares means shows significance at 60 min and 120 min (p values 0.033 and 0.020, respectively). 
 
4.4.2.4. Power spectral analysis of Actiheart data 
A sample of actiheart data taken during the gas exchange monitor at the end of the temperature 
intervention (when patients were at rest, under standardised quiet, light-dimmed conditions) was 
chosen for analysis (table 7).  Independent sample t tests were performed; heart rate was significantly 
different between the two study intervention arms (p = 0.0318).  Other measurements did not reach 
significance. 
 
 Thermoneutral Cooling 
Mean HR (bpm) 55.5 ± 13.7 57.4 ± 14.5 
Log10 RMSSD 1.77 ± 0.46 1.77 ± 0.53 
Log10 LF power (ms2) 1.73 ± 0.18 1.73 ± 0.19 
Log10 HF power (ms2) 1.62 ± 0.37 1.61 ± 0.36 
Log10 LFHF ratio -0.11 ± 0.54 0.12 ± 0.55 
 
Table 7.  Comparison of temperature interventions on power spectral analysis of actiheart data.  
Mean Actiheart data taken during the gas exchange monitor at the end of the temperature 
intervention.  Two-tailed paired t test analysis showed a statistically significant difference between 





4.4.3. Biochemical response to cooling 
4.4.3.1. Leptin 
Plasma leptin concentration was measured at all time points.   All subject/group rows passed 
D’Agostino & Pearson omnibus and Shapiro-Wilk normality tests and so the data was not log 
transformed.   The data set acquired is shown in table 5.   Figure 20 shows this data as a scatter plot 
so that the variability and spread of individual data points can be seen (figure 20a).   Ordinary means 
of these values are shown in figure 20b and suggest that leptin concentration decreases over time for 
both treatment groups, without any discernible difference between groups (a decrease potentially 
due to the ongoing fasting state).   However, it can also be seen that the baseline means are different 
between groups, and so gain scores were calculated (shown in table 8) and plotted (figure 20c). 
 
Leptin concentration (ng/ml) 
Pre-test Post-test 
Individual Group 0 min 30 min 60 min 90 min 120 min 180 min 
1 1 0 -0.4 -0.4 -0.9 -1.3 -1.7 
2 1 0 -0.1  -0.1 -0.2 -0.2 
3 1 0 -0.3 -0.4 -0.5 -0.7 -0.9 
4 1 0 -0.9 -0.8 -0.6 -1.1 -2 
5 1 0      
6 1 0 -0.2 -0.4 -0.8 -0.4 -0.6 
7 1 0 -1.1 -0.9 -1.1 -1.2 -1.6 
8 1 0 0 -0.3 -0.5 -0.5 -0.7 
9 1 0 -0.1 -0.2 -0.3 -0.3 -0.4 
10 1 0 -0.5 -0.8 -1 -1.2 -1.4 
11 1 0 -0.1 -0.2 -0.2 -0.2 -0.3 
12 1 0 0 0 -0.1 -0.1 0 
13 1 0  -0.2 -0.3 -0.3  
14 1 0 -0.2 -0.2 -0.3 -0.4 -0.7 
 Mean 0.00 0.33 0.40 0.52 0.61 0.88 
 SD 0.00 0.35 0.29 0.34 0.44 0.65 
1 2 0 -1 -1.1   -3 
2 2 0 0 -0.1   0 
3 2 0 -0.3 -0.5 -0.5 -0.7 -1 
4 2 0 -0.8 -1.9 -2.2 -2.8 -4.1 
5 2 0 0.2 0 -0.1 0 -0.7 
6 2 0 -0.4 -1.3 -1.4 -1.7 -1.9 
7 2 0 -0.8 -1.4 -1.8 -1.8 -2.5 
8 2 0 -0.4 -0.7 -0.8 -0.9 -1.1 
9 2 0 -0.1 -0.2 -0.2  -0.2 
10 2 0 -0.4 -0.2 -0.7 -0.6 -1 
11 2 0  -0.1 -0.1 -0.1  
12 2 0 -0.2 -0.2 -0.2 -0.3 -0.4 
13 2 0 -0.4 -0.4 -0.5 -0.3  
14 2 0 0 -0.2 -0.4 -0.4 -1 
 Mean 0.00 0.35 0.59 0.74 0.87 1.41 
 SD 0.00 0.35 0.60 0.70 0.87 1.23 
120 
 
Table 8. Leptin concentration temperature intervention data set.  Including 14 participants in two 
groups (thermoneutral and cooling), with leptin concentrations taken at 0 mins, and 30 min intervals 
up to 120 min. A final level was taken an hour after treatment cessation at 180 min.  
 
This shows a considerably more discernible pattern of decrease in leptin concentration, which is more 
marked for the cooling group.  A two-tailed t test was not significant at any time point, however.  It 
does appear that the gain score means are showing a biological effect, and so the data was next 
analysed using an ANCOVA-POST model. 
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Figure 20.  Effect of temperature intervention on leptin concentration.  (a) All data points for 
thermoneutral (black) and cooling (grey) groups with lines at each time point to denote corresponding 
means.  It can be seen that there is a large degree of variability between subjects in both groups.  (b) 
Group means with error bars (SEM); it is clearly seen that the cooling group baseline mean (t0) starts 
at a higher value than that of the thermoneutral mean.  (c) Group means of gain scores (calculations 
shown in table 8) with error bars (SEM).  No group differences at any time point was significant for (b) 
or (c) using multiple two-tailed paired t tests.  Vertical dotted line denotes treatment cessation at t120. 
 
4.4.3.1.1. ANCOVA analysis using pre-test as a quantitative covariate (ANCOVA-POST) 
Goodness of fit statistics for the dependent variable gives an R2 value of 0.986, suggesting that almost 
all of the variability is explained by the model parameters included.  Analysis of leptin variance gives 
an F value of 535.07 for the model with p <0.0001, suggesting that the model fits well.  Model 
parameters reveal that post-test scores after adjusting for pre-test scores reflect a very strong overall 
effect due to time (F-test p<0.0001), and this is also strongly significant at each individual time point.  
Importantly, analysis shows that the treatment group has a statistically significant effect on overall 
leptin concentration, albeit weaker than for time (p = 0.002).   
The ANCOVA modelling output also produces least squares means (also known as the estimated 
population marginal means), which represent the means of each group once the covariate has been 
controlled for and are derived from the regression intercept B0.  In other words, they are within-group 
means appropriately adjusted for the other quantitative effects in the model, namely the pre-test 
score, and are shown in table 9 and figure 21 along with their standard error and 95% confidence 
intervals.  Both thermoneutral and cooling groups show a reduction in leptin concentration over time 
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(highly significant, p<0.0001), and an overall group effect is also seen (p = 0.002) with the cooling arm 
showing lower leptin concentrations at all time points, with an increasing difference as time 
progresses, even 60 minutes after cessation of treatment at t180.  Multiple two-tailed paired t tests on 
LS mean differences at each time point show that the group difference at t180 is significant (p = 0.003). 
Group Time LS mean Standard error Lower bound (95%) Upper bound (95%) 
1 30 3.373 0.084 3.207 3.539 
1 60 3.298 0.084 3.132 3.464 
1 90 3.102 0.081 2.942 3.262 
1 120 3.018 0.080 2.858 3.177 
1 180 2.791 0.084 2.625 2.957 
2 30 3.372 0.081 3.213 3.532 
2 60 3.098 0.078 2.944 3.251 
2 90 2.867 0.084 2.700 3.033 
2 120 2.785 0.088 2.612 2.959 
2 180 2.404 0.084 2.237 2.571 
 
Table 9.  Treatment group effect on leptin concentration LS means using ANCOVA-POST analysis.  LS 
means shown at post-test time points, adjusted by ANCOVA-POST modelling on the pre-test values as 
a covariate using the XLSAT package for Microsoft Excel.  Group 1, thermoneutral and group 2, cooling. 
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Figure 21.  Effect of temperature on LS means of leptin concentration (ANOVA-POST).  LS means 
shown with error bars (SEM 95% CI) at post-test time points, adjusted for the pre-test covariate by 
ANCOVA-POST modelling.  Overall effect of time and group statistically significant (see main text).  A 
two-tailed paired t test was also performed between groups on each individual time point (30, 60, 90, 
120, and 180 min) giving p values of 0.993, 0.093, 0.054, 0.061, and 0.003, respectively.  Vertical 
dotted line denotes treatment cessation at t120. 
 
4.4.3.1.2. ANCOVA analysis using dv subtracted from baseline value (ANCOVA-CHANGE) 
Rather than using raw pre-test scores as a covariate for raw post-test scores, this model incorporates 
analysis of change values to the model.  The pre-test score is a subtraction of the baseline value from 
t30, and post-test scores are derived from baseline subtractions from subsequent time points, as 
illustrated in table 10 for the first 4 subjects in group 1 below (for illustrative purposes). 
 
 
   post-test 
Group Subject pre-test t1 t2 t3 t4 
  (t30-t0) (t60-t0) (t90-t0) (t120-t0) (t180-t0) 
1 1 -0.4 -0.4 -0.9 -1.3 -1.7 
1 2 -0.1  -0.1 -0.2 -0.2 
1 3 -0.3 -0.4 -0.5 -0.7 -0.9 
1 4 -0.9 -0.8 -0.6 -1.1 -2 
Table 10. Gain score method for ANCOVA-CHANGE analysis. 
 
Goodness of fit statistics for the dependent variable gives an R2 value of only 0.644, suggesting that 
this method may indeed be inferior to the ANCOVA-POST method.  The analysis of leptin variance 
gives an F value of 18.99, but still with a highly significant p value (<0.0001).  Model parameters reveal 
that time still has a highly significant effect on leptin concentration overall (p<0.0001), and also at 
each time point.  Again, a significant overall effect of group on leptin concentrations is observed (p = 
0.01).  The LS means adjusted for baseline differences are shown in figure 22 along with 95% 
confidence intervals.    
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As with analysis using ANOVA-POST, both thermoneutral and cooling groups show a statistically 
significant reduction in leptin concentration over time with the cooling group exhibiting lower 
concentrations than in the thermoneutral group and with increasing differences as time progresses.  
Multiple two-tailed paired t tests on LS mean differences at each time point show significance for the 
difference at t4 (p = 0.014). 
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Figure 22.  Effect of temperature on LS means of leptin concentration (ANOVA-CHANGE).  LS means 
shown with error bars (SEM 95% CI) at post-test time points, adjusted for the pre-test covariate by 
ANCOVA-CHANGE modelling.  The overall effect of group with time is statistically significant (see main 
text).  A two-tailed paired t test was also performed between groups on each individual time point, 




4.4.3.1.3. Repeated measures ANOVA 
As discussed, repeated measures ANOVA (RANOVA) does not take into account baseline differences 
between subjects, and so for the model to have practical use with this data, the critical indication of a 
differential effect of the group (treatment) factor is the presence of a significant interaction between 
groups and time.  In other words, the group*time interaction tests whether the pattern of change is 
different between groups over time.  RANOVA analysis of leptin concentration was performed and 
showed that the covariance parameters (variance and sigma 1) were highly significant (both p<0.0001 
with Z test scores of 7.681 and 3.591, respectively) and the null model likelihood ratio test was also 
highly significant (p<0.0001 with chi-square of 407.2), both suggesting that the model was valid for 
the data.  Type III tests of fixed effects show that time has a significant effect on the data (p<0.0001) 
but not the group (p=0.905) or group*time interaction overall (p=0.167).  However, the individual 
group2*time interaction at 180 minutes was significant (p=0.017) suggesting that the strong signal at 
the last time point found by the other analyses was also seen using RANOVA. 
 
4.4.3.1.4. Repeated measures ANOVA using mixed models 
This analysis takes into account both fixed and random effects in a single general linear model (GLM), 
and is able to incorporate repeated measures in a similar way to RANOVA.  Its output includes type I, 
II, and III tests of the fixed effects.  Running this model gives similar results to the RANOVA shown 
above, observing that time has a significant effect on the data (p<0.0001) but not the group (p=0.901) 
or group*time interaction overall (p=0.133).  The individual group2*time interaction at 180 minutes 
is again significant (p=0.013).  Unsurprisingly, both RANOVA analyses do not show any significant 
effect of group on the overall variance of leptin concentration as the derived group*time means used 






The study sought to test whether a cooling-induced calorie deficit would have any effect on circulating 
BDNF levels, by measuring it at 30 minute intervals during the temperature intervention and 60 
minutes after.  Raw data suggested an overall trend in greater BDNF concentration in the cooling 
group, with an increase at 90 minutes of cooling (figure 23b).  However, two-tailed paired t tests on 
means at each time point were not significant.  Adjusting for baseline differences, ANCOVA-POST 
analysis gave an R2 value of only 0.121, and the analysis of variance showed that the validity of the 
model was not significant (p = 0.426).  Due to these results suggesting that the model was not valid, 
the assumptions of the ANCOVA model were subsequently tested firstly by running an ANOVA to 
check that there were no significant differences in the pre-test values between groups, and secondly 
running an ANCOVA on post-test scores using pre-test and group covariates to check that the 
group*pre-test interaction had no significant between-subject effects (thereby testing the assumption 
of homogeneity of regression correlation).  The first test showed that there were between-group 
differences in pre-test scores (p = 0.001), but the second test showed that the assumption of 
homogeneity was valid (group*pre-test interaction p = 0.609).  As there were statistically significant 
differences in the pre-test scores between groups, running these checks on a gain score 
transformation of the data set (figure 23d) showed that there were no differences between groups in 
the pre-test scores (p = 0.268)  and also that the assumption of homogeneity was valid in this data 
format.   
An ANCOVA-CHANGE analysis was therefore performed and showed that the R2 value was better at 
0.380, and the validity of the model was highly significant (p <0.0001).  This analysis showed that there 
were no significant effects of group overall on BDNF levels (although did approach significance, p = 
0.080).  The least squares means derived from this analysis did, however, suggest that there was a 
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Figure 23.  Effect of temperature intervention on BDNF concentration.  Complete data was available 
on 14 participants.  (a) All data points measured with horizontal means shown at each time point.  (b) 
Group means with error bars (SEM).  (c) Group means of gain scores with error bars (SEM).  (d) Least 
squares means with error bars (SEM 95% CI) derived from ANCOVA-POST analysis that adjusts for 
baseline differences.  This model was found to be invalid due to statistically significant group 
differences in pre-test scores (see main text).  (e) Least squares means with error bars (SEM 95% CI) 
derived from ANCOVA-CHANGE analysis, which was found to be a valid model but also did not show 
any statistically significant group effect.  There was a nominally significant group difference at the t4 




4.4.3.3. Glucose homeostasis 
 
4.4.3.3.1. Glucagon 
Plasma glucagon concentration was measured before and after the temperature intervention at t0 and 
t120.  There was significant overlap in glucagon concentrations between groups (figure 24a), but there 
appeared to be a trend for an increase in glucagon concentration over time in the thermoneutral 
group and a decrease in the cooling group (figure 24b), but a two-tailed paired t test at 120 minutes 
was not significant nor when using a change score.  ANCOVA analysis did not show any statistically 
significant group or time effect, although there is a downward trend with cooling (figure 24c). 
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Figure 24. Effect of temperature intervention on glucagon concentration.  Complete data was 
available on 11 participants.  (a) All data points measured with horizontal means shown at each time 
point.  (b) Group means with error bars (SEM).  (c) Group means of gain scores with error bars (SEM).  
(d) Least squares means with error bars (SEM 95% CI) derived from ANCOVA-POST analysis that adjusts 
for baseline differences.  ANOCVA-POST modelling did not show any group effect and there were no 
statistically different group differences at any time point for (b) - (d) using multiple two-tailed paired 






Blood glucose concentration was also measured before and after the temperature intervention at t0 
and t120.  There was no statistically significant difference in means and change score means (figure 
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Figure 25. Effect of temperature intervention on glucose concentration.  Complete data was available 
on 14 participants.  (a) All data points measured with horizontal means shown at each time point.  (b) 
Group means with error bars (SEM).  (c) Group means of gain scores with error bars (SEM).  (d) Least 
squares means with error bars (SEM 95% CI) derived from ANCOVA-POST analysis that adjusts for 
baseline differences.  ANOCVA-POST modelling did not show any group effect and there were no 
statistically different group differences at any time point for (b) - (d) using multiple two-tailed paired 





Plasma insulin was measured before the temperature intervention, every 30 minutes during it, and 60 
minutes afterwards (as per leptin and BDNF).  Raw data suggested an initial downward trend in insulin 
concentration with both treatment groups followed up an upward trend after intervention cessation.  
However, two-tailed paired t tests on means were not significant (figure 26b).  Adjusting for baseline 
differences, ANCOVA-POST analysis gave an R2 value of 0.618 meaning 62% of the variance was 
explained by the covariates.  Most of this came from the pre-test values predicting the post-test values 
(p <0.0001), but also the effect of time (p = 0.002).  Grouping did not affect the post-test scores (p = 
0.574) and there was no group effect over time (group*time interaction, p = 0.819).      
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Figure 26. Effect of temperature intervention on insulin concentration.  Complete data was available 
on 14 and 13 subjects in the thermoneutral and cooling groups, respectively.  (a) All data points 
measured with horizontal means shown at each time point.  (b) Group means with error bars (SEM).  
(c) Least squares means with error bars (SEM 95% CI) derived from ANCOVA-POST analysis that adjusts 
for baseline differences.  Data shows an upward trend after the temperature intervention cessation 
but this was not statistically significant.  No group differences at any time point was significant for (b) 
- (c) using multiple two-tailed paired t tests.  Vertical dotted lines denote treatment cessation at t120. 
 
4.4.3.4. Cortisol 
Serum cortisol was measured before the temperature intervention, every 30 minutes during, and 60 
minutes afterwards (as per leptin and insulin).  Raw data suggested an overall downward trend in 
cortisol concentration, with a greater negative effect with the cooling group (figures 27a and 27b).  
However, two-tailed paired t tests on means at each time point were not significant.  Adjusting for 
baseline differences, ANCOVA-POST analysis gave an R2 value of only 0.219, and the analysis of 
variance showed that the validity of the model was not hugely significant (p = 0.006).  Nonetheless, 
the type II and III sum of squares analysis did show there was a marginal overall effect from the pre-
test scores, but none from the time or group covariates.  Due to these atypical results, the assumptions 
of the ANCOVA model were subsequently tested firstly by running an ANOVA to check that there were 
no significant differences in the pre-test values between groups, and secondly running an ANCOVA on 
post-test scores using pre-test and group covariates to check that the group*time interaction had no 
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significant between-subject effects (thereby testing the assumption of homogeneity of regression 
correlation).  The first test did show that there were between-group differences in pre-test scores (p 
= 0.016), but the second test showed that the assumption of homogeneity was valid.   
As there were significant overall differences in the pre-test scores between groups, running these 
checks on a gain score transformation of the data set (figure 27d) showed that there were no 
differences between groups in the pre-test scores (p = 0.457)  and also that the assumption of 
homogeneity was valid in this data format.  An ANCOVA-CHANGE analysis was therefore performed 
and showed that the R2 value was better at 0.528, and the validity of the model was highly significant 
(p <0.0001).  However, this analysis showed that there were indeed no significant effects of group or 
time on cortisol levels.  The least squares means derived from this analysis did not show individual 
statistical significance at any individual time frame (figure 27e). 
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Figure 27. Effect of temperature intervention on cortisol concentration.  Complete data was available 
on 14 participants.  (a) All data points measured with horizontal means shown at each time point.  (b) 
Group means with error bars (SEM).  (c) Group means of gain scores with error bars (SEM).  (d) Least 
squares means with error bars (SEM 95% CI) derived from ANCOVA-POST analysis that adjusts for 
baseline differences.  This model was found to be invalid due to statistically significant group 
differences in pre-test scores (see main text).  (e) Least squares means with error bars (SEM 95% CI) 
derived from ANCOVA-CHANGE analysis, which was found to be a valid model but also did not show 
any statistically significant group effect.  No group differences at any time point was significant for (b) 
- (e) using multiple two-tailed paired t tests.  Vertical dotted lines denote treatment cessation at t120. 
 
4.4.3.5. Thyroid function 
Thyroid function was measured before the temperature intervention, every 30 minutes during, and 
one hour after its cessation.  There was no significant difference between the two intervention groups 
in thyroid function, measured using the assay platform Advia Centaur. 
 
4.4.2.5.1. Thyroid stimulating hormone (TSH) 
The cooling group appears to have higher TSH levels compared to thermoneutral, but that both 
decrease during intervention before returning to their baseline 60 minutes after treatment cessation 
(figure 28b).  These differences were not statistically significant at each time point when evaluating t 
test scores on the ordinary means.  When baseline differences are adjusted for using ANCOVA-POST 
analysis (R2 = 0.921 and analysis of variance model p <0.0001) there is a nominally significant group 
effect seen (p = 0.052) on type I sum of squares (SS) analysis, but this is not significant on type II (p = 
0.974) and type III (p = 0.954) SS analysis, and so should be discounted.  A plot of derived LS means is 
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Figure 28. Effect of temperature intervention on TSH concentration.  Complete data was available 
on 14 subjects in each group.  (a) All data points measured with horizontal means shown at each time 
point.  (b) Group means with error bars (SEM).  (c) Least squares means with error bars (SEM 95% CI) 
derived from ANCOVA-POST analysis that adjusts for baseline differences.  Data shows an upward 
trend after the temperature intervention cessation but this was not statistically significant.  No group 
differences at any time point was significant for (b) - (c) using multiple two-tailed paired t tests.  
Vertical dotted lines denote treatment cessation at t120. 
4.4.2.5.2. Free thyroxine hormone (fT4) 
The cooling group appears to have lower fT4 levels at all time points (figure 29b), and a statistically 
significant difference is seen when comparing the overall means of the two groups unadjusted for 
baseline, (not shown).  However, when baseline differences are adjusted for using ANCOVA-POST 
analysis (R2 = 0.848 and analysis of variance model p <0.0001) no difference is seen.  Type I, II, and III 
sum of squares analysis shows that only the pre-test scores have an effect on post-test scores, and 
not group or time factors.  A chart of derived LS means is shown in figure 29c, and there are no 
significant differences between groups at any time point. 
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Figure 29.  Effect of temperature intervention on fT4 concentration.  Complete data was available on 
14 subjects in each group.  (a) All data points measured with horizontal means shown at each time 
point.  (b) Group means with error bars (SEM).  (c) Least squares means with error bars (SEM 95% CI) 
derived from ANCOVA-POST analysis that adjusts for baseline differences.  Data shows an upward 
trend after the temperature intervention cessation but this was not statistically significant.  No group 
differences at any time point was significant for (b) - (c) using multiple two-tailed paired t tests.  




4.4.2.5.3. Free triiodothyronine (fT3) 
In the unadjusted data, there appeared to be a trend for lower fT3 concentration means in the cooling 
group (figure 30b), but this apparent trend was lost after adjustment for baseline differences using 
ANCOVA-POST analysis (R2 = 0.776 and analysis of variance model p <0.0001).  Type I, II, and III sum of 
squares analysis shows that only the pre-test scores have an effect on post-test scores, and not group 
or time factors, although the group factor approached significance (p = 0.074).  A chart of derived LS 
means is shown in figure 30c, and there are no significant differences between groups at any time 
point. 
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Figure 30.  Effect of temperature intervention on fT3 concentration.  Complete data was available on 
14 subjects in each group.  (a) All data points measured with horizontal means shown at each time 
point.  (b) Group means with error bars (SEM).  (c) Least squares means with error bars (SEM 95% CI) 
derived from ANCOVA-POST analysis that adjusts for baseline differences.  No group differences at 
any time point was significant for (b) - (c) using multiple two-tailed paired t tests.  Vertical dotted lines 





4.4.4. Energy expenditure response to cooling 
 
4.4.4.1. Energy expenditure 
A gas exchange monitor was used to measure energy expenditure (EE) and respiratory quotient (RQ).  
Measurements were taken after 60 minutes at a thermoneutral temperature (Tn60, just before the 
temperature intervention, referred to here as ‘pre-test’), and after 2 hours of the temperature 
intervention (at Ti120, referred to here as ‘post-test’).  Measurements were taken under controlled 
conditions in a quiet, dimly lit room, and the participant was closely observed to ensure they did not 
fall asleep.  At the time of recording consecutive time epochs were examined.  When the difference 
between consecutive epochs was <10%, a five minute period of data was taken and averaged for each 
of the 15 participants.  As the participants were starved, energy expenditure in the above conditions 
is considered equivalent to the basal metabolic rate (BMR). 
The raw plots shows a trend for an increase in energy expenditure mean pre- and post-test for both 
temperature intervention groups, with higher values for the cooling group (31a and 31b).  However, 
the differences in gain scores (‘delta-test’) do not show any statistically different results with a two-
tailed paired t test (p = 0.33, figure 31c), and although the baseline-adjusted least squares means 
derived from ANCOVA modelling also show a trend for greater EE with cooling (figure 31d), this also 
did not reach significance (R2 = 0.612, p = 0.32).   
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Figure 31. Effect of temperature intervention on energy expenditure.  Complete data was available 
on 15 participants.  (a) All data points with means pre-test and post-test.  (b) Group means with error 
bars (SEM).  (c) Group means of gain scores with error bars (SEM).  (d) Least squares means with error 




4.4.4.2. Energy expenditure and correlation with body fat  
It was not possible to set up an ANCOVA model that adjusted for baseline using pre-test scores as a 
quantitative covariate for the dependent variable of post-test scores, whilst also using percentage 
body fat as another quantitative covariate, and so three separate ANCOVA models were performed 
using percentage body fat as the covariate for either pre-test, post-test, or delta-test (the gain score 
of post-test minus pre-test) as the dependant variable, with the temperature intervention group 
added as a qualitative covariate.  Percentage body fat did not appear to affect any of the dv (type III 
sum of squares analysis showed p values of 0.163, 0.461, and 0.493, respectively), and there were no 
%fat*group interactions seen.  Correlation between pre-test, post-test, and delta-test values against 
percentage body fat, total mass, and height, was also assessed individually using a linear regression 
model, and no correlations were found although a non-significant trend was seen for greater EE with 
increasing percentage body fat (figure 32 and table 11).   
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Figure 32. Correlation between percentage body fat and energy expenditure.  Scatter plot for four 
groups of data (pre-test and post-test scores for thermoneutral and cooling groups.  Linear trend lines 
were drawn, and although each appears to have a pattern for greater EE with increasing body fat, 




    Thermoneutral Cooling 
   Pre-test Post-test Delta-test Pre-test Post-test Delta-test 
R²   0.353 0.567 0.267 0.268 0.097 0.069 
F  1.999 4.805 1.339 1.341 0.394 0.271 
P value  0.173 0.022 0.312 0.311 0.760 0.845 
Height 
F 0.396 0.041 0.980 1.021 0.638 0.005 
Pr>F 0.542 0.842 0.343 0.334 0.441 0.947 
Mass 
F 2.536 3.006 0.000 0.017 0.155 0.220 
Pr>F 0.140 0.111 0.998 0.898 0.702 0.648 
% Fat 
F 0.188 0.816 0.230 0.458 0.320 0.009 
Pr>F 0.673 0.386 0.641 0.513 0.583 0.926 
 
Table 11. Correlation of height, mass, and percentage body fat with energy expenditure. Pre-test, 
post-test, and delta-test (gain score) for the thermoneutral and cooling groups.  Linear regression lines 
shown on a scatter plot for all 15 participants.  No correlation is seen between any of the groups or 
factors assessed.  Calculated using XLSTAT package for Microsoft Excel.  All data sets passed tests of 
normality. 
 
4.4.4.3. Respiratory quotient 
The respiratory quotient (RQ), calculated by dividing the volume of carbon dioxide eliminated by the 
amount of oxygen consumed, provides a measure of the primary substrate utilised as an energy source 
by the body.  Respiratory quotients of 1 represent carbohydrate utilisation, whereas those of 0.7 
represent fat.  The RQ was measured before and after the temperature intervention under resting, 
fasted conditions in a dimly lit, quiet room.  The same five minute period of data used for BMR 
calculation was averaged for each of the 15 participants.   
There appeared to be a lower RQ in the cooling group of the study (figure 33a and 33b) but this trend 
reversed when plotting the gain score (figure 33c) and a two-tailed paired t test show no significant 
differences between means (p = 0.21).  The baseline-adjusted least squares means derived from 
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Figure 33. Effect of temperature intervention on respiratory quotient.  Complete data was available 
on 15 participants.  (a) All data points measured with means shown at pre-test and post-test.  (b) 
Group means with error bars (SEM).  (c) Group means of gain scores with error bars (SEM).  (d) Least 
squares means with error bars (SEM 95% CI) derived from ANCOVA-POST analysis that adjusts for 
baseline differences.  ANOCVA-POST modelling did not show any group effect and there were no 
statistically different group differences at any time point for (b) - (d) using multiple two-tailed paired 
t tests.   
 
4.4.4.4. Respiratory quotient and correlation with body fat  
As per analysis for energy expenditure, three separate ANCOVA models were performed using 
percentage body fat as the covariate for either pre-test, post-test, or delta-test (the gain score of post-
test minus pre-test) as the dependant variable, with the temperature intervention group added as a 
qualitative covariate.  Percentage body fat did not appear to affect any of the dv (type III sum of 
squares analysis showed p values of 0.524, 0.332, and 0.666, respectively), and there were no 
%fat*group interactions seen.   
Correlation between pre-test, post-test, and delta-test values against percentage body fat, total mass, 
and height, was also assessed individually using a linear regression model, and no correlations were 
found with percentage body fat, but as one might expect here was correlation with RQ and mass, and 
RQ and height for some of the factors (figure 34 and table 12).   
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Figure 34. Correlation between percentage body fat and respiratory quotient. Scatter plot for four 
groups of data (pre-test and post-test scores for thermoneutral and cooling groups.  Linear trend lines 
shown, none statistically significant. 
 
    Thermoneutral Cooling 
   Pre-test Post-test Delta-test Pre-test Post-test Delta-test 
R²   0.628 0.072 0.354 0.524 0.194 0.205 
F  6.186 0.285 2.014 4.036 0.883 0.945 
Pr > F  0.010 0.836 0.171 0.037 0.480 0.452 
Height 
F 6.151 0.205 4.183 6.626 0.411 1.460 
Pr>F 0.031 0.659 0.066 0.026 0.535 0.252 
Mass 
F 12.417 0.017 5.512 1.049 0.014 0.797 
Pr>F 0.005 0.899 0.039 0.328 0.908 0.391 
% Fat 
F 1.252 0.238 1.513 0.092 0.120 0.024 
Pr>F 0.287 0.635 0.244 0.768 0.736 0.879 
 
Table 12. Correlation of height, mass, and percentage body fat with the respiratory quotient. Pre-
test, post-test, and delta-test (gain score) for the thermoneutral and cooling groups.  Linear regression 
lines drawn on a scatter plot for all 15 participants.  No correlation is seen between any of the groups 




4.4.4.5. Energy intake and fat preference 
Energy intake was assessed one hour after the cessation of the temperature intervention. We used a 
paradigm that we had previously developed where subjects were given a 15g anonymised taste 
sample of the three test meals (20, 40 and 60% fat content, meals identical in appearance, mouth-feel 
and taste) and asked a visual analogue score was performed for each to assess how much the 
participant “liked” it. The three test meals were then provided and subjects were then allowed to eat 
ad libitum, and total consumption of each was measured by weight. The visual analogue scales were 
then repeated in an identical manner.  This paradigm has been previously used to show that patients 
with disrupted leptin-melanocortin signalling (from MC4R mutations) eat more high fat food, without 
any change in their “liking” ratings, indicating that this may be a subconscious biological effect. 
 
 
Meal Fat (%) Protein (%) Carbohydrate (%) Caloric density 
(kcal g-1) 
Low fat 20 25 56 1.1 
Medium fat 40 19 42 1.5 
High fat 60 13 28 2.0 
 
Table 13. Macronutrient composition of the meals used in the fat preference test.  Percentage of 
energy derived from each macronutrient is shown. Kcal=Calories. 
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Figure 35. Likings ratings for the fat preference meals premeal (a) and postmeal (b). Results show 
mean with standard error of mean. Likings ratings in the premeal VAS scores did not reach significance, 
although showed a trend towards preference for the high fat meal in the cooling study arm.  The post-
meal VAS scores showed a significant preference for the low fat meal in the cooling arm of the study 
when a two-tailed paired t-test was applied (p = 0.009), but there was no significant difference for the 
other two test meals. Hunger and fullness was additionally assessed before and after the fat 
preference meal.  Premeal measurements showed a trend for participants to be more hungry and less 
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full in the cooling study arm, this did not reach statistical significance when a paired t test was applied 
(p = 0.0561 and 0.32, respectively). Postmeal hunger and fullness scores did not show any difference 
between the two study arms.  
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Figure 36. Total intake of low, medium and high fat meals following temperature intervention.  
Results show mean consumption (kCal) with standard error of mean.  A two-tailed paired t test was 
applied and showed a significant increase in consumption of the high fat meal in the cooling arm of 
the study (p = 0.0048). There was no significant difference in consumption of the low and medium fat 






4.4.5. Neurocognitive response to cooling 
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Figure 37. Changes in perception of neurocognition as measured by visual analogue scale.  A visual 
analogue scale was performed before and after the temperature intervention to assess the subject’s 
perception of their neurocognitive state. A paired t test showed that the subjects in the cooling arm 
felt significantly more stressed than in the thermoneutral arm (p = 0.0428), but other parameters did 





4.4.5.2. Changes in neurocognitive tasks in response to cooling 
 
4.4.5.2.1. Rey auditory verbal learning test (RAVLT) test 
The RAVLT test evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of 
learning, learning strategies, retroactive and proactive interference, presence of confabulation and 
confusion in memory processes, information retention and differences between learning and 
retrieval.  Participants are given a list of 15 unrelated words repeated over five different trials.  
Another list is of 15 unrelated words are given and the client must again repeat the original list of 15 
words then and again after 20 minutes.  There was no difference in score between the two study 
intervention arms. 
 


















Figure 38. RAVLT scores in the thermoneutral and cooling study intervention arms. There was no 





4.4.5.2.2. Verbal fluency 
The verbal fluency test is a short test of verbal functioning.  The test used in this study was of letter 
fluency; subjects were given a letter and asked to list as many words as they could beginning with that 
letter in one minute. The letter used was changed each time to limit any learning-related improvement 
in the task. It tests verbal ability and executive control. Participants in the cooling arm of the study 
were able to generate significantly more words in one minute than they were after two hours at a 
thermoneutral temperature.  




























Figure 39. Post temperature intervention verbal fluency. Subjects in the cooling arm of the study 
were able to generate significantly more words than in the thermoneutral arm (n = 14). Data shown 





4.4.5.2.3. Digit span 
The digit span is a test where participants are asked to repeat number sequences of increasing length. 
This is followed by a similar test where participants are asked to repeat number sequences in reverse.  
The first element tests short term memory and the second working memory. The scores for the two 
tests are then added together to give an overall score. Participants in the cooling arm scored 
significantly more highly in the cooling arm than the thermoneutral arm of the study. 





















Figure 40. Digit span scores in response to cooling. Participants in the cooling arm were significantly 
better at the digit span test than those exposed to two hours at a thermoneutral temperature. Data 
shown is mean with standard error of mean and was available of 14 subjects. A paired t test 





4.4.5.2.4. Hayling test 
The Hayling test is a measure of response initiation and response suppression. Subjects are asked to 
complete a list of fifteen sentences with the last word missing.  They are then given a second set of 
sentences missing the last word and are asked to complete the sentences with a word missing with a 
word that is completely unrelated to the sentence in every way.  The time taken for both of these 
responses is measured. The first part of the test measures response initiation time, and the second, 
response suppression (a frontal lobe function) and thinking time. A composite score is awarded based 
on the two test elements. There was no significant difference between the two study arms in the 
response to the Hayling test. 
 




















Figure 41. Effect of cooling on the Hayling test. Complete data was available on 14 participants. A 





4.4.5.2.5. Trail making test 
The trail making test examines visual attention and task switching. It consists of two parts; in the first 
part (A) the subject is instructed to connect a set of 25 numbered dots as quickly as possible, while 
still maintaining accuracy. In the second part (B) the numbers are interspersed with letters. The test 
can provide information about visual search speed, scanning, speed of processing, mental flexibility, 
as well as executive functioning. While there was a trend towards higher scores in the cooling arm of 




































































Figure 42. Effect of cooling on the trail making test. Data was available on 14 participants, and shows 
mean with standard error of mean. A paired t test was applied separately to both parts of the test, 





4.4.5.2.6. Rey diagram 
The Rey diagram requests subjects to reproduce a complex line drawing, first by copying it freehand 
(recognition), and then by drawing it from memory after a time period of three minutes (recall). It 
tests many different elements of cognition, including visuospatial abilities, memory, attention, 
planning and working memory.  No difference in time taken for task completion was seen for wither 












































































Figure 43. Effect of cooling on Rey diagram completion. Data was available on 14 subjects. No 
significant difference was observed between the two study arms in either the copying or recall 







The neurobiological response to cold is complex. Environmental cooling is detected by skin 
thermoreceptors, which signal via the lateral parabrachial nucleus to the median preoptic nucleus, 
which then relays via the lateral preoptic area to the dorsomedial hypothalamus. This signals via the 
sympathetic premotor neurons in the rostral raphe pallidus to spinal intermediolateral nucleus, to 
stimulate brown adipose tissue. The sympathetic response also drives peripheral vasoconstriction and 
piloerection to reduce heat loss. Communication with higher centres drives behavioural change to 
minimise heat loss. If these mechanisms are insufficient to maintain body temperature and there is 
continued exposure to cold then a shivering response is induced.  This is a process with several stages; 
initially muscle tone increases, followed by sporadic muscle twitches, before rhythmic muscular 
contraction begins.  The shivering threshold varies between individuals, and is affected by adiposity, 
gender, lean muscle mass and length of cold exposure. Shivering is a very energy intensive process, 
and any assessment of energy expenditure would therefore be uninterpretable if the shivering 
threshold were breached. In this study, the temperature of the cooling intervention was thus chosen 
to activate brown adipose tissue while avoiding shivering. To ensure that the participants did not 
shiver we performed an electromyogram (EMG) during the temperature intervention, which 
confirmed that none of the participants shivered during the intervention.  
In the present study we have performed a randomised crossover trial of cooling for two hours at 16oC 
versus two hours at thermoneutrality (25oC) to explore the physiological, biochemical and 
neurocognitive effects of cooling. Past studies (Chen, Cypess et al. 2016) have indicated that this 
degree of cooling is sufficient to induce activation of brown adipose tissue in adults.  
 
4.5.1 Evidence of cooling 
Different research paradigms have been proposed for the study of cooling on humans. Environmental 
cooling, by decreasing the air temperature in sealed calorimetry room has been explored (Langeveld, 
Tan et al. 2016). They took healthy, normal weight adults (5 males, 5 females)and exposed them to 
either thermoneutrality (24°C) or mild cooling (18°C) for 2.5 hours after an overnight stay at 
thermoneutrality, measuring skin temperature, blood biochemistry, cold and hunger scores, and 
metabolic rate were measured every 30 minutes during the temperature intervention. They used a 
thermography camera to assess for possible brown adipose tissue activation in the supraclavicular 
fossa and the sternal area for comparison. They showed that at thermoneutrality the temperature of 
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both remained stable. The temperature of both areas increased in response to mild cold, and the 
temperature drop was greater in the sternal area than in the supraclavicular fossa. Other groups have 
similarly used the controlled temperature of indirect calorimetry rooms to explore the effects of mild 
cold.  However we chose a protocol constructed by collaborators in Germany (Iwen, Backhaus et al. 
2017), that had previously been shown to result in 18FDG-PET-proven BAT activation. 
Our study protocol was designed in accordance with the BARCIST 1.0 report (Chen, Cypess et al. 2016) 
written to standardise the approach to the study of BAT activation. Thus subjects were screened for 
recent cold exposure, fasted, wore standardised clothing under a cooling suit, and subjects were cold-
exposed for two hours (BARCIST guidelines recommend minimal cold exposure of 1 hour).  A fixed-
temperature approach (rather than a personalised protocol where a subject is cooled to a 
temperature a set number of degrees above their shivering threshold) was used as the study group 
was standardised and not heterogeneous.  It is reasonable to assume that exposure to temperatures 
of 16oC for two hours is sufficient to activate brown adipose tissue as this similar protocols have been 
effective at doing so, as shown by 18FDG-PET scans (van Marken Lichtenbelt, Schrauwen et al. 2002, 
Bredella, Fazeli et al. 2012). 
Skin temperature, measured digitally by ibuttons, demonstrated that while cooling reduced peripheral 
skin temperature, it did not reduce the temperature of the skin overlying the supraclavicular fossa.  
Retrospectively, if this study could be performed again, placing the iButtons over the inter-scapular 
region might provide a more reliable measure of BAT activation as it is located away from major blood 
vessels and so may be more representative of BAT activation, rather than just core temperature. 
However, this approach was used as it was consistent with protocols used by other study groups who 
had demonstrated 18FDG-PET-proven activation of BAT. Further analysis was conducted to see if this 
represented a central-peripheral gradient, or whether the temperature of the supraclavicular fossa 
was maintained over-and-above the surrounding area, which might constitute an indication of brown 
adipose tissue activation in this region.  Whilst the recorded temperatures in the chest region were 
higher than those recorded peripherally, it was still significantly lower than those taken from the 
supraclavicular fossa.  This indicates that while peripheral vasoconstriction in response to cold 
exposure contributes to the marked drop seen in peripheral temperatures, the supraclavicular fossa 
temperatures appear to be protected above those taken in the region.  This may indicate heat 
generation from brown adipose tissue activation.  Core body temperature was not affected.   
This data is consistent with the findings of other study groups. Van der Lans and colleagues 
demonstrated that subjects exposed to either thermoneutral temperatures (25.6oC) or air cooling 
(15.8oC) for 60 minutes found that the temperature of the skin overlying the supraclavicular fossa 
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dropped significantly less (-0.9 ± 0.6oC) than peripheral skin temperature (-3.8oC ± 0.6oC) when 
measured by the same methods used here (van der Lans, Vosselman et al. 2016). 
There was a wide inter-individual range of response to cooling; some subjects underwent a marked 
vasoconstriction on exposure to cold, whereas others did not. This limited the number of blood 
samples that were collected as for some subjects the vasoconstriction was so profound that it was not 
possible to draw blood. The reasons for this individual variation were not clear.  
 
4.5.2 Mechanisms mediating the thermogenic response  
Mitochondrial uncoupling in BAT is mediated by uncoupling protein-1 (ucp1), a 32 kDa protein 
expressed in the inner membrane of the mitochondria, which dissipates the proton gradient of the 
inner mitochondrial membrane without ADP phosphorylation. Brown adipose tissue is activated by 
sympathetic efferents from the rostral raphe pallidus (Cao and Morrison 2006).  It is therefore 
reasonable to expect that participants in the cooling arm of the study will show other markers of 
sympathetic drive, relative to the thermoneutral arm. Mean heart rate, measure by actiheart, was not 
significant in the cooling arm of the study, nor were pulse rate measurements taken at 30 minute 
intervals during the study.  Systolic blood pressure was significantly elevated in the cooling arm of the 
study, indicating that the cooling intervention was sufficient to increase sympathetic tone.  
Studies in rodents and humans have shown that BAT thermogenesis is activated by noradrenaline and 
thyroid hormone, and inhibited by corticosteroids. Both noradrenaline and thyroid hormone stimulate 
lipolysis and increase BAT uptake of free fatty acids. Mice with triple KO of all three B adrenoceptors 
have defective cold-induced BAT thermogenesis (Jimenez, Leger et al. 2002). Hypothyroid mammals 
may develop hypothermia because they are resistant to noradrenaline-induction of BAT 
thermogenesis.  
Disruption of the Dio2 (dio2-/-), the gene encoding the thioredoxin-fold-containing selenoenzyme that 
converts the prohormone thyroxine to the active hormone tri-iodothyronine, results in brown-
adipose-specific hypothyroidism, in an otherwise euthyroid animal. Cold exposure in these animals 
results in hyperadrenergic stimulation of BAT, resulting in increased lipolysis, and expression of ucp-1 
and PPAR-γ mRNA. This exaggerated response suppresses the stimulation of BAT lipogenesis that is 
normally seen after 24-48h in mice. The availability of free fatty acids is therefore rapidly exhausted, 
and impairs the thermogenic response of BAT (Fonseca, Werneck-De-Castro et al. 2014) . Thyroid 
hormone signalling, and in particular induction of deiodinase 2 enzymes, additionally play a central 
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role in BAT adipogenesis in vitro, and BAT development in mouse embryos (Bianco AC, Lancet Diabetes 
Endocrinol, 2013).  
Expression of Dio 2 is dependent on cAMP. Thus BAT stimulation with noradrenaline creates a state 
of localised thyrotoxicosis within brown adipocytes.  Saturation of thyroid hormone receptors with T3 
results in Ucp-1 induction (Lee, Takahashi et al. 2012). Therefore on cold stimulation it might be 
anticipated that there would be an increase in noradrenaline-mediated sympathetic drive, with 
resulting deiodinase 2 stimulated conversion of T4 to T3.  No significant effects on thyroid hormone 





4.5.3 Cooling and the stress response 
On cooling, there was no significant difference in pulse rate between the two study arms, but systolic 
blood pressure was significantly increased in the cooling arm of the study. This is consistent with an 
increase in sympathetic drive, and previously published literature on cooling.   
The interplay between the acute and chronic stress response is complex and has significant inter-
individual variability. The central sympathetic nervous system comprises of catecholaminergic, 
norephinephrine-synthesizing cell groups in the pons and medulla and the locus coeruleus. These form 
a complex stimulatory and inhibitory network with multiple sites of interaction with the CRH neurons 
located in the paraventricular nucleus of the hypothalamus. CRH secretion is stimulated by the action 
of norepinephrine on the a1-noradrenergic receptors. There are also autoregulatory negative 
feedback loops that exist in both the PVN, CRH and brainstem catecholaminergic neurons, which 
inhibit the corresponding presynaptic CRH and a2-noradrenergic receptors. Additionally there are 
multiple regulatory inputs from the seratonergic and cholinergic system, inhibitory input from the 
GABA/BDZ system and the opioid neuronal system of the brain.  Glucocorticoids also have an 
inhibitory effect (Herman 2018).  Secretion of CRH results in the breakdown of POMC, releasing ACTH 
which subsequently releases cortisol from the adrenal glands. Additionally B endorphin is released, 
resulting in an analgesic effect, and AVP is released, further contributing to blood pressure effects.  
One of the key net outputs of activation of the stress response is to stimulate an adaptive redirection 
of energy, with increased gluconeogenesis and lipolysis to mobilise fuel stores to allow for a ‘fight or 
flight’ response. Thus the characteristic tightly controlled pulsatile release of CRH is disrupted by 
stress; during acute stress the amplitude and synchronicity of both CRH and AVP increase. 
Glucocorticoids are the final hormone effectors of the HPA axis. The inactive glucocorticoid receptor 
resides in the cytosol as a hetero-oligomer with heat shock proteins. Upon ligand binding the receptors 
dissociate and homodimerise, translocating to the nucleus where they interact with specific 
glucocorticoid response elements of the DNA to transactivate or repress target genes (Savory, 
Prefontaine et al. 2001). Most adverse effects are mediated by transactivation, whereas 
transrepression is thought to control many of the anti-inflammatory effects of glucocorticoids via 
suppression of inflammatory pathways e.g. AP-1, NF-kB. Glucocorticoids have a negative feedback 
effect on both CRH and ACTH secretion. 
Physiological stress results in a peak cortisol response by 120 minutes. We might therefore expect an 
increase in serum cortisol levels in the cooling arm of the study relative to the thermoneutral arm.   
However, this was not observed, and while there was a downward trend for cortisol in the cooling 
intervention, there was no significant difference between the two study arms.  
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4.5.4 Effect of cooling on glucose, insulin and glucagon  
An increase in sympathetic drive results in a mobilisation of fuel reserves to allow for a “fight or flight” 
response. It might therefore be expected that cooling results an initial increase in glucagon to liberate 
glucose from glycogen, and that insulin is suppressed.  However, no significant difference was 
observed between the study arms for these measures. This may reflect the timing of the samples: the 
described response is an acute one, taking place in the initial minutes following exposure to a stressor. 
Glucose and glycogen samples were taken before, and 120 minutes after initiation of cooling, and the 
first insulin samples were taken at 30 minutes.   
 
4.5.5. Leptin 
Cooling is known to reduce ob gene expression in the white adipose tissue on mice (Trayhurn P, 
Biochem J, 1995) and there is limited data to suggest that cooling also reduces circulating leptin levels 
in humans (Ricci, Fried et al. 2000). Reducing the amount of circulating leptin in effect creates a state 
of partial leptin deficiency. We confirmed these findings in this study, and a significant percentage 
reduction in leptin was seen in the cooling arm of the study.  This is intriguing, and may indicate that 





4.5.6. Energy expenditure and respiratory quotient 
Reductions in circulating leptin have a powerful orexigenic effect.  Leptin is additionally known to drive 
thermogenesis and energy expenditure via its action on PrRP-containing neurons in the dorsomedial 
hypothalamus (Dodd, Worth et al. 2014).  It is reasonable to hypothesise that cooling will therefore 
lower circulating leptin levels, resulting in an increase in hunger and a reduction in energy expenditure.  
However, acting contrary to this is the effect of brown adipose tissue activation on energy 
expenditure.  The net effect we observed was an increase in basal metabolic rate with the cooling 
intervention.  
Respiratory quotient is calculated by the volume of carbon dioxide eliminated divided by the amount 
of oxygen consumed. It provides a measure of substrate utilisation; a respiratory quotient of 1 
indicates a carbohydrate energy source, whereas a respiratory quotient of 0.7 indicates a fat source.  
The mean respiratory quotient found in the thermoneutral arm of the study was significantly higher 
than in the cooling arm (0.78 and 0.75, respectively). This is in keeping with an increase in fat utilisation 
in the cooling arm of the study and is in keeping with published literature on substrate utilisation in 
cooling (Cannon and Nedergaard 2004).  
 
4.5.7. Food intake and fat preference 
Impairment of leptin-melanocortin drives a preference for high fat food an avoidance of high sucrose 
food (van der Klaauw, Keogh et al. 2016). We therefore hypothesised that cooling, a state of partial 
leptin deficiency, would result in an increased preference for high fat food. Whilst we did not observe 
any significant differences in visual analogue scales assessing “liking” of high, medium or low fat food, 
we did see a significant increase in the amount of high fat food consumed in the cooling arm of the 
study.  This is in keeping with our previous findings of fat preference in patients with MC4R mutations 
and further corroborates the importance of leptin-melanocortin circuitry in fat preference. In future 
studies it would be interesting to see if there was a decrease in the amount of high sucrose food in a 
sucrose-preference test after cooling, as this is also reduced in patients with MC4R mutations.  
Brain-derived neurotrophic factor (BDNF) is a protein that acts to support the maintenance and 
survival of existing neurons and encourages the growth and differentiation of new neurons. It is active 
in brain areas associated with memory and neurocognition, including the hippocampus, basal 
forebrain and cortex. It is upregulated exercise and fasting (Szuhany, Bugatti et al. 2015) and central 
administration of BDNF reduces food intake, leptin and insulin levels and decreases fat mass (Noble, 
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Billington et al. 2011).  We did not find a statistically significant difference in BDNF between the two 
study arms.  It would be interesting to investigate this in a larger study sample as this might provide 
an interesting mechanistic insight into the links between negative energy balance and neurocognition. 
 
4.5.8. Cooling results in an improvement in attention on neurocognitive testing 
Prior to the administration of the neurocognitive tests there was an increase in the subject’s 
perception of anxiety on the visual analogue scale score.  This could be in keeping with the increase in 
sympathetic tone previously described.  
There was a significant improvement in both the verbal fluency and digit span tests after the subjects 
had been cooled. Both these tests assess executive control, with the verbal fluency additionally 
assessing verbal ability, and the digit span short term and working memory. There was no difference 
between the two study arms in the RAVLT, Hayling, trail-making or Rey diagram tests. In some cases, 
for instance with the RAVLT test, this may be because most of the subjects scored highly, and the test 
was therefore not discriminating. The Hayling test is a test of response initiation and suppression (a 
frontal lobe function), and there seemed to be no effect of cooling on these functions, nor on the 
visuospatial skills required for the Rey diagram completion. With the trail making test there was a 
trend towards improvement in the second part of the study, which tests mental flexibility and 
executive function. It may be that this is within the variation that may normally be seen within testing, 
or that the trend shows that the study is underpowered.  
Whether the improvements seen represent a genuine improvement in some elements of 
neurocognition, or whether they simply represent an increase in attention due to the increased 
sympathetic drive is not possible to deduce from these data. 
 
4.6. Conclusions 
Here we present data illustrating the physiological effects of mild cooling on humans. We confirm, in 
keeping with previous studies, that cooling results in an increase in sympathetic drive, and that skin 
temperature overlying BAT deposits is maintained, relative to skin temperature in other regions. We 
confirm that cooling increases energy expenditure and reduces respiratory quotient, driving substrate 
utilisation towards fat. Collectively it is probable that these data represent activation of brown adipose 
tissue, and similar paradigms have shown 18-FDG-PET confirmed confirmation of this.   
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We show that cooling results in significant reductions in circulating leptin levels with a resulting 
increase in fat preference. This is important as it provides evidence of leptin acting as a central 
regulator of cooling-induced energy deficit. There was no statistically significant difference between 
the cooling and thermoneutral interventions in BDNF concentration. It would be interesting to explore 
the effects of cooling on BDNF in a larger data set as this could provide an enticing explanation for our 
leptin data.  
We have shown that some neurocognitive tests improve with cooling, and did not show any evidence 
of torpor. It is not possible to discriminate whether these improvements were secondary to an 











CHAPTER FIVE: THE EFFECTS OF COOLING ON THE METABOLOMIC 













We conducted a randomised cross over trial of two hours of cooling (16oC) versus two hours at 
thermoneutrality (25oC) to investigate the metabolic effects of mild cold exposure on human 
physiology.  The cooling temperature was chosen as existing literature indicated that this would be 
sufficient to result in brown adipose tissue activation, without inducing shivering. We were interested 
in exploring the effects of cold exposure on substrate utilisation and in comparing this data to that 
obtained during caloric restriction. We hypothesised that the response to calorie deficit, whether from 
cold exposure or secondary to caloric restriction, is regulated by central leptin-mediated mechanisms 
and sought to employ a metabolomics approach to address this question.  
Metabolomics, the measurement of hundreds of small molecule metabolites, their precursors, 
derivatives, and degradation products, has emerged as a useful tool for the study of physiology and 
disease. We used liquid chromatography-tandem mass spectrometry (LC-MS) methods to characterize 
changes in carbohydrates, lipids, amino acids, and steroids in eight normal weight heathy men at 
baseline, every 30 minutes during a temperature intervention, and one hour after cessation of the 
temperature intervention. We compared the metabolomics profiles of subjects in the two 
temperature intervention study arms (thermoneutral at 25oC versus cooling at 16oC).  
We found that the differences between participants were greater than any change caused by the 
temperature intervention. We therefore took a paired intra-individual approach to analysis to look for 
cooling-triggered metabolomics changes. One key finding was that lysophosphatidylethanolamines, 
lipids that are derived from the plasma membrane increased in the cooling arm of the study suggesting 
an increase in lipid turnover. Additionally an increase in the fatty acid (22:6), docosahexaenoic acid, 
was seen. This is an arachidonic acid-derived omega-3 polyunsaturated fatty acid, which is associated 
with a neuroprotective effect (Kim 2014). This finding is of particular interest, given the RBM-3 
mediated link between cooling and neuroprotection and the improvements in cognitive function 
observed in the data presented in Chapter 4. Further studies with larger sample sizes will be needed 






Cold exposure has been shown to activate brown adipose tissue in adult humans (Cypess, Lehman et 
al. 2009), resulting in increased insulin sensitivity and an increase in lipid metabolism. In lean healthy 
humans acute cold-induced BAT activation has been associated with elevated appearance rates of free 
fatty acids (Locke, Kahali et al. 2015) from the lipolysis of white adipose tissue (WAT) and increased 
uptake of free fatty acids into BAT depots (Ouellet, Labbe et al. 2012, Blondin, Tingelstad et al. 2017). 
Furthermore, prolonged cold exposure (5-8 hours) increased whole-body lipolysis, FFA cycling and FFA 
oxidation in obese human males (Chondronikola, Volpi et al. 2016). Collectively these studies indicate 
that BAT activation signals to the white adipose tissue to trigger mobilisation of energy substrates via 
lipolysis and β-oxidation of FFA.  Non-shivering thermogenesis predominantly utilises free fatty acids, 
with low levels of glucose use, mainly utilised for the synthesis of glycerol-3-phosphate and 
triglycerides, and de novo synthesis of free fatty acids (Cannon and Nedergaard 2004, Virtanen, Lidell 
et al. 2009). Cumulatively these observations are likely to explain improvements in lipid metabolism 
and insulin sensitivity that have been observed in clinical studies (Festuccia, Blanchard et al. 2011, 
Ouellet, Labbe et al. 2012, Chondronikola, Volpi et al. 2016). 
However, to date, the detailed biochemical mechanisms that mediate the effects of cold-induced BAT 
activation are not fully understood.   
We have collaborated with our colleague Prof. Sebastian Schmid and his team (University of Lubeck) 
for the design of this study.  His team have demonstrated that acute cold exposure increases the 
expression of selected genes involved in lipolysis and FA-oxidation measured in human peripheral 
blood using a similar paradigm and an identical water-perfused suit. They additionally performed 
Botnia clamps (an intravenous oral glucose tolerance test followed by a euglycaemic, 
hyperinsulinaemic clamp) to determine whole body glucose utilisation and insulin sensitivity in cooling 
relative to thermoneutrality. Furthermore they demonstrated 18-FDG-PET proven brown adipose 
tissue activation in two participants undergoing this protocol (under review).  
Metabolomics, the systematic study of small-molecule products of biochemical pathways by mass 
spectrometry, has offered a sensitive technique to allow new insights into the dynamics of 
metabolism, and has proved a useful technique to dissect out the effects on molecular pathways 
caused by a specific perturbation. The metabolomic profile at a given time point represents the 
cumulative effects of the diet, genome, transcriptome, proteome, and gut microbiome–host 
interaction on small molecule metabolites whose concentrations change rapidly (Guo, Milburn et al. 
2015).  This has allowed new methods to predict, diagnose and discover several metabolic disorders. 
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Metabolomics has shown that elevated levels of specific branched-chain amino acids (isoleucine, 
leucine, valine) are strongly associated with the development of type 2 diabetes mellitus, and that 
prediction of progression to disease could be made on the basis of elevations in a combination of 
these amino acids, with a fivefold increase in risk for subjects with values in the top quartile (Wang, 
Larson et al. 2011). A systematic review of metabolomics studies in obese children identified changes 
in amino acid metabolism that were associated with obesity. They also found increases in branched 
chain amino acids, aromatic amino acids and acylcarnitines were predictors of insulin resistance (Zhao, 
Gang et al. 2016). We were interested in exploring the effects of cooling on the metabolomic profile 
of lipids and amino acids in fasting healthy young men with cold-activated brown adipose tissue, 
relative to thermoneutral conditions.  
Metabolomics has been previously used to define a unique profile associated with acute calorie 
restriction (participants received 10% of total daily energy requirement for 48 hours), which 
highlighted the expected shift from carbohydrate to fat metabolism, with an increase in lipolysis and 
β-oxidation of fatty acids (Collet, Sonoyama et al. 2017). There was decrease in specific antioxidants 
(plasmalogen phosphatidylethanolamines) and an increase in branched chain amino acids and 
dehydroxyepiandrosterone sulphate.  As caloric restriction and cold exposure both result in a net 
calorie deficit, we were interested in comparing the results of these two studies, to test if there were 
common metabolic processes involved.  
We performed a carefully controlled experimental study to directly examine the effects of cold 
exposure in eight normal weight young men housed in a clinical research facility where diet, fluid 
intake, timing of meals, and sleep were precisely controlled and standardised.  Fasting blood samples 
were obtained at the following time points: baseline (after an overnight fast), 30, 60, 90 and 120 
minutes into the temperature intervention, and 1 hour after cessation of the temperature 
intervention. We used a high throughput IDQP180 Biocrates panel for our metabolomics assay 
employing using liquid chromatography-tandem mass spectrometry methods to measure small 
molecule metabolites involved in carbohydrate, fat, protein, and steroid metabolism. Additional lipid 
measurements were made by an in-house assay. By measuring the metabolome in the same 
individuals during two study arms which were identical, with the exception of the temperature 
intervention, our aim was to identify the metabolites that change significantly with cooling. Both study 
arms are performed after an overnight fast as food given prior to the temperature interventions would 




 From the 15 participants who undertook the complete study protocol, eight subjects were identified 
where samples across all time points were of sufficient quality with no haemolysis to perform 
metabolomics.  These samples were taken forward for analysis. The AbsoluteIDQ® Biocrates p180 Kit 
(Biocrates Life Sciences AG, Innsbruck, Austria).was used to measure 175 metabolites across six 
compound classes (hexoses, amino acids, biogenic amines, acylcarnitines, glycerophospholipids and 
sphingolipids). Additional analysis of lipid samples were conducted on an in-house assay by the NIHR 
BRC metabolomics and lipidomics facility. Blood samples from 8 individuals were taken at baseline 
(Tn60), 30 minutes, 60 minutes, 90 minutes, and 120 minutes after the start of (Ti30, Ti60, Ti90 and 
Ti120, respectively), and 60 minutes after the end of the intervention (Group A = thermoneutral 
condition; Group B = cooling condition). Metabolomic measurements for all the above samples were 
performed at the Department of Biochemistry, the University of Cambridge, using AbsoluteIDQ® 
Biocrates p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria) (Amino Acid panel). An additional 
in-house lipid panel was performed that had been developed using a method for open profiling of 
lipids by DIHRMS (Han and Gross 2003, Graessler, Schwudke et al. 2009). The relative quantity of 
metabolites was obtained by normalization of the metabolite signal intensity to that of an internal 
standard. The combined results comprised: 20 amino acids, 24 amino acid derivatives, 13 cholesteryl 
esters (Locke, Kahali et al.), 16 ceramides (Cer), 14 diacylglycerols (DAGs), 2 monoacylglycerols 
(MAGs), 30 free fatty acids (FFAs), 5 fatty acid ester of hydroxyl fatty acids (FAHFAs), 48 
lysoglycerophospholipids, 201 glycerophopholipids, 42 sphingomyelins, and 70 triacylglycerols (TAGs). 
The metabolites of Tp60 from one individual (CS001192) in thermoneutral condition (Group A) were 
haemolysed and unable to be processed as were the metabolites in lipid panel in Tp60 from another 
individual (CS01176). They were therefore excluded from the relevant analyses. The other missing 







Cluster analysis was performed separately for the metabolites in the two panels (Amino Acid panel 
and Lipid panel) from the two conditions (Group A and B), based on the Euclidean distance, where 
each sample is a vector with all of the metabolite values, using the online software, Metaboanalyst 
(http://www.metaboanalyst.ca/faces/home.xhtml). In all four time-group combinations, the samples 
from the same individuals tended to cluster together regardless of the time-points (Figure 44), 
suggesting that the inter-personal differences were greater than the impact of the intervention. 
 
5.4.1. Hierarchical clustering of the metabolome across participants 
We first examined large scale changes across the samples in the study.   Hierarchical clustering of 
metabolomics data was performed using Metabolanalyst, an online program that ascribes each 
sample a vector value and clusters samples based on Euclidean distance. The samples are then 
grouped based on their similarity, generating a heat map. From this analysis we can see that samples 
largely cluster according to participant, and not intervention. This indicates that the difference 





























































































Figure 44. A heat map derived from hierarchical clustering of the metabolomic data. Clustering was 
performed using complete linkage and Euclidean distance, where each sample is a vector with all of 
the metabolite values. The colour scale correlates with relative metabolite abundance across the 
samples: the white indicates median value, red an elevation above the median, and blue a decrease 
below the median. These panels were created using Metaboanalyst, a program to order the samples 
based on their similarity to each other. Figures (a) and (b) show the results of the amino acid panel in 
the thermoneutral arm and cooling arm of the study, respectively. Figures (c) and (d) show the results 
of the lipid panel in the thermoneutral and cooling study arms, respectively. The patient’s unique 











5.4.2. Large scale changes with cooling intervention across participants 
Amino acid and lipid changes were analysed separately as there is established software available for 
pathway analysis of amino acid data (KEGG), whereas the analysis of lipidomic data is less 
standardised.   
 
5.4.2.1. Cooling-induced changes in amino acids 
The AbsoluteIDQ® Biocrates p180 Kit measures 21 amino acids and 21 biogenic amines. A full list of 
metabolites is provided by Biocrates (http://www.biocrates.com/products/research-
products/absoluteidq-p180-kit).  
Using KEGG pathway analysis, the data on amino acids measured during the thermoneutral and 
cooling arms of the study were compared. This analysis revealed that whilst for some participants the 
cooling intervention resulted in changes to specific metabolites, these were not consistent and did 
not reach statistical significance after Benjamini-Hochberg correction.  
However, general trends in the data were observed.  When compared to the thermoneutral arm of 
the study the cooling arm was enriched for increases in nitrogen, arginine and proline metabolism. 
Additionally there were increases in aminoacyl tRNA synthesis. These are enzymes that attach the 
appropriate amino acid onto the tRNA strand by catalyzing the esterification of a specific cognate 
amino acid or its precursor to one of all its compatible cognate tRNAs to form an aminoacyl-tRNA.  
Collectively these results indicate an increase in protein synthesis in the cooling arm of the study 
(Figure 45). 
Directly comparing the metabolomics data from the cooling study to the previously performed caloric 
restriction study (Collet, Sonoyama et al. 2017) is challenging, as the effect size of the cooling 
intervention was much smaller than that of the caloric restriction.  Additionally, the sampling time 
points of the two studies were very different, which is a significant limitation when trying to 
understand the complexities of such a dynamic process. However, taking into account these 
limitations, we can make some observations. In the caloric restriction study there was an increase in 
the glucogenic amino acids. In the cooling study these were not universally elevated; in common with 
calorie restriction cooling caused an increase in alanine. The other glucogenic amino acids did not 
increase in the cooling study, and glutamate and serine paradoxically decreased.  The ketogenic 
branched chain amino acid leucine increased in both, whereas isoleucine, which increased with caloric 
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restriction did not change during cooling. These findings suggest that, in line with data in animals 
(Blouet, Jo et al. 2009), leucine is the most sensitive marker of negative energy balance. 
Changes were also seen in other amino acid breakdown products (figure 45). Histamine, a biogenic 
amine derived from the breakdown of histidine plays a pivotal role in the acute allergic response, and 
in chronic inflammatory reactive diseases such as asthma. It was reduced in the cooling arm of the 
study, but did not change in the thermoneutral arm. The relevance of this finding is unclear but central 
histaminergic signalling is known to play a role in energy homeostasis.  
Serotonin is a tryptophan-derived monoamine neurotransmitter.  Approximately 90% of the body’s 
serotonin is found in the enterochromaffin cells of the gastrointestinal tract where it plays a key role 
in gut motility. Additionally it has important central roles in regulation of mood, appetite and sleep. 



























Figure 45. Differential concentrations of amino acids & derivatives. Ti120 vs Tn60 within each arm. 
LIMMA, a program that was devised to fit linear models to microarray data, was used to fit a linear 
model (~subjectID+{A.Tn60, A. Ti120, B.Tn60, B.Ti120}) and two different contrasts inspected: 
(A.Ti120 vs A.Tn60) and (B.Ti120 vs B.Tn60); see Methods. 
A. Volcano plot for arm A; B. Volcano plot for arm B; C. For species with (Locke, Kahali et al.) p<0.2, 
the fold-change within A is compared to the fold-change within B. (Left: the largest fold-changes are 
driven by 0's in the original units, right: zoomed in to the centre). Names: Red: p<0.2 in B, p>0.2 in A, 
green: p>0.2 in B, p<0.2 in A, purple: p<0.2 in both A and B. Asterisks indicate p<0.05: Red: p<0.05 in 
B, p>0.05 in A, green: p>0.05 in B, p<0.05 in A, purple: p<0.05 in both A and B. D. Examples shown as 
paired scatter plots. Left, Glutamic acid (Glu), identified as down in B only (raw p<0.05). Right, 




Cooling: Ti120 - Tn60 
 
Thermoneutral: Ti120 - Tn60 
species.idx logFC.B AveExpr.B P.Value.B adj.P.Val.B 
 
logFC.A AveExpr.A P.Value.A adj.P.Val.A 
Glu -0.449 5.397 0.011 0.192 
 
-0.114 5.397 0.487 0.985 
Gln 0.170 9.561 0.011 0.192 
 
0.017 9.561 0.783 0.999 
Asn 0.253 5.652 0.015 0.192 
 
0.126 5.652 0.188 0.955 
SDMA 0.360 -1.703 0.040 0.367 
 
0.042 -1.703 0.802 0.999 
Lys 0.181 7.885 0.060 0.367 
 
0.046 7.885 0.618 0.985 
Histamine -5.696 -3.794 0.062 0.367 
 
0.003 -3.794 0.999 0.999 
Sarcosine 0.415 4.047 0.070 0.367 
 
-0.120 4.047 0.594 0.985 
Serotonin 0.219 -0.539 0.075 0.367 
 
0.072 -0.539 0.548 0.985 
Leu 0.101 7.241 0.087 0.373 
 
-0.053 7.241 0.352 0.985 
His 0.149 6.457 0.114 0.373 
 









KEGG Pathway Total Expected # Hits Raw p FDR Hits 
Aminoacyl-tRNA 
biosynthesis 
75 0.187 4 1.25E-05 0.001 
L-Histidine; L-Glutamine; L-Lysine; 
L-Leucine 
Nitrogen metabolism 39 0.0972 2 0.00368 0.1474 L-Glutamine; L-Histidine 
Arginine and proline 
metabolism 
77 0.1919 2 0.01394 0.3717 L-Glutamine; Sarcosine 
 
D 
Metaboanalyst pathways total expected # hits Raw p FDR Hits 




Table 14. Analysis of the effect of cooling on amino acid metabolomics profile.  A. LIMMA results for 
the contrasts (B.Ti120 vs B.Tn60) and (A.Ti120 vs A.Tn60) after fitting to the linear model with design. 
B. Species with p<0.2 in the cooling arm only (red points with y>0 in Fig 45C) and used for pathway 
analysis. C. Metaboanalyst KEGG pathway enrichments. D. Enrichment for Metaboanalyst curated 
pathways (via HMDB identifiers).  
Label Query Match HMDB PubChem KEGG 
Gln Glutamine L-Glutamine HMDB00641 5961 C00064 
His His L-Histidine HMDB00177 6274 C00135 
Leu Leu L-Leucine HMDB00687 6106 C00123 
Lys Lys L-Lysine HMDB00182 5962 C00047 
Sarcosine Sarcosine Sarcosine HMDB00271 1088 C00213 
SDMA SDMA Symmetric dimethylarginine HMDB03334 169148  
Serotonin Serotonin Serotonin HMDB00259 5202 C00780 
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5.4.2.2. Cooling-induced changes in lipids 
The AbsoluteIDQ® Biocrates p180 Kit measures 90 species of glycerophospholipids and 15 species of 
sphingolipids.  A full list of lipid species measured is provided 
(http://www.biocrates.com/products/research-products/absoluteidq-p180-kit). An additional in-
house panel of lipid measurements was performed to allow the analysis of additional species to 
provide a comprehensive panel.   
There is no pathway analysis equivalent to KEGG for lipids, and analysis of lipidomics usually depends 
on in-house expertise, rather than a consortium-recognised approach. We were interested in 
examining the lipids that changed most significantly in the two study groups, and in comparing the 
effect on lipids of cooling with those of caloric restriction.  This data was analysed by looking at fold 
change of lipid species in both study arms, and then examining the species that reached an 
(uncorrected) p value of <0.2 and <0.05. We then looked in more detail at the lipid species that 
increased most significantly.  
The top ten lipid species (Table 14, ordered by p value) highlight the species that changed more in 
cooling than the thermoneutral study arm. We can see that half of these species are 
lysophosphatidylethanolamines, lipids that are derived from the plasma membrane. They result from 
the hydrolysis of phosphatidylethanolamine, a reaction catalysed by phospholipase A2. Little is known 
about the role of these species in human plasma, however, lower levels of LPE have been found in the 
lipidomic studies of diseased coronary arteries (Kurano, Kano et al. 2017)(Kurano M, J Lipid Res, 2017). 
The increase of these, in addition to the lysophosphatidylcholines and glycerophosphoserines in the 
cooling arm of the study may indicate an increase in lipid turnover. Cooling may affect the structure 
of the lipid bilayer in cell membranes (Bazinet and Laye 2014). 
Additionally an increase in the fatty acid (22:6), docosahexaenoic acid, was seen. This is an arachidonic 
acid-derived omega-3 polyunsaturated fatty acid, which is associated with a neuroprotective effect, 
including for Alzheimer’s disease (Freund LY, J Int Med, 2014; Hashimoto M, J Neurochem, 2002). It 
has additionally been associated with improvements in synaptic plasticity (Jump DB, J Biol Chem, 
2002), and dietary supplementation with DHA increases BDNF levels in rodents (Wu A, Cell Neurosci, 
2008). This finding is of particular interest, given the RBM-3 mediated link between cooling and 
neuroprotection described by our collaborator Prof Mallucci (Peretti D, Nature 2015) and the 

























Figure 46. Differential concentrations (Ti120 vs Tn60, within each arm) of lipids. LIMMA was used to 
fit a linear model (~subjectID + {A.Tn60,A. Ti120, B. Tn60, B. Ti120}) and two different contrasts 
inspected: (A.Ti120 vs A.Tn60) and (B.Ti120 vs B.Tn60); see Methods. A. Volcano plot for arm A. B. 
Volcano plot for arm B. C. For species with (Locke, Kahali et al.) p<0.2, the fold-change within A is 
compared to the fold-change within B. Left, colours: Grey: 0.05<p<0.2 in either A or B or both, red: 
p<0.05 in B, p>0.05 in A, green: p>0.05 in B, p<0.05 in A, purple: p<0.05 in both A and B. Right, colours: 
Red: p<0.2 in B, p>0.2 in A, green: p>0.2 in B, p<0.2 in A, purple: p<0.2 in both A and B. 
 
   Cooling: Ti120-Tn60 Thermoneutral: Ti120-Tn60 
Name Prefi
x 
Class LogFC Ave 
exp 
P Adj p LogFC Ave 
Expr 
P Adj p 
LPE_18:2_[M-H]1- LPE Lysophosphatidylethanolamines -0.376 -4.399 0.0003 0.127 -0.311 -4.399 0.002 0.342 
BA(DCA)_[M-H]1- BA Bile acid derivatives -1.300 -8.277 0.003 0.708 -1.092 -8.277 0.011 0.430 
MG_18:1_[M+NH4]
1+ 
MG Monoradylglycerols 1.363 -8.449 0.005 0.708 0.308 -8.449 0.488 0.823 
LPE_20:2_[M-H]1- LPE Lysophosphatidylethanolamine -0.346 -1.688 0.007 0.708 -0.409 -1.688 0.002 0.342 
LPE_18:2_[M+H]1+ LPE Lysophosphatidylethanolamine -0.606 -8.178 0.010 0.708 -0.684 -8.178 0.004 0.383 
PS-P_30:1_[M+H]1+ PS-P Phosphatidylserine -2.727 -
11.034 









0.011 0.708 0.035 -
10.843 
0.922 0.982 








-0.415 -8.469 0.015 0.755 -0.112 -8.469 0.485 0.823 
FA(22:6)_[M-H]1- FA Fatty acyls (docoshexaenoic acid) 0.317 -2.901 0.018 0.801 0.284 -2.901 0.032 0.458 
 
Table 15. LIMMA results for the contrasts (B.Ti120 vs B.Tn60) and (A.Ti120 vs A.Tn60). After fitting 
to the linear model with design (~subjectID+{A.Tn60, A. Ti120, B. Tn60, B. Ti120}). This table shows 




5.4.3. Power calculations 
Due to the novel nature of this experiment, pre-test power calculations were problematic to calculate 
as the potential effect size of the results were not known.  As can be seen from the data, these did in 
fact vary substantially depending on the amino acid or lipid protein investigated, and also between 
individuals.  Some differences within and between arms were as great as 50 per cent, and others much 
smaller. 
A linear regression model was applied to calculate the necessary number of observations associated 
with an R2 that is statistically significant from zero, using the XLSTAT statistical package for Excel.  For 
each experiment there is only one independent variable; time (when comparing the effect within each 
temperature intervention arm) or temperature (when comparing between arms).  The power required 
was conservatively set at 0.9 (1-beta, where beta is the type II error).  Calculation of the number of 
subjects required tested three different effect sizes: 0.10, 0.30, and 0.50.  Alpha (type II error) was set 
at 0.05.  A simulation plot was also generated to show the range of sample sizes needed to achieve a 
power between 0.80 and 0.95. Naturally, the larger the effect size, the smaller the sample size needed 
to achieve the desired power.  Figure 47 shows that the sample sizes required to achieve a power of 
0.9 were 107, 37, and 23 for effect sizes of 0.10, 0.30, and 0.50, respectively.  
 
Effect size 0.10 0.30 0.50 
Power 0.9 0.9 0.9 
alpha 0.05 0.05 0.05 
Sample size 107 37 23 
 
   
 
Figure 47. Power calculations with respect to the effect size.  Above, table of sample sizes required 
to achieve a power of 0.9 depending on the effect size. Below, simulation plots showing sample size 
needed dependant on the effect size and desired power (between 0.8 and 0.95). 
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 5.5. Conclusions 
In this study we sought to dissect the metabolomic changes that occur in response to cooling. There 
have been several factors that limited the conclusions that can be drawn from this data.  Firstly, the 
effect size of the cooling intervention was small. The temperature of the cooling intervention was 
carefully chosen, as other studies have shown that this is sufficient to activate brown adipose tissue, 
without initiating shivering within the given timeframe (Chen, Cypess et al. 2016). However, as 
participants were only exposed to mild cold for a relatively short period of time, the effect size of the 
metabolomics change was small. This is also reflected in some of the biochemical data; the effect size 
for many of the measured parameters was small. There was also considerable variability between 
individuals, both in their response to cold, and the changes in metabolomic profile. The Metaboanalyst 
derived-data demonstrates that differences between individuals were greater than the effect of the 
temperature intervention. Although a paired approach to analysis was taken, the study was 
underpowered.  
Metabolomics has been previously used to examine the metabolic effects of acute caloric restriction 
(Collet, Sonoyama et al. 2017).  In this study metabolomics were performed on the samples of eight 
normal weight healthy men. Baseline samples were compared with those taken after 48 hours of 
calorie restriction (10% of total daily energy needs), and after a further 48 hours of eating ad libitum.  
The effect size of this intervention was much greater than that of cooling.  Comparison between the 
two studies is additionally limited because the platforms used for the two studies were different; the 
caloric restriction study was performed by the company Metabolon, which tests a much broader range 
of metabolites and break down products (770 in total).   
There are some limitations to the metabolomics panels we chose for analysis in this study. There is no 
examination of glycolysis or the citric acid cycle, and it is therefore not possible to compare our study 
results with those of the caloric restriction study for these elements, where we demonstrated a 
decrease in pyruvate.  However, despite these limitations it is possible to comment on some general 
trends seen within the data. While it is not possible to comment on directly on glycolysis, citrate was 
measured, and increased in both studies, and this might represent a decrease in flux of the TCA in 
both studies.  
In the caloric restriction study there was an increase in the glucogenic and branched chain amino acids. 
In the cooling study these were not universally elevated, but in common with calorie restriction 
cooling resulted in elevated alanine and leucine levels. The other glucogenic amino acids did not 
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increase on cooling, with decreases in glutamate and serine seen, in addition to a drop in the ketogenic 
branched chain amino acid isoleucine. 
In short, there are some differences and some similarities between the two studies.  This may be due 
to differences in effect size; the effect of reducing a participant’s calories to 10% of those required for 
48 hours is inevitably much larger than exposure to mild cold for two hours. Furthermore, the 
markedly different time courses between the two studies make it hard to draw comparisons, as the 
processes under study are all highly dynamic.  It is therefore difficult to draw firm conclusions about 
shared biology between the two studies. Both arms of the cooling study were performed following an 
overnight fast, so there were features consistent with fasting in both study arms. Additionally, as none 
of the corrected p values reach statistical significance, a larger sample size will need to be studied to 


























This thesis focuses on further understanding the mechanisms involved in thermogenesis in humans. I 
have taken two approaches to this problem.  Firstly, I have undertaken studies in healthy male 
volunteers, where they have undergone an experimental manipulation in the form of mild cold 
exposure to examine the physiological and metabolic changes with cooling. Secondly, I have 
characterised the first rare human variants in a gene known to be involved in thermogenesis in 
animals, GPR10.  
 
6.1. Cooling as an experimental manipulation 
The experimental paradigm of two hours of exposure to a temperature of 16oC was chosen on the 
basis of published evidence that a similar degree of cooling leads to brown adipose tissue activation 
as measured by 18FDG-PET CT. In the original NEJM issue of articles demonstrating the presence of BAT 
in adult humans (2009), Van Marken Lichtenbelt demonstrated active BAT in healthy young men 
exposed to temperatures of 16oC via a climatic chamber for two hours (van Marken Lichtenbelt, 
Schrauwen et al. 2002), whilst Orava used a similar paradigm of air exposure to 17oC in a chilled room 
to demonstrate BAT activation (Orava, Nuutila et al. 2011). There is little published literature on the 
use of cooling via a cooling suit. However, our colleague Dr Sebastian Schmid, Lubeck Germany has 
used identical suits for a cooling study, and has demonstrated activation of BAT using an 18FDG-PET CT 
(Iwen, Backhaus et al. 2017). We can therefore have confidence that our paradigm is likely to activate 
brown adipose tissue. 
On cooling we observed a significant drop in peripheral skin temperature, an increase in systolic blood 
pressure, compatible with an increased sympathetic drive. The gas exchange monitor demonstrated 
a trend towards an increase in resting metabolic rate compared to the thermoneutral arm, with a shift 
towards fatty acid oxidation shown by a reduction in respiratory quotient, but this did not reach 
significance. Differences in thyroid function were not significant, nor was serum cortisol.  Leptin levels 
reduced significantly more in the cooling study arm. In common with our previously reported findings 
on increased preference for high fat foods in patients with disrupted leptin-melanocortin signalling, 
we have found that the partial state of leptin deficiency resulting from cooling is also reflected by a 
significant increase in preference for high fat food on the fat preference meal (van der Klaauw, Keogh 
et al. 2016). Changes in BDNF levels did not reach significance. There was an improvement in some 
neurocognitive tests; the verbal fluency and digit span tests significantly improved.  
Although there were clear physiological changes induced by the temperature intervention, we have 
not been able to show significant changes in the metabolome, although the study was underpowered 
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to detect an effect. Metabolomics has been previously used to examine the effects of 48 hours of 
calorie restriction (10% of daily energy needs) in healthy normal weight men. In that study we observe 
an increase in branched chain amino acids, increased lipolysis of triglycerides, acylcarnitines, ketone 
bodies, 3-OH fatty acids, sphingolipids and endocannabinoids, and a decrease in phospholipids and 
plasmalogens.  None of the results in the cooling study reached statistical significance after Benjamini-
Hochberg correction to control for false discovery rate. This is probably because the effect size of 48 
hours of calorie restriction is much greater than two hours of mild cooling; a greater effect size may 
have been seen if participants were cooled to a lower temperature and for longer. However, we were 
concerned that this would result in the adaptive response of shivering with resulting increases in 
energy expenditure, and that this might confound our interpretation of results. 
 
6.2. The effect of chronic cold exposure and acclimatisation on thermogenesis 
There have been several previous studies examining acclimatisation to chronic cold exposure.   
Population studies show that indigenous black Africans have reduced shivering thermogenesis in the 
cold and less cold induced vasodilation in fingers and toes compared to Caucasians and Inuit (Daanen 
and Van Marken Lichtenbelt 2016).  These findings are in keeping with others that show that both 
males and females from circumpolar regions have basal metabolic rates between 3-19% higher than 
would be predicted on the basis of people from temperate zones (Leonard, Sorensen et al. 2002). 
However, other groups have shown that both black and white people living in subtropical zones have 
the same amounts of brown adipose tissue, indicating that it is exposure to extreme temperatures, 
rather than innate ethnic differences that explain these findings (Perkins, Mshelia et al. 2013).  
Together, these findings demonstrate that while people who are habituated to a cold environment 
may have an increased basal metabolic rate, it is unclear whether this is secondary to ethnic 
differences in the amount or activity of brown adipose tissue, or whether it is simply due to 
environmental conditioning.  
Brown adipose tissue is activated by cold, increased sympathetic drive and thyroid hormones. It has 
been hypothesised that cold adaptation might result in changes in thyroid activity and that this is 
essential in Arctic and cold-exposed populations. This theory was supported by the finding that serum 
thyroglobulin was highest amongst Arctic hunters and settlement dwellers who were markedly cold 
exposed. They additionally had the lower measurements of T3; TSH was not affected (Andersen, 
Kleinschmidt et al. 2012). These findings are consistent with an increase in consumption of thyroid 
hormone, and a higher thyroid hormone turnover. 
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6.3. Other approaches to the study of energy expenditure 
There are other experimental approaches to studying energy expenditure. Just as changes with 
thyroid hormone have been observed in cold-acclimatised populations, studies on the action of 
thyroid hormone on brown adipose tissue have yielded new insights on its biology. Induction of the 
deiodinase 2 enzyme results in BAT adipogenesis in vitro and its development in mice embryos. Brown 
adipocytes express high levels of deiodinase II and low levels of deiodinase 3, resulting in high rates of 
conversion of thyroxine to triiodothyronine, and low levels of inactive reverse T3. Enhanced thyroid 
hormone signalling results in the activation of several genes, including PPARγ1a and ucp1. 
The effects of thyroid hormone on BAT activation have been explored in patients with thyroid 
carcinoma, before and after the initiation of TSH-suppressive thyroxine therapy following surgery, 
with 18FDG-PET imaging. These case reports have shown improvements in metabolic markers and 
glycaemic control with increasing levels of BAT activation (Skarulis, Celi et al. 2010, Broeders, Vijgen 
et al. 2016). No data from human clinical trials of THRb stimulation have been reported, but both 
mouse and primate models suggest that THRb selectively stimulates BAT and promotes adaptive 
thermogenesis. (Grover, Mellstrom et al. 2003). 
While collectively these studies demonstrate a role for thyroid hormone in the activation of brown 
adipose tissue, administration of levothyroxine is not a “clean” method of investigating brown adipose 
tissue biology; thyroid hormone, acting via its nuclear receptors THRa and THRb, activates in excess of 
200 different genes. The effects of levothyroxine are therefore wide-ranging, and will not allow the 
examination of BAT in isolation. Additionally, administration of thyroid hormone as a weight loss tool 
is likely to be of very limited potential due to the negative cardiovascular profile and effects on bone 
density. 
 
6.4. Insights from the genetics of energy expenditure in humans 
The heritability of energy expenditure has been illustrated by seminal studies examining the effects 
of overfeeding in monozygotic twin pairs. Twelve adult pairs of monozygotic twins were overfed by 
~1000 kcal per day, six days per week for a total of 84 out of 100 consecutive days. The total excess 
consumption was 83,000 kcal. They demonstrated that weight gain was highly variable, ranging from 
4.4 to 13.3kg, with a mean weight gain of 8.3kg. There was a significant similarity within each twin 
pair in the amount of weight gained, with approximately three times more variance between twin 
pairs than within twin pairs (Bouchard, Tremblay et al. 1990).  
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There are no described cases of human monogenic obesity resulting from rare mutations in molecules 
known to be involved in human thermogenesis, for instance ucp-1 or the β3 adrenergic receptor. 
However, a common polymorphism in ucp-1 has been described; the Trp64Arg polymorphism of 
ADRβ3 generates less cyclic AMP in response to adrenergic agonists than does the wild-type receptor, 
and lowers the response to β3 adrenergic agonists in transfected 3T3-L1 preadipocytes. Also 
described is a common polymorphism in the DIO2 enzyme (Thr92Ala) that is associated with type 2 
diabetes. Individuals possessing both variants, have a propensity to obesity (Kimura, Sasaki et al. 
2000). Additionally, rare human mutations in KSR2 (kinase suppressor of Ras 2), an intracellular 
scaffolding pathway with effects on multiple pathways, that impair cellular fatty acid oxidation and 
glucose oxidation in vitro. Affected patients have a low basal metabolic rate and heart rate, in addition 
to severe childhood hyperphagia, weight gain and insulin resistance (Pearce, Atanassova et al. 2013). 
GPR10 is known to be downstream of leptin and is important for its thermogenic effects (Dodd, Worth 
et al. 2014).  There is therefore there is a clear rationale for studying human mutations that may affect 
its function, and this thesis describes the first rare human mutations in this molecule that are obesity 
associated.  
 
6.5. Rare variant analysis and establishing causality  
Establishing whether variants contribute to a person’s obesity can be challenging. We planned to 
perform a detailed clinical phenotyping of the patients, but this was difficult as many of them were 
not available for study. We have studied variants found in both cases and controls, and have 
performed a thorough functional characterisation and have demonstrated a dominant negative effect 
of the mutant receptor on the wild type, in cells cotransfected with both. We explored the use of C. 
elegans in demonstrating the association of mutations in GPR10 with obesity by using CARS 
microscopy; these efforts were frustrated by the degree of variability in fat content in both wild type 
and npr-6 null worms. We are therefore in the process of creating a heterozygous mouse of the P193S 
mutation – one of the three mutations that demonstrate an in vitro loss of function and a dominant 
negative effect on the wild type receptor, in collaboration with Professor Simon Luckman, who has 
contributed much of the rodent work conducted on GPR10 signalling. The phenotype of the 
heterozygous mouse will hopefully help to elucidate whether this human mutation can cause obesity. 
Whilst human studies are very challenging, and there are many potential pitfalls to the approach we 
have taken, we know that drugs that act on targets validated by studies resulting from human genetic 
data have a much greater chance of reaching the market (Nelson, Tipney et al. 2015). Whilst the 
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challenge of neuropeptides as a potential treatment for obesity is creating drugs that can be 
peripherally administered and cross the blood brain barrier, there has been much industry work on 
creating lipidised versions of PrRP that have therapeutic potential (Maletinska, Nagelova et al. 2015). 
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